19TH ANNUAL

BIOTECH IN EUROPE FORUM

FOR GLOBAL PARTNERING & INVESTMENT

25TH - 26TH SEPTEMBER 2019
CONGRESS CENTER BASEL
SWITZERLAND

CONFERENCE GUIDE
www.sachsforum.com
SACHS ASSOCIATES ARE DELIGHTED TO WELCOME YOU TO THE:

19TH ANNUAL
BIOTECH IN EUROPE FORUM

25TH - 26TH SEPTEMBER 2019
CONGRESS CENTER
BASEL SWITZERLAND

Following the success of previous years, the forum once again provides access to an exciting cross-section of venture-funded and small-cap companies with leading investors and pharmas.

This forum is highly transactional and is comprised of a series of panels and presentations from leading investment, pharmaceutical and biotech companies, each one providing an expert outlook on growth and investment activity in Europe’s Biotech industry.

GENERAL INFORMATION

The registration desk will be open from 7.20am on September 25th and from 8am on 26th September although you are welcome to join the event at any time. Please collect a copy of the agenda for information on timing and room allocation for each session.

Networking at the summit is facilitated by our online One-2-One meeting system, which is available to all participants. The One-2-One meetings are being held in room Shanghai. Please bring with you a copy of your diary. Should you have any queries about your schedule, the Sachs team situated by the meeting tables is available for your assistance.

Wireless internet connection is available throughout the venue for the duration of the event. Please ask for an access code at the registration desk.

Networking reception (Buffet & Drinks) for the event will take place at the Grand Hotel “Les Trois Rois” on 25th of September from 18.30 – 21.00 (Function space - Salle Belle Epoque). Reception is sponsored by Kanton Basel-Stadt. Upon arrival please provide your conference badge.

Address for the reception: Blumenrain 8, 4001 Basel, Switzerland (map available online: https://goo.gl/SUQ7jo)

REQUEST FOR PRESENTATIONS

Please use the agenda to mark off presentations that you are interested in and email your request to Silvia@sachsforum.com after the conference. We will endeavor to send you the requested presentations as soon as we have been granted permission to do so by that specific presenter.

Please note that we DO NOT have copies of the slides that are shown during the conference.
EVENTS DIARY

For the regular updates, sponsorship, presenting and attending opportunities and further information regarding any of our future events, please contact Silvia Kar on Silvia@sachsforum.com.

3RD ANNUAL NEUROSCIENCE INNOVATION FORUM
12TH JANUARY 2020 • MARINES’ MEMORIAL CLUB • SAN FRANCISCO • USA

Building on the success of our 2nd Annual Neuroscience Innovation Forum we are pleased to announce the 3rd Annual Neuroscience Innovation Forum that will take place at Marines’ Memorial Club on the 12th of January 2020, a day before the JP Morgan meeting. The target audience are buy and sell side analysts from investment banks, funds and partnering executives from pharma and medtech/digital health companies. We anticipate around 250 delegates and 30+ company presentations by established and emerging companies.

EUROPEAN HEALTHTECH CEO FORUM
18TH FEBRUARY 2020 • HILTON ZURICH AIRPORT HOTEL • ZURICH • SWITZERLAND

Following the success of the HealthTech forum in Basel, we are happy to announce the European HealthTech CEO Forum, which will take place on the 18th of February at Hilton Zurich Airport Hotel, just a day before our European Life Sciences CEO Forum. We anticipate over 200 delegates, covering innovation in the digital health and medtech and devices sectors. The programme will feature topical keynotes and panels with industry leaders and over 20 corporate presentations by public, private and growth companies, and 20+ pitches by seed companies.

13TH ANNUAL EUROPEAN LIFE SCIENCES CEO FORUM
19TH - 20TH FEBRUARY 2020 • HILTON ZURICH AIRPORT HOTEL • ZURICH • SWITZERLAND

Back for its 13th Annual edition, this global bio-pharma industry forum addresses through its conference programme the main challenges for 2020 in investment, partnering and alliance management. Key players contribute their insights in panels which cover the macro picture as well as innovation in the different therapeutic sectors. The forum will feature keynote speeches by KOL and about 60 selected corporate presentations from established (public and private) and emerging biotechs, and 20+ pitches by seed companies, seeking to promote investment and partnering opportunities. We expect over 350 delegates to attend the event.

6TH ANNUAL IMMUNO-ONCOLOGY BD&L AND INVESTMENT FORUM
29TH MAY 2020 • WALDORF ASTORIA CHICAGO HOTEL • CHICAGO • USA

Taking place on the first day of ASCO, the 6th Annual Immuno-Oncology BD&L and Investment Forum is designed to bring thought leaders together from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering, funding and investment. The event will focus on biotech partnering and investment giving you an excellent opportunity to network with executives from top pharma, biotech companies, and investors. We expect around 250 delegates and about 30 presentations by listed and private biotechnology companies seeking licensing & investment.
The 20th Annual Biotech in Europe Forum is recognised as the leading international stage for those interested in investing and partnering in the biotech and life science industry. This highly transactional event draws together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives. Supported and designed by leading figures within Europe’s pharmaceutical and biotech industry, this event will once again be covered by our regular media partners. We expect over 700 delegates and over 100 presenting companies, and 30+ pitches by seed companies.

The programme will feature a number of plenary panels/workshops covering BD & Licensing in the main therapeutic areas.

**ONLINE ONE-2-ONE MEETING SYSTEM AVAILABLE AT ALL SACHS EVENTS**

In order to offer the best possible provision for networking opportunities and dealmaking Sachs Associates provides delegates with access to our online One-2-One meeting system, allowing you to set up, accept or decline private One-2-One meetings with other conference attendees. These meetings last for 20 minutes in duration. Individual passwords and logins are provided to allow immediate access and ensure full security.
**Nasdaq OMX**

**ADAM KOSTYÁL**

Senior Vice President, Head of Listings EMEA

Adam Kostyál is the Senior Vice President of the Global Listing Services and head of European Listings for Nasdaq. Besides the Nordic Exchanges, Nasdaq has approximately 200 companies that are either primarily listed or dual listed on Nasdaq in the USA. In addition Nasdaq has launched the Nasdaq Private Market which is an offering focused on supporting private growth companies in managing liquidity events.

Adam has been with Nasdaq for the past 10 years. He started his career at OMX and has been in various commercial roles within the organization. Prior to his current role he had overall responsibility for Nasdaq Market Technology for the European, Central and Eastern European regions. Prior to Nasdaq, Adam held various positions with Enron, Cell Network and Bloomberg.

He holds a BSc in Economics and Marketing from Vrije Universiteit de Bruxelles and speaks four languages including English, Swedish, Italian and French. He is also the father of five.

---

**NxR Biotechnologies GmbH**

**ALAIN VERTÈS**

Managing Director

Dr. Vertès is Managing Director at NxR Biotechnologies, a boutique global consulting firm based in Basel, Switzerland, where he advises clients on strategy, business development, in/out-licensing, entrepreneurship and investment. He brings to his role extensive experience in the pharmaceutical and industrial biotechnology sectors, in Europe, North America and Asia and in different functions including research, manufacturing, contract research, and strategic alliances. NxR’s track record comprises projects with big pharma, biotech, generics companies, financial investors, CROs, academia, and start-ups. Active in alliance management for Mesoblast, prior to NxR Biotechnologies Dr. Vertès held positions of increasing responsibility in pharmaceuticals at Lilly and Pfizer, as well as at Roche where he notably led through an external innovation partnering function the global cell therapeutics strategy and implementation team from 2007-2010. In addition, he has worked in petrochemicals at Mitsubishi Chemical Corporation, public research at the Institut Pasteur and RITE/Kyoto, contract research at Battelle Memorial Institute and PPD/BioDuro, and has done consulting for the Australian Strategic Policy Institute. With a focus on innovation commercialization, he has been a key player in the evaluation, selection, deal making, implementation and alliance management of numerous novel products and emerging technologies.

Dr. Vertès received his M.Sc. degree from the University of Illinois at Urbana-Champaign, his Ph.D. from the University of Lille Flandres Artois and is a Sloan Fellow from London Business School (MBA/M.Sc.). Dr Vertès is a lead editor of several science and strategy books in the fields of regenerative medicine and sustainable chemistry.

---

**Themis Bioscience GmbH**

**ALEXANDER KORT**

SVP Corporate Development

2016: Senior Vice President Corporate Development, Themis Bioscience GmbH, Vienna, Austria

Responsible to implement Project Portfolio Management process, managing product development projects for new indications including EU funded project under the Horizon2020 program and helping to optimize manufacturing platform towards a robust and scalable manufacturing process. Implementing quality management and business process management systems to facilitate company growth.

2015-2016: Senior Expert Project Management, Strategic Projects Operations, IDT Biologika GmbH, Dessau, Germany
Nasdaq OMX

ADAM KOSTYÁL
Senior Vice President, Head of Listings EMEA

Adam Kostyál is the Senior Vice President of the Global Listing Services and head of European Listings for Nasdaq. Besides the Nordic Exchanges, Nasdaq has approximately 200 companies that are either primarily listed or dual listed on Nasdaq in the USA. In addition Nasdaq has launched the Nasdaq Private Market which is an offering focused on supporting private growth companies in managing liquidity events.

Adam has been with Nasdaq for the past 10 years. He started his career at OMX and has been in various commercial roles within the organization. Prior to his current role he had overall responsibility for Nasdaq Market Technology for the European, Central and Eastern European regions. Prior to Nasdaq, Adam held various positions with Enron, Cell Network and Bloomberg.

He holds a BSc in Economics and Marketing from Vrije Universiteit de Bruxelles and speaks four languages including English, Swedish, Italian and French. He is also the father of five.

NxR Biotechnologies GmbH

ALAIN VERTÈS
Managing Director

Dr. Vertès is Managing Director at NxR Biotechnologies, a boutique global consulting firm based in Basel, Switzerland, where he advises clients on strategy, business development, in/out-licensing, entrepreneurship and investment. He brings to his role extensive experience in the pharmaceutical and industrial biotechnology sectors, in Europe, North America and Asia and in different functions including research, manufacturing, contract research, and strategic alliances. NxR’s track record comprises projects with big pharmas, biotechs, generics companies, financial investors, CROs, academia, and start-ups. Active in alliance management for Mesoblast, prior to NxR Biotechnologies Dr. Vertès held positions of increasing responsibility in pharmaceuticals at Lilly and Pfizer, as well as at Roche where he notably led through an external innovation partnering function the global cell therapeutics strategy and implementation team from 2007-2010. In addition, he has worked in petrochemicals at Mitsubishi Chemical Corporation, public research at the Institut Pasteur and RITE/Kyoto, contract research at Battelle Memorial Institute and PPD/BioDuro, and has done consulting for the Australian Strategic Policy Institute. With a focus on innovation commercialization, he has been a key player in the evaluation, selection, deal making, implementation and alliance management of numerous novel products and emerging technologies.

Dr. Vertès received his M.Sc. degree from the University of Illinois at Urbana-Champaign, his Ph.D. from the University of Lille Flanders Artois and is a Sloan Fellow from London Business School (MBA/M.Sc.). Dr Vertès is a lead editor of several science and strategy books in the fields of regenerative medicine and sustainable chemistry.

Corion Biotech S.r.l.

ALESSANDRO ROLFO
Founder & Chief Scientific Officer

Alessandro Rolfo is Founder and Chief Scientific Officer of Corion Biotech S.r.l., Start up based in Turin (Italy) developing innovative solutions for Women’s Health. Moreover, he is Assistant Professor in Obstetrics and Gynaecology at the University of Turin (Italy) where he leads a research team investigating human pregnancy-related disorders and therapeutic applications of placenta derived stem cells.
**Themis Bioscience GmbH**

**ALEXANDER KORT**  
SVP Corporate Development

2016: Senior Vice President Corporate Development, Themis Bioscience GmbH, Vienna, Austria  
Responsible to implement Project Portfolio Management process, managing product development projects for new indications including EU funded project under the Horizon2020 program and helping to optimize manufacturing platform towards a robust and scalable manufacturing process. Implementing quality management and business process management systems to facilitate company growth.

2015–2016: Senior Expert Project Management, Strategic Projects Operations, IDT Biologika GmbH, Dessau, Germany

2013–2015: Head of Project Management Group, Contract Manufacturing Human Viral Vaccines, IDT Biologika GmbH, Dessau, Germany

2009–2013: Project Manager, Contract Manufacturing Human Viral Vaccines, IDT Biologika GmbH, Dessau, Germany

**Syndendos Therapeutics AG**

**ANDREA CHICCA**  
Co-Founder & CEO

Since 2019, Andrea is co-founder and CEO of Syndendos Therapeutics, a spin-off of the University of Bern (Switzerland) that develops first-in-class endocannabinoid modulators to treat unmet needs in neuropsychiatric disorders. Andrea holds a PhD in Pharmacology from the University of Pisa (Italy). In 2010, he joined the group of Prof. J. Gertsch at the University of Bern and in 2018 he obtained the venia docendi (Privatdozent) in Biochemistry and Molecular Medicine. In the same year, he also obtained the habilitation for professorship in Pharmacology from the Italian Ministry of Education and Research. Andrea is co-author of 45+ scientific articles published in international peer-reviewed journals. He strongly contributed to the elucidation of endocannabinoid membrane transport mechanism, development of new class of endocannabinoid modulators (Selective Endocannabinoid Reuptake Modulators, SERIs) and identification of SERIs’ drug target (new and not published yet). Before joining the University of Bern, Andrea worked for almost 2 years as a scientific adviser in the corporate marketing of Chiesi Pharmaceuticals (Italy), where he acquired hands-on experience in preclinical and clinical drug development.

**Locust Walk**

**ANDY MEYERSON**  
Vice President

Andy brings experience across the life sciences industry, including an extensive legal background working with emerging growth companies and venture capital funds. While with Locust Walk, he has worked on buy-side, sell-side and consulting services engagements for numerous life sciences clients, with a particular recent focus in CNS and oncology.

Prior to joining Locust Walk, Andy was an associate at Gunderson Dettmer, one of the nation’s leading business law firms for entrepreneurs, emerging growth companies and venture capitalists. Andy’s legal practice encompassed all areas of general corporate and securities law, with extensive experience in corporate financings, including public offerings and private placements of equity and debt, and mergers and acquisitions. Andy also represented life sciences companies in all stages of their life cycles, from start-ups to public companies. Andy was also previously an associate in the Corporate and Financial Services group at Willkie Farr & Gallagher.
Click Therapeutics, Inc.

**AUSTIN SPEIER**
Chief Strategy Officer

Austin Speier is Chief Strategy Officer at Click Therapeutics, where he works to align product development, go-to-market and regulatory strategy for Click's pipeline of digital therapeutics. He also coordinates efforts both internally and with external partners to identify new product opportunities, support co-development initiatives, manage intellectual property, and lead regulatory approvals. Prior to joining Click, Mr. Speier advised clients on the design and execution of regulatory and evidence development strategies for complex or first-in-class products, especially those with a digital software-based component. He has particular expertise working with early-stage and venture-backed clients to identify and address the most critical scientific, clinical, regulatory and reimbursement issues on the pathway to market for their products. He brings to Click over 10 years of strategic consulting and FDA regulatory experience with over 250 companies and many first-in-class digital products. Mr. Speier’s experience spans a wide range of product categories and therapeutic areas including work with numerous neurology, cardiovascular, oncology, wound care, gastroenterology, drug delivery, women’s health, diagnostic, and consumer products. He previously conducted research at the Brigham & Women’s Hospital Center for Neurodegeneration and Disease, where he focused on characterizing the molecular and cellular pathology of Alzheimer’s Disease. Mr. Speier holds an A.B. cum laude in Biology from Harvard College, where he also completed the interdisciplinary Honors Neurobiology program to receive a certificate in Mind, Brain, and Behavior Studies.

High-Tech Gründerfonds Management GmbH

**BERND GOERGEN**
Partner

Dr Bernd Goergen, Partner, has been a part of High-Tech Gründerfonds’ Life Science Team since early 2008. He holds a PhD in biology and is a certified biotech analyst with the German Association for Financial Analysis and Asset Management (DVFA). He brings with him five years of research experience in the field of virology and immunology and seven years in international diagnostics marketing for German and international companies. Between 2000 and 2007, Dr Goergen also acquired extensive knowledge in M&A and capital market deals while working in the investment banking division of a major German bank.

Oryzon Genomics S.A.

**CARLOS BUESA**
Founder & CEO

He is a specialist in the Biotech Industry. Dr Buesa is BSc in Biology and got his PhD in Biochemistry (Molecular Biology) from the University of Barcelona, Spain. He was EU post-doctoral fellow in the Faculty of Medicine at the University of Ghent in Belgium and later Senior Investigator at the Flemish Institute of Biotechnology (VIB). He has also taken the executive education programme (PADE) at the IESE Business School in Barcelona and several other additional educational programs in finances. In 2000, he founded Oryzon, where, since inception, he has served as CEO and Chairman of the Board.

Under his leadership the company has got +65M € in several equity funding rounds +70 M € in non dilutive funds. After a transforming partnering deal of +$500 M with Roche in 2014, Dr Buesa leaded Oryzon to become a public company in 2015 in the Madrid Main Stock exchange. Through this listing in the Spanish market, the company secured $36M in the period, (€16.5M ($19M)) in equity complemented with €15.5M debt ($17M)). In 2016, Oryzon was selected as one of the 3 Finalists in healthcare for the 7th Annual Most Innovative EU Biotech SME Award, a contest that congregated 41 companies from 13 European countries. In 1Q2017 he led a successful 18.2M € Pipe ($20m) offering that included institutional investors specialized in healthcare and life sciences from the US, Spain and rest of Europe. In 2018 he led an additional 13M € Pipe further reinforcing and diversifying the Company’s shareholder base.
The company has evolved from being a Genomics R&D oriented company in its early days to a clinical stage biopharma company highly specialized in epigenetics. With a strong focus on one of the most promising targets of the field, the histone demethylase LSD1, the two most advanced molecules Iadademstat and Vafidemstat are being explored currently in five Phase IIA trials in Oncology and in CNS respectively. These, and the rest of its pipeline, place today Oryzon at the forefront of the global Epigenetics space.

**Immunicum AB**

**CARLOS DE SOUSA**  
CEO

Carlos de Sousa is a medical doctor by training, having earned his degree at School of Medicine University of Lisbon and holds an Executive MBA from the Stern School of Business New York University. He has more than 25 years of senior level experience in the global pharmaceutical and biotech industry including business development, mergers & acquisitions, global market-ing and clinical development. Prior to joining Immunicum he held senior positions at Nycomed/Takeda, Pfizer, Novartis, Newron Pharmaceuticals and Zealand Pharma among others.

**HBM Partners AG**

**CHANDRA LEO**  
Partner

Chandra P. Leo joined the Private Equity Team of HBM Partners in 2007. His board and investment experience includes biotech and medtech companies such as CardiacAssist (acquired by LivaNova), ChemoCentryx (IPO NASDAQ), ESBAtech (acquired by Alcon/Novartis), Homology Medicines (IPO NASDAQ), ObsEva (IPO NASDAQ), Symbiomix Therapeutics (acquired by Lupin), Turning Point Therapeutics (IPO NASDAQ), as well as Galecto Biotech and Gynesonics (both still private).

Chandra previously served as a postdoctoral scientist at Stanford University Medical Center, as a physician at the University Hospital Leipzig (Germany) and as a principal in the life sciences team at Wellington Partners. He completed his medical studies in Berlin and London and holds a doctoral degree from the Freie Universität Berlin (Charité) and an MBA degree with distinction from INSEAD.

**Novartis International AG**

**CHARLES BAILEY**  
Head, Neuroscience BD&L

Charlie Bailey leads business development activities for the Neuroscience portfolio at Novartis Pharmaceuticals, with a focus on clinical stage assets across neurology, psychiatry and neuromuscular diseases. A broad CNS portfolio at Novartis encompasses conventional small and large molecules as well as gene therapy and digital therapeutics. Charlie has been closely involved in transformative deals including partnership with Amgen in Migraine and Alzheimer’s, acquisition of Multiple Sclerosis product rights from GSK and company acquisition of AveXis and Spinifex Pharmaceuticals.

During 16 years of work in business development, Charlie has been responsible for transactions, search and evaluation and alliance management with a focus on neuroscience and oncology. Prior to his current role, he was responsible for licensing and M&A in Novartis Molecular Diagnostics. He also led R&D out-licensing activities in Roche Partnering and completed several oncology licensing deals in roles at Roche and Mundipharma International.
**Neuraxpharm**

**CHRIS BRITTEN**

Head, M&A

Chris is currently Head, M&A at Neuraxpharm, a privately-owned European CNS specialty pharmaceutical company. He has over 20 years’ pharmaceutical industry experience in R&D, corporate development and investment banking. Previously roles include Global Head M&A at Sandoz (Munich), Managing Director at Torreya Partners (London), Head of Business Development at Sanofi Pasteur MSD (Lyon) and Director, Life Sciences at Deloitte Corporate Finance (London). Chris also spent many years at GSK in both drug discovery and corporate development. He is currently a Non-Executive Director at N4 Pharma plc.

Chris holds a PhD in Biochemistry from the University of Pennsylvania and University of York, as well as an MBA from the London Business School.

**LifeSci Advisors**

**CHRIS MAGGOS**

Managing Director, Head of Europe

Chris has 25 years of experience in the life sciences industry covering investor relations, public relations, business development, journalism, investing and molecular neurobiology. He established the European operations of LifeSci Advisors in Geneva, Switzerland, in 2015. Chris was a member of the executive committee at Addex Therapeutics (SIX:ADXN; Geneva, Switzerland), initially serving as head of investor relations & communication and then as director, business development. He also worked as a journalist, based in Paris, for the leading biotechnology trade publication BioCentury and as an investor at a biotech-focused investment fund, partially owned by and operated out of the NYC offices of Hambrecht & Quist (now JP Morgan). He participated in molecular neurobiology research at The Rockefeller University, where he co-authored 12 peer-reviewed publications. Chris holds a BA in English Literature from Yale University, where he also completed pre-medical studies.

**Dementia Discovery Fund**

**CHRISTIAN JUNG**

Partner

Christian joined the DDF as a Partner in 2019. Prior to DDF, Christian was a Principal at Wellington Partners Life Sciences, where he was focused on investing in opportunities covering novel therapeutics and medical devices. Before joining Wellington, Christian was as a Senior Investment Manager with High-Tech Gründerfonds, Europe’s leading seed fund with €896 million under management. There, Christian completed and led the investments in nine seed- and early-stage companies, including Amal Therapeutics SA (acquired by Boehringer Ingelheim in 2019 for up to €325 million) and Rigontec GmbH (acquired by MSD in 2017 for up to €464 million). During the course of his PhD, Christian was supporting the Life Science Team of Atlas Venture in Munich.

Christian obtained his MSc degree in Molecular Biotechnology from the Technical University of Munich and was awarded a PhD with distinction in Medical Science and Technology from the Technical University of Munich for his work on patient-specific induced pluripotent stem cells. The key articles generated in the context of his PhD were published in the New England Journal of Medicine, EMBO Molecular Medicine and FASEB Journal and have so far been cited more than 1000 times. In 2013, the thesis was recognized with the “Outstanding PhD thesis award” by the Luxembourg National Research Fund.
Innogest Capital

CLAUDIO GIULIANO
Managing Partner

Claudio Giuliano is a player in the venture capital industry since year 2000. Claudio co-founded in 2007 Innogest Capital, a Venture Capital firm with about €200 Mln under management, and is a partner in the Healthcare and Cardiovascular practice at Innogest. Claudio served as chairman of the VC Committee at the Italian VC and PE association (AIFI) and is part of several private and public bodies involved in start-up and entrepreneurship development.

Prior to Innogest, Claudio was Associate Director at The Carlyle Group (London) Strategy consultant at Bain&Co (Italy) Supply Chain Manager at Hewlett-Packard (California and France)

Claudio holds a Summa cum Laude Master of Science in Electronic Engineering from Politecnico di Torino (Italy), a Summa cum Laude Diplôme d’études approfondies in Microelectronics from l’Institute Nationale Polytechnique in Grenoble (France) and an MBA from INSEAD (Dean’s List), in Fontainebleau (France)

BeiGene Ltd.

CORINNE VENOT
Senior Director Business Development

Biologist by training with a PhD from the University of Pierre & Marie Curie in Paris and a Master in biotech & pharma management from ESCP-EAP Paris. She has always been focused in the Oncology field, taking various positions from marketing, early drug discovery, R&D partnering to Business Development & Licensing. Joining Aventis, she was team leader for 8 years in oncology drug discovery projects, moving forward projects from target identification until preclinical candidate, major accomplishment was towards IGF1R project developing small molecule as well as antibody. During 8 years within Sanofi Oncology Division, as director of oncology business opportunities, she was specialized in preclinical/discovery assets with an emphasis on oncobioinformatics including antibody drug conjugates. She has been playing a major role in building the following licenses and partnerships: in-licensing p53/mdm2, small molecule inhibitor from Ascenta/Univ of Michigan; Dana Farber/Belfer Institute, strategic research collaboration; in licensing of antibody products for ADCs from Oxford Biotherapeutics; Caprion Target identification license & research collaboration; Algeta research collaboration for Thorium RadiolmmunoTherapy; several technology deals to build ADC next generation (Innate Pharma BTG technology, Catalent SMART Tag technology, Glykos new linkers, Avipep small format). Within the Immuno-Oncology space the license and research collaboration with Innate Pharma for NK Cell Engagers.

She moved to Servier in 2016, to lead the oncology portfolio licensing activities within the BD&L department. During here time at Servier, she has put in place the Pieris re-search collaboration and license agreement covering 8 immuno-oncology bispecific anti-calins, 2 research collaboration and license agreements on undisclosed targets with Vernalis and the WEHI, as well as a technology license with Transgene for CART Cell therapy. More recently she actively contributed to the Shire Oncology portfolio acquisi-tion Recently joined Beiogene, as Senior Director BD&Licensing.
**HOOKIPA Pharma, Inc.**

**DANIEL PINSCHEWER**
Founder & CSO

Daniel Pinschewer is founder and Chief Scientific Officer (CSO) of HOOKIPA Pharma Inc. and is responsible for enhancing HOOKIPA’s research capabilities. After graduating from the University of Zurich Medical School in 2000, he became a postdoctoral researcher. He specialised in molecular virology, working alongside Juan Carlos de la Torre (The Scripps Research Institute, USA), and in immunology with Rolf Zinkernagel and Hans Hengartner (University of Zurich, Switzerland). In 2007, Daniel Pinschewer was appointed Associate Professor of Immunology at the University of Geneva Medical School and, in 2013, was recruited to the University of Basel, where he continues to serve as a Professor of Virology. Throughout his career he has been recognised for his contributions to the scientific community, including receiving awards from the European Research Council (ERC starting grant) and from the Swiss National Science Foundation (stipendiary professorship). National and international honors include: the Georges-Köhler-Prize of the German Society for Immunology, the Loeffler-Frosch-Prize of the Society for Virology, the Debiopharm Group Life Sciences Award, the Pfizer Research Prize, and the Prix Leenaards. Daniel Pinschewer’s research discoveries have formed the technological foundation on which HOOKIPA is founded.

**Panakes Partners SBMT SpA**

**DIANA SARACENI**
Co-Founder & General Partner

Diana Saraceni is Co-Founder & General Partner at Panakes, a recently launched Venture Capital firm dedicated to early stage investments in healthcare in Europe and Israel. Over 20 years of Venture Capital experience, she has also co-founded and managed 360 Capital Partners, one of the leading Venture Capital firm in Europe. She has led investments in a significant number of companies all over Europe, not only in the medical device sector, and generated several exits as IPO and M&A transactions. Ms Saraceni has a strong knowledge of the Venture Capital community in Italy/Europe and hold an Msc in Engineering and an MBA from Luiss University.

**Grabulovski Consulting Services GmbH**

**DRAGAN GRABULOVSKI**
Founder & CEO, ex Co-Founder & CSO of Covagen

Dragan received his Master’s degree and PhD in Pharmaceutical Sciences from ETH Zürich. From 2007 to 2014 he was co-founder and CSO of Covagen, a Swiss biotech company acquired in 2014 by Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson. As Covagen’s CSO, he was responsible for developing and overseeing the execution of the overall strategy for research and development. As a member of Covagen’s executive management team, Dr. Grabulovski was instrumental in Covagen’s trade sale to Johnson & Johnson, in establishing deals with Roche and Mitsubishi Tanabe and in the closing of Covagen’s CHF 45M ($44.5M) Series B round in 2014. Since 2015 he is a serial entrepreneur and Biotech consultant at Grabulovski Consulting Services.
**Novartis Oncology**

**EMANUELE OSTUNI**

Head of Cell & Gene Therapy Oncology Region Europe

Emanuele is Head of Europe for Cell and Gene Therapies at Novartis Oncology, where he oversees the commercialization of this portfolio in Europe. Emanuele is with Novartis since 2012. He joined the Sandoz Division with the Global Strategy Team, where he managed the collaborations with Novartis Pharmaceuticals and Alcon. He then became Head of Specialty and Hospital Franchises, Central/Eastern Europe, where he developed a specialty expansion strategy. Emanuele later served as Business Unit Head, Rx in Romania. In this role he grew the team to drive the expansion into CNS, respiratory, and rheumatology franchises. Prior to joining Novartis in Europe he was based in the USA where he was Vice President of Business Development at Nano Terra, Engagement Manager at McKinsey & Co and a Senior Research Investigator at Surface Logix, where he helped to establish the company’s drug discovery platform.

Emanuele holds a PhD in Physical Chemistry from Harvard University and BS and MS degrees in chemistry from Georgetown University.

**PDC*line Pharma SA**

**ERIC HALIOUA**

President & CEO

Serial entrepreneur that combines strong managerial, technological, product development and fund-raising experience in biotechnology. He raised more than €100 million over the course of his career and has had numerous successes in the sale and initial public offering of biotechnology companies.

Eric Halioua is President and CEO of PDC*line Pharma, a clinical-stage biotech company that develops a new class of therapeutic cancer vaccines based on a line of Plasmacytoid Dendritic cells (PDC*line). He is as well Board member of the biotechnology company Bioxodes (Belgium), HairClone (UK), VitriCell (Belgium) and member of the strategic advisory board of Innobiochips (France). He was CEO at Promethera Biosciences a biotechnology company that develops cell therapy products to treat liver diseases. He is co-inventor of the first GMP approved mobile manufacturing unit for cell therapy.

Eric is as well co-founder of three biotechnology companies called Myosix, Murigenetics and Digital-Orthopaedics:

- **Myosix** is a tissue engineering company specialising in musculoskeletal cells culture used in the regeneration of the heart muscle. The company has been bought by Genzyme mid-2002.
- **Murigenetics** is a Biotechnology company developing therapies for genetic disorders.
- **Digital Orthopaedics** is a Digital Health company providing access to a comprehensive Clinical Decision Support System for musculoskeletal pathologies.

Eric was also a Board Member of a French public biotechnology company called Valneva, which specializes in the development and commercialisation of vaccines and monoclonal antibodies.

He was as well principal of the international life sciences practice of Arthur D. Little based in Paris and Boston during 11 years. He has led work in the areas of strategy, Due Diligences, M&A and technology & innovation management for biotechnology and pharmaceutical companies. He worked for IsoHealthcare Group (eventually acquired by the Monitor Group) as a Senior Consultant where I focused on leading healthcare and life sciences issues. Eric also worked as a strategic marketing manager for the “Centre Européen de Bioprospective” and as project leader in the corporate R&D centre of Astra-Zeneca in UK.

Eric holds two master degrees (DEA and Magistère) in Pharmacology and Molecular Biology and a MBA from ESSEC business school (Paris, France), with an advanced degree from the Health Care ESSEC chair.
Seventure Partners SA

ERIC DE LA FORTELLE

Venture Partner

Eric is a Venture Partner with Seventure Partners, a Paris-based venture capital investor investing broadly in life sciences (Rx, Dx, medical device) with a specific focus on the human microbiome. Seventure has raised the first fund worldwide dedicated to the microbiome, called Health for Life, in Dec 2015. Eric is a Board member of Mint Solutions BV, Maat Pharma SA, TargEDys SA, A-Mansia Biotech SA, and is an observer on the Boards of BiomX, DayTwo and Anaeropharma Science, all as a representative for Seventure. He is also an independent Board member of Sensorion SA in his personal capacity.

Formerly, Eric was CEO of Delenex Therapeutics, a Zurich-based biotechnology company discovering and developing antibodies for topical application to the skin. Prior to that he led Roche’s global function of External Research and Technologies. In this role, he had a dual mandate of BD&L (finding partners, negotiating contracts, managing alliances), leading to more than 200 deals being signed, and prospective (future scenarios to 2020 and R&D strategy recommendations).

Eric is a scientist by training, with contributions in the field of protein structure determination by X-ray crystallography. He was trained as an engineer and physicist at Ecole Centrale de Paris, holds a Ph.D. in Biophysics from Paris XI University, a post-graduate diploma in biomedicine from IFSBM (Institut Gustave-Roussy), and an MBA (honors) from INSEAD.

DCPrime B.V.

ERIK MANTING

CEO

After obtaining an MSc in Medical Biology and a PhD in Molecular Microbiology, Erik worked for a number of years in the field of immunology before making a career switch to banking in 2001. He spent the next 15 years in different commercial and management roles and his last five years in banking as Executive Director Corporate Finance at Kempen & Co, an investment bank with a focus on Life Sciences & Healthcare. By combining medical-scientific insights with strategic thinking, Erik aims to drive the DCprime team and DCprime collaborators to explore new and relevant solutions to the treatment of cancer. Erik joined DCprime in 2017, first as business development consultant and from March 2018 as CEO.

TargImmune Therapeutics AG

ESTEBAN POMBO VILLAR

CEO

Dr. Esteban Pombo-Villar is the Chief Executive Officer of TargImmune Therapeutics, and has 30 years of experience in leading biopharmaceutical R&D, business development and alliance management. Previously he was Chief Operations Officer (COO) for Oxford BioTherapeutics, and a Member of their Boards of Directors. He was responsible for the development data and manufacturing activities of their lead antibody and antibody-drug conjugate projects and their collaboration projects. Prior to joining Oxford BioTherapeutics, Dr. Pombo-Villar was at Novartis and Sandoz for over 23 years, the last 12 years engaged in Business Development and Alliance Management at the Novartis Institute for Biomedical Research (NIBR), for alliances in all therapeutic areas up to proof-of-concept in man. Prior to that he led Medicinal Chemistry efforts in the Neuroscience group as Chemistry Expert, and was Laboratory Head and Chemistry Project Leader for multiple projects. He obtained a PhD, MSc and BSc in organic chemistry from the University of Warwick (UK), was visiting researcher at the University of Newcastle upon Tyne (UK) and completed postdoctoral studies at the ETH in Zurich. Dr. Pombo-Villar is a Fellow of the Royal Society of Chemistry, and member of several scientific societies, and has completed executive business studies at IMD (MTE, Lausanne), Harvard Business School (US), and the Tuck School of Business (Dartmouth, US).
19TH ANNUAL BIOTECH IN EUROPE FORUM
FOR GLOBAL PARTNERING & INVESTMENT

Dr. Pombo has been on the faculty of the European Course for Biobusiness Development (University of Basel and ETH Zurich, 2007-2009), lectured in many conferences and workshops and is a member of the Licensing Executive Society.

 Lonza Pharma & Biotech

FATMA AYBEGUM SENKESEN
Director & Head of Strategic Marketing & Insights for Cell & Gene Technologies

Fatma Aybegum Senkesen is the Director and Head of Strategic Marketing and Insights for Cell & Gene Technologies at Lonza where she oversees the Market Intelligence, Forecasting and Marketing activities. Before joining Lonza, Fatma founded and worked for market research and analytics consulting companies servicing the Pharma & Biotech companies. During her career that spans two decades, she focused on primary and secondary market research methods and forecasting. Fatma holds a BSc degree in Chemistry from Bogazici University and an MBA from University of Miami.

 PharmaVentures Ltd.

FINTAN WALTON
CEO

In 1992 Dr Walton co-founded CONNECT Pharma, a predecessor company to PharmaVentures focused on assisting pharmaceutical and biotechnology companies worldwide in all aspects of deal making. In 1997 this company became PharmaVentures. Since its inception, PharmaVentures has worked with blue chip clients on a global basis, delivering more than 700 assignments for companies in 38 countries. Clients have included major pharmaceutical and biotechnology companies as well as diversified chemical corporations, medical device, generic and OTC companies. Its clients have included major banks, investment/merchant banks, and private equity and venture capital groups. In 1996 he also founded PharmaDeals, the leading database and publishing business related to dealmaking. Thousands of customers from around the world have either bought or subscribed to these PharmaDeals publications. PharmaDeals was sold to IMS Health in Aug 2012.


 VISCHER AG

FIONA (YUE) GAO
Manager of China Life Sciences Group

Fiona focuses on cross-border transactions (foreign direct investment, M&A, corporate and commercial) and Life Sciences. She advises Swiss and international clients, in particular Chinese clients, of all sizes.

With 10 years of multi-jurisdictional legal advisory experiences in leading law firms and in-house team of multinational companies, she brings a unique and comprehensive legal expertise to Sino-Swiss clients.

www.sachsforum.com
Florence Dal Degan joined Novo Nordisk A/S in May 2016 as External Innovation Director. The R&D External Innovation team of Novo Nordisk is global, with a presence at the Danish Headquarters, as well as a regional presence in Shanghai, Boston, New-York and Paris. Florence is based in Paris and is responsible for search and evaluation of new opportunities within Europe and Middle-East across the therapeutic areas that Novo Nordisk is dedicated to, such as diabetes, obesity, NASH, chronic cardio-vascular diseases, nephropathy and haemophilia. Florence has a PhD in biochemistry from The National Institute of Agronomy (Agro-Paris Tech, France). She has over 20 years of experience in Research and Development in academic, biotech and pharma environments. Since 2000, Florence has worked with drug discovery and early development and has held several leadership positions within R&D. She has been working with external innovation since 2012.

Frauke is co-founder and Chief Business Officer of Adrenomed AG since 2011, heading and executing all business development and marketing activities leading to the vision to become a leader in targeting vascular integrity for treating life threatening diseases. In that position she is overseeing company business planning and execution, company and product positioning and fundraising (last raise 24 Mio€ in Nov 18). Prior to that she was Director R&D at BRAHMS AG / Thermo Fisher Scientific and responsible for financial and strategic planning and coordination of global R&D projects in the field of innovative biomarkers in cardiology, liver disease, sepsis and neurodegeneration. Before joining BRAHMS she build up and led the team responsible for assessment and managing of R&D product grants of life science companies in Brandenburg and advised financing and strategic planning for innovative bio-/medtec start-ups at Brandenburg Economic Development Board, Germany.

Frauke studied Biology, Philosophy and Linguistics at the Westfälische WWU Muenster with a Diploma in Biology and a Ph.D. in Biology about molecular plant-pathogen interactions at the Institute of Biochemistry and Biotechnology of Plants. She is currently Jury Member of the innovation award Berlin-Brandenburg, Member of the Board of Trustees of Technology Foundation Brandenburg and Board Member of the research alliance InfectControl2020 in Jena, Germany, granted by the German bmbf to developing new strategies for the early recognition and control to fight infectious diseases.

Gabe Cavazos is a Managing Director in Investment Banking at SVB Leerink. Mr. Cavazos joined SVB Leerink in 2008 from J.P. Morgan where he was a member of the Mergers & Acquisitions group in the New York office. He covers East Coast and European biopharma companies and has 10+ years of transaction experience, including more than 80 transactions across M&A advisory, equity and equity linked financings. Prior to J.P. Morgan, Mr. Cavazos spent eight years in the pharmaceutical industry at Merck and Pfizer. Mr. Cavazos earned his M.B.A. from the Kellogg School of Management at Northwestern University and a B.S. from The University of Michigan.
**Abingworth LLP**

**GENGHIS LLOYD-HARRIS**
Partner

Genghis joined Abingworth in 2004 from Credit Suisse First Boston (CSFB) where he was a Managing Director in the European Equity Research Group based in London. Genghis was responsible for coverage of the European biotechnology industry and was ranked first for Pan-European Biotechnology in the Institutional Investor surveys each year from 2001 to 2003. Before joining Equity Research at CSFB, he worked for CSFB’s Health Care Group in the Investment Banking Division in New York. Genghis was previously a paediatrician in Melbourne, Australia. Genghis holds a Medical Degree from the University of Liverpool in the UK, a PhD in Clinical Pharmacology from the University of Melbourne, Australia, and an MBA from Harvard Business School. Genghis’ current and past board positions include Avilion, GenSight Biologics, Healthcare Brands International, Nouscom, Novexel, Solexa, Synosia, Syntexin and Wilson Therapeutics.

---

**Medicxi**

**GIOVANNI MARIGGI**
Partner

Giovanni is a Partner at Medicxi and has been with the firm since its inception in 2016. Prior to Medicxi, Giovanni was a Principal at Index Ventures for four years, having joined in 2012. He led Medicxi’s investment in Osveva and currently serves on the boards of a number of portfolio companies, including Gadeta, SuperX, Kymo Therapeutics and Janpix.

Prior to joining Index, Giovanni was at Cancer Research UK’s London Research Institute (now the Crick Institute) where he conducted research on vascular biology and angiogenesis, whilst also delivering competitive intelligence projects in oncology as an independent consultant to various biopharma.

Giovanni received a BSc in Biochemistry from Imperial College London and a PhD in Biochemistry and Molecular Biology from University College London.

---

**Cantargia AB**

**GÖRAN FORSBERG**
CEO

Dr Göran Forsberg has been CEO for Cantargia since 2014 and was responsible for Cantargia’s IPO in 2015. In total more than 50 M€ has been raised. Cantargia’s lead project is an immuno-oncology antibody in phase Ia clinical development focused on non-small cell lung cancer and pancreatic cancer. Dr Forsberg has a PhD in biochemistry, and is an associate professor and author of over 40 scientific publications. He has worked for pharmaceutical and biotechnology companies for 30 years in various positions, including at KabiGen, Pharmacia, Active Biotech and the University of Adelaide, Australia. He has a large amount of drug development experience, with a special focus on oncology. Dr. Forsberg also has significant experience in business development from previous engagement as Chief Business Officer at Active Biotech AB. He is a board member of Isogenica Ltd and AIM Pharma AB.
Johnson & Johnson Innovation | Janssen Business Development

GREGOR MACDONALD
Senior Director, Neuroscience Scientific Licensing

Dr. Gregor Macdonald graduated with a B.Sc. (Hons.) degree in Organic Chemistry from Edinburgh University in 1992, before joining the Medicinal Chemistry department of the Wellcome Foundation in London. In 1994, he moved to the University of York where he obtained his Ph.D. in natural product synthesis in 1997. Between 1997 and 2004, he worked for SmithKline Beecham and then GlaxoSmithKline, playing a prominent role in leading discovery programs within both the Psychiatry and Neurology disease areas towards the identification of several late stage clinical candidates.

In 2004, Dr. Macdonald joined Janssen Pharmaceutica in Belgium, to lead the Psychiatry Medicinal Chemistry team and then later a combined Psychiatry and then Neuroscience team. From 2007 to 2016, Dr. Macdonald was head of Neuroscience Medicinal Chemistry in Europe, leading teams in Beeser (Belgium) and Toledo (Spain) in the identification of multiple clinical candidates from the mGluR and PDE programs, together with supporting significant research efforts to develop disease modifying treatments for Alzheimer's disease, including BACE inhibitors and gamma-secretase modulators. In 2016, Dr. Macdonald moved into Janssen Business Development to lead Neuroscience Scientific Licensing. Throughout his time within Janssen, Dr. Macdonald has been involved in managing several external drug discovery collaborations, including those with Addex Therapeutics, the Vanderbilt Centre for Neuroscience Drug Discovery, Shionogi, Neurosearch and Evotec. He is a co-author and co-inventor on over 100 scientific publications and patents and has been an invited speaker and panelist at several international conferences.

IKU

GREGORY RIGANO
Founder & CEO

Gregory has provided counsel to over $1 billion in transactions for drug and software R&D, at global scale, often working closely with eminent scientists (National Academy of Science in the U.S. and Taiwan, Nobel teams) and multi-national corporations in bringing novel biochemistry to the market. He currently serves as advisor to Stanford SPARK Translational Research Program and is collaborating with Oxford Innovation to establish a similar low-cost-at-scale bio r&d approach. Gregory’s experience as an intellectual property lawyer for both software and biotechnology aided in designing IKU’s blockchain enforcement licensing mechanism general architecture. His current responsibilities as CEO for IKU are network development and scientific relations. Ultimately, Gregory is a biohacker and his focus is to decentralize computation to end aging.

BioNTech SE

HOLGER KISSEL
Vice President Business Alliances

Dr. Kissel received his initial training at the Universities of Mainz and Hamburg, and his PhD at the Memorial Sloan Kettering Cancer Center in New York City. After postdoctoral training at the Rockefeller University he joined Artemis Pharmaceuticals (now Taconic) in 2005 in Project Management and Business Development roles. In 2013 Dr. Kissel joined BioNTech as Director of Business Development to build BioNTech’s pharma collaborations and help advance the company through its early funding rounds. Currently Dr. Kissel is managing BioNTech’s global partnerships in his role as Vice President Business Alliances, including partnered programs with Sanofi, Pfizer, Eli Lilly, Genentech/Roche, Genmab and Bayer.
Boehringer Ingelheim Venture Fund GmbH

ILKA WICKE
Investment Manager

Ilka has studied organic chemistry and obtained her PhD from the Johann Wolfgang Goethe University in Frankfurt. Following her graduation she spent a year in academic research as a postdoctoral fellow at the Sloan Kettering Cancer Center in New York investigating retroviral gene therapy approaches. She joined Boehringer Ingelheim in 1996 as head of an interdisciplinary research laboratory specializing in new drug discovery approaches. Thereafter, Ilka spent more than 13 years in the Corporate Licensing Division of Boehringer Ingelheim where she was responsible for the evaluation, negotiation and the management of several global licensing transactions. In 2009, Ilka participated in the creation of the Boehringer Ingelheim Venture Fund as a strategic component of Boehringer Ingelheim and has since then been an active Investment Manager in the Fund.

Over the last years, Ilka has been involved in several investments of the fund. She served as board member of Promethera Bioscience in Brussels and Pcovery in Copenhagen. She is currently on the Boards of Metabomed in Tel Aviv, Cardior Pharmaceuticals in Hannover, AgomAb in Ghent and Anagenesis in Strasbourg. In addition, she is member of the Investment Committee of the High Tech Gründer Fund (HTGF III) the largest publicly backed Seed Investment Fund in Germany based in Bonn.

Staatz Business Development & Strategy

IRINA STAATZ-GRANZER
Owner & CEO

Irina Staatz has more than 20 years of business development experience and has successfully negotiated a broad variety of global, regional and local agreements with an aggregate deal value exceeding USD 1.7 BN.

She and her team advise and support leading VC firms as well as international biotech and pharmaceutical companies in the strategy and the operations of their project / product licensing, collaborations and divestment/acquisitions including M&A on both, the sell and the buy side. Further, the market access group within her team supports and advises clients specifically regarding market access strategy and operations in Europe.

Prior to her own business she held various industrial C level positions (including CEO/VP) at Hermal (Merck KGaA), Boots Healthcare International, Knoll (later Abbott), Scil Technology, U3 Pharma, Blink Biomedical.

She is Vice Chairman of Innate Pharma, France and Chairman of Talix Therapeutics, Belgium.

Silicon Valley

IAN MURCHIE
Director

Ian Murchie is a Director of Life Sciences and Healthcare at Silicon Valley Bank’s UK Branch. He works with Life Sciences businesses based across Europe ranging from early growth-stage through to established multinational businesses. As part of an international team he helps clients with innovative financing solutions through the bank’s broad platform of investment & commercial banking.

Prior to joining SVB, Ian worked as a Director in the Barclays Corporate Healthcare team where he helped to establish a lending practice to later stage Biotechnology companies.
Versameb Ltd.

ISABEL FERREIRA
Chief Business Officer

Dr. Isabel Ferreira joined Versameb in August 2019 as Chief Business Officer. Previously, she served Roche Partnering as Director Global Business Development. In this role, she had broad responsibility across Pharma Business Development including strategy, search, evaluation, senior stakeholder management, leading cross-functional due diligence and negotiation teams to deal closure. Before joining Roche, Isabel served as Senior Director Business Development at Prosensa. During this time, she was instrumental in establishing transformative licensing transactions, supporting non-dilutive and private financing events, managing (The Netherlands).

HBM Partners AG

IVO STAIJEN
Head Public Equity, Portfolio Manager

Ivo joined HBM Partners in 2003 as Investment Advisor for the biotechnology and pharma sector. He currently heads up the Public Equity team at HBM Partners and is Portfolio Manager of the HBM Global Biotechnology Fund. HBM Partners acts as advisor to, and fund manager of, several healthcare funds, the best-known of which is HBM Healthcare Investments. Prior to HBM Partners, Ivo worked as a senior biotechnology analyst at Bank Sarasin, and before that as a Department Head at MDS Pharma Services Switzerland. Ivo studied chemistry at the University of Groningen, the Netherlands, and was a visiting scholar at the Department of Biology at MIT in 1991. He obtained his PhD in Biology from the ETH in Zurich, Switzerland, in 1996. He has over 18 years’ experience in investment management and research and is a CFA Charter Holder since 2004.

Innovate Biopharmaceuticals, Inc.

JAY MADAN
Founder, President & CBO

Mr. Madan founded Private Innovate in 2012 and began serving as its president and as a member of its board of directors at such time, and he became our president and a member of our board of directors in connection with the completion of the Merger. In March 2018, Mr. Madan was also appointed as our chief business officer and serves as our interim principal financial officer and interim principal accounting officer. Prior to founding Private Innovate, Mr. Madan was an independent contractor advising multiple life sciences companies, including Reliance Life Sciences, Millipore, Baxter, Dade Behring and Goodwin. This experience in working across multiple teams led him to develop a global network of healthcare professionals. From July 2007 to November 2008, Mr. Madan served as the vice president of business development at Reliance Biopharmaceuticals Pvt. Ltd., a part of Reliance Industries Ltd., India's largest conglomerate. While at Reliance and Goodwin, Mr. Madan was focused on the development of their contract manufacturing businesses. Mr. Madan holds a B.S. in chemical engineering from University of Mumbai and an M.S. in chemical engineering from Washington State University. We believe that Mr. Madan’s role as a founder of Innovate and extensive experience in the life sciences and biotech industries qualifies him to serve on our board of directors.
Boehringer Ingelheim International GmbH

JEAN-CHRISTOPHE AUDONNET
Senior Director, Vaccines R&D

Jean-Christophe AUDONNET obtained his DVM degree at the Veterinary School in Alfort, Paris, France in 1980. After 2 years of practice, mainly in the large animal production field, he went back to the University for a Ph.D. in Molecular Bacteriology. Dr. Audonnet has also a degree in Molecular Virology from Institut Pasteur Paris, France, and Masters certificates in Molecular Biology, Genetics, and an Immunology.

After 3 years spent at Virogenetics, Albany, New York, USA as a member of the research team who did the pioneering work on the modified vaccinia (NYVAC) and canarypox (ALVAC) vaccine vectors, Dr. Audonnet came back to Lyon, France where he held a number of positions as Head of research labs and Head of Discovery Research for Rhône-Mérieux and then Merial between 1992 and 2008. During these years, Dr. Audonnet has been in charge of various veterinary vaccine research projects which led to the development of successful commercial products, Vaxxitek being a key one. He was then, as Head of Research Strategy and Key Alliances for Bio R&D, in charge of scouting and assessing new technologies in the fields of vaccinology and immunogens expression platforms.

Apollo Ventures

JENS ECKSTEIN
Managing Partner

Jens has more than 15 years of venture capital experience in biopharma and 10 years of operational experience in drug discovery and development. Jens is a Kauffman Fellow and a mentor for life science entrepreneurs and start-up teams in the area of innovative life science and healthcare IT companies.

Before joining Apollo Ventures, Jens served as President of SR One for eight years. He is also co-founder and Managing Director of Action Potential Venture Capital (APVC). Previously, Jens was a General Partner at TVM Capital leading early-stage investments in Boston and was CEO and President of SelectX Pharmaceuticals. Before his investment career, Jens was leading research teams and pharma collaborations at Enanta Pharmaceuticals (NASDAQ: ENTA) and Mitotix.

GeNeuro SA

JESÚS MARTÍN-GARCÍA
Chief Executive Officer

Jesús began his career in 1983 at the World Economic Foundation, and in 1989 at McKinsey & Co where he led studies in the pharmaceutical and food industries.

By 1993, he chose the entrepreneurial path by creating, investing and leading start-ups in Switzerland and the United States. He was for example a co-founder of LeShop in 1996, which became the Swiss leader in e-commerce and was sold to Migros.

In 2003, he created Eclosion, a public-private partnership for translating scientific discoveries in the field of life sciences into innovative drugs with disruptive potential. This unique structure was instrumental in the creation of GeNeuro, which was led by Jesús since its creation in 2006. Jesús holds a bachelor’s degree in industrial sciences, a master in law from Geneva University and an MBA from Harvard Business School. He serves on the board of several biotech companies and industrial and business associations.
AbbVie, Inc.

JOACHIM VOGT
Director, Search & Evaluation, Western Europe

Joachim Vogt is Director Search & Evaluation Western Europe at AbbVie. He is responsible for the identification of European business opportunities across all indications and technologies of interest for AbbVie and serves as key contact for European partners, including academic institutions, biotech companies, venture capital, governments and non-profit organizations.

Joachim spent more than 15 years in the pharmaceutical and biotech industry in BD and research roles. He gained broad experience in- and outlicensing of preclinical and clinical projects as well as research technologies. Before joining AbbVie, Joachim was Director of Early Stage Partnering at Roche, served as Senior Manager at Wilex AG and was Head of IP Licensing at the tech transfer office Bayerische Patentallianz. Joachim holds a diploma in chemistry and received his PhD in protein crystallography at the University of Freiburg.

BeiGene Ltd.

JOHN ADAMOU
Vice President, Business Development

Mr. Adamou has over 20 years of business development, strategic transactions, and scientific experience in the pharmaceutical and biotechnology industries. Prior to joining BeiGene, Mr. Adamou was Vice President of Corporate and Business Development at rHEALTH LLC, where he led the corporate and business development strategy from 2017 to 2019. Prior to rHEALTH, Mr. Adamou spent sixteen years with Boehringer Ingelheim Pharmaceuticals as Head of Strategic Transactions and Alliance Management located in Connecticut. In that role, he led a transaction team responsible for structuring, negotiating and managing global partnerships. He has an established track-record and experience with a broad array of deal structures across various therapeutic categories including, platform technologies, R&D collaborations, co-development and commercialization alliances, IP licenses, equity investments, and out-licensing arrangements. Before Boehringer Ingelheim, Mr. Adamou began his business development career in 2000 at MedImmune. Earlier in his career, Mr. Adamou held various research roles of increasing responsibility with MedImmune, SmithKline Beecham Pharmaceuticals, and Allelix Biopharmaceuticals. Mr. Adamou holds B.S. and M.S. degrees in Molecular Biology and Genetics from the University of Guelph, Canada, and an M.B.A. Mr. Adamou resides in New Milford, Connecticut with his wife, Julie, two sons, Nick and Matt and daughter, Lindsey.

EIT Health e.V.

JOY CÜRTEN
Business Creation Manager

Joy Cürten has been nurturing EIT Health start-ups as a Business Creation Manager for almost three years. In this time more than 500+ start-ups have been supported. Specifically, she continues to shape the financial programs EIT Health has to offer which include the part-European Investor Network, the European equity Crowdfunding Platform by Aescuvest (powered by EIT Health) and the Gold Track program for highly scalable start-ups. As a Silicon Valley native, with additional academic degrees in Public Health and Microbiology, Joy has a keen interest to create start-up pathways so investment, impact and clinical need can triumph.
Faron Pharmaceuticals Ltd.

**JUHO JALKANEN**
Chief Development Officer

Dr. Jalkanen holds degrees from both Business and Medical School. Dr. Jalkanen is specialist in vascular surgery and has a PhD from molecular biology. Dr. Jalkanen has published over 20 peer-reviewed research articles and conference papers, and has written a book on strategic groups in the biopharmaceutical industry. By heart Dr. Jalkanen is a practitioner, but now works to bring new treatments to life on the industry side. Dr. Jalkanen is one of the founding member of Faron Pharmaceuticals and prior to joining the company full time in 2017 he served on the Board of the Company from 2014 to 2017. During the past 15 years Dr. Jalkanen has gained vast experience in all aspects of the value chain of drug development from preclinical to translational and clinical studies. He is also well experienced in market research and valuation of research projects and clinical programs for their commercial application and marketability.

KPMG

**JUEMIN ZHU**
Head of China Desk Switzerland

Juemin is Head of China Desk at KPMG Switzerland. With a broad set of experience in strategy and M&A consulting, she bridges and leads cross-border investment and business between Switzerland and China. Juemin is well connected and positioned in the Swiss-Chinese business community. She has acquired 12-years of comprehensive experience with international projects in 14 countries. Prior to joining KPMG, Juemin worked for Fosun, a Chinese international conglomerate and investment company, as Associate Director for European Investments. She holds a Master degree in Mechanical Engineering from Karlsruhe Institute of Technology, Germany.

IATI (Israel Advanced Technology Industries)

**KARIN MAYER RUBINSTEIN**
President & CEO

Karin Mayer Rubinstein is the President & CEO of IATI, Israel’s Umbrella Organization of the High-tech, Life Science and other advanced technology industries, with hundreds of paying members from every level and aspect of the ecosystem, including Venture Capital Funds, Israeli R&D Centers of Multinational Companies, Start-Ups, Incubators & Accelerators, leading global Stock Exchanges, Tech Transfer Organization, Academic Institutions, Innovation Centers, Hospitals, Municipalities, service Providers and more. Through this broad range of members, IATI connects Israel’s tech ecosystem, provides solutions and support at all levels, and integrates the various sectors of the industry with strategic and ongoing governmental goals.

Prior to her current position, Karin served as a senior partner and managing director of business development in leading commercial law firms.

Karin is a member of steering committees and a keynote speaker of many leading global events and conferences around the world. She is a member of the board of Governance of Tel Aviv University; a Director in the Israel-America Chamber of Commerce; a Co-Founder and Co-Manager of Israel 2048 Council, a union of civil and business organizations which act to create a whole vision for the State of Israel; a member of the 5X2 Initiative’s Steering Committee; a Council for the Advancement of Women in Science and Technology of the Ministry of Science and Technology; an Honorary Ambassador of GISEP; and more.

Karin is a keynote speaker at many leading global conferences. She regularly sits as a jury member in leading technology competitions and awards worldwide.

Karin holds a BA in Economics, an LLB and an MBA from Tel-Aviv University. Karin was named, twice in a row, as one of the Top 100 Influential Young Business Persons in Israel by Forbes Magazine, as well as one of the Marker’s Top 40 Leading Young Business Persons.
Ekaterina (Katya) Smirnyagina is a partner with the Capricorn Health-Tech Venture Fund. Prior to this she was with Alta Partners, a US healthcare focused venture firm. Her current and past board memberships include Adocia (Euronext: ADOC.PA), Con-foTherapeutics NV, HalioDx SA, ISTAR Medical SA, Nexstim plc, Abylnx, Cerenis Therapeutics, Innate Pharma and Kiadis Pharma. Katya is also on the board of InvestEurope (fka EVCA) and is the current Chair of its VC Council. Previously she has worked in business development at Genset S.A. and management consulting at the Mitchell Madison Group. Katya was a postdoctoral fellow in microbiology & immunology at the Stanford University School of Medicine and holds a Ph.D. in cellular & molecular biology from the University of Wisconsin-Madison and a B.Sc. in biochemistry from Moscow State University.

Kjell Stenberg, PhD served as a partner of the Canadian investment fund Medwell Capital Corp. At BioMS Medical Corp. he was the Chief Operating Officer developing a new drug in phase III studies for MS. In 2008 BioMS entered into a partnership with Eli Lilly that was awarded Licensing Deal Of the Year by Scrips. Previously, Dr. Stenberg was the Chief Executive Officer and founder of Combio A/S in Denmark. Dr Stenberg’s engagements in drug discovery and development also include Chief Science Officer at Cepep AB, later merged into Orexo AB in Sweden, founder of Celus Pharmaceuticals, USA and founding partner of Accueo AB, Sweden. From 1975 to 2000, Dr. Stenberg served as Senior Researcher and Manager at Astra/AstraZeneca, where he was instrumental in bringing various drugs to market in the capacity of Director of Research and Development and as Global License director. Neurology He is Chairman of Aptaem AB and board member of Novation Pharmaceuticals.

Klaus Wilgenbus has worked for more than 25 years in the biopharmaceutical industry and served most recently as CEO of Biosilu Healthcare AG and held leading management positions at Boehringer Ingelheim for many years, including Global Head of Business Development, Licensing and Strategy. Klaus Wilgenbus has gained significant management experience covering General Management, R&D, Business Development, Corporate Venture Capital and Corporate & Commercial Strategy. Klaus Wilgenbus was trained as a Medical Doctor in Germany and the US.
Dr. Laura Corradini received her degree in medicinal chemistry and pharmaceutical technology, and qualified as pharmacist at the University of Milan (Italy). Subsequently, she obtained her PhD in biotechnology at the same university.

Dr. Corradini worked for more than ten years in research at Schering-Plough and Pfizer developing drug discovery expertise in several CNS therapeutic space: neurodegeneration, psychiatry and chronic pain. Since joining Boehringer Ingelheim (BI) in 2009, she has held several positions as CNS Pharmacologist for pain and ophthalmology.

Dr. Corradini currently acts as Deputy Global Head of Business Development & Licensing CNS. She is responsible for search and evaluation of partnering opportunities in the therapeutic area CNS with focus to innovative programs addressing unmet medical needs in neuropsychiatry. Dr Corradini is chair of a BI’s cross-functional CNS Licensing Advisory Committee and champion of the next generation of Life-Science Innovators by leading Grassroots initiative in UK.

The strategic partnering focus of Dr. Corradini and her team is novel therapeutic approaches to treating neuropsychiatric disorders.
Galilee Cannabis Consortium

LAURA HERSCHLAG
Manager

Laura is a highly skilled marketing and communications professional who has served in management level roles in multiple companies as well as managing her own boutique consultancy. Laura has a particular passion for working with technology oriented initiatives, supporting the strategic goals of innovative companies and entrepreneurs. She has extensive experience in market research, strategy, planning, implementation, communications, and lead generation in various industries.

Laura is currently leading the establishment of a vertically integrated medical cannabis operation for the Galilee Development Company, the economic development arm of 35 kibbutzim in northern Israel. Prior to this position, she served as director of business development at BOL Pharma where she identified potential partners and cultivated relationships that led to the signing of overseas significant sales contracts. Laura has developed and continues to cultivate a worldwide network of connections in the medical cannabis, foodtech, and ag tech industries and has acquired extensive knowledge on business and regulatory environments around the world.

Laura holds an MBA from the joint Northwestern and Tel Aviv Universities Kellogg-Recanati executive MBA program and a BA in Social Psychology from Hampshire College, Massachusetts. Born in the United States, Laura came to Israel for the first time at the age of 18 and moved there in 1982.

Athira Pharma, Inc.

LEEN KAWAS
President & CEO

Leen Kawas has led the company in business and financial growth through two oversubscribed financing rounds. The funds raised will support and accelerate growth of the company and take the lead candidate through the early stages of human testing.

For her leadership and accomplishments at Athira, Leen has won many awards and recognitions including: Selection as Young Leader by the French-American Foundation (2019), GeekWire Startup CEO of the Year (2019), 40 under 40 in Life Science Leader (2017), PharmaVOICE 100 honoree (2017), Entrepreneur of the Year award from the Association of Washington Business (2016), was selected as one of EY’s Winning Women Entrepreneur (2016), 40 under 40 award from the Puget Sound Business Journal (2016), Entrepreneur of the Year Finalist for EY (2016) and a Young Entrepreneur of the Year Finalist for GeekWire (2016). She was named one of Seattle’s Most Influential People by Seattle Magazine (2015) and one of the Women to Watch in Life Sciences by the Washington Biotechnology and Biomedical Association (2015). As a company, Athira was also a finalist for Health Innovation of the Year (2019) and one of Seattle’s 10 hottest startups(2016), both by GeekWire.

She also serves on multiple boards, including the Washington Governor’s Life Science Advisory Board, Scientific Review Board for the Alzheimer’s Drug Discovery Foundation and Alzheimer’s Association-Washington Chapter Board. She also co-chairs the International Alzheimer’s Association Business Consortium.

She earned a doctorate in molecular pharmacology from Washington State University in 2011, and received the Harriett B. Rigas and Karen DePauw awards for academic achievement and leadership skills. She holds a Doctor of Pharmacy (PharmD.) from the University of Jordan (2008). Dr. Kawas also completed the Executive Training Program at the Foster School of Business, University of Washington (2014).
**Boston Consulting Group**

**LORENZO POSITANO**
Managing Director & Partner

Lorenzo Positano leads Boston Consulting Group’s Health Care practice in Italy, Greece, and Turkey, and is a core member of BCG’s global Health Care and Operations practices with a focus on biopharma operations. Lorenzo has extensive experience in leading strategic, operational, and organizational transformations, both in solution design and implementation, having worked on many projects in the EU, the US, the Middle East, and Asia. He has led projects for leading companies in the pharma and medtech sectors.

In his recent work with global pharmacos, Lorenzo has worked on several diagnostic, solution design, and transformation programs for operations functions, covering manufacturing, quality, and supply chain management. He has also supported several operations strategy programs, footprint network optimizations, turnarounds, and digital transformations.

Before joining the firm, Lorenzo worked for nine years at McKinsey & Company, and for three years at Accenture.

Areas of Expertise: Digital transformation, Postmerger management and integration in pharma, Compliance programs, Governance model design, Pharma operations strategy, Network optimization, COGS optimization

Education: Master of Finance, Istituto per l’attività educative

MSc, Industrial Engineering, magna cum laude, University of Federico II

---

**Locust Walk**

**LUBOR GAAL**
SVP, Head of Europe

Lubor Gaal, PhD is Head of Europe at Locust Walk, a global life science transaction firm with offices in Boston, San Francisco, Tokyo and Europe. Over the last 10 years, we have worked with many Biopharma and MedTech clients to secure the right partner for their assets, access capital or acquire new assets prior to doing an IPO or trade sale. Lubor is responsible for all activities in Europe from executing licensing to M&A and financing transactions for European biotechnology or pharmaceutical companies.

Lubor has been doing business development for biopharma companies in Europe and the USA for more than 20 years. Prior to joining Locust Walk, he was the Head of External Innovation and Licensing and a member of the R&D Management Committee at Almirall. From 2006 to 2015, Lubor held various senior BD positions at Bristol-Myers Squibb such as Global Head of Fibrosis, Neuroscience, Immunoscience and Head of Europe, Search and Evaluation. Before that, he held executive management roles at CNS company Neuro3d in France and for Immuno-Oncology company Vectron Therapeutics AG in Germany. In the US, Lubor was the Head of CNS and CV Licensing for Schering AG (now Bayer) in New Jersey and advised and transacted for biotechnology and pharmaceutical companies at Burrill & Co. in San Francisco, California.

Lubor has a B.Sc. in Neuroscience from the University of Sussex in the UK and a Ph.D. from the University of California at Berkeley, USA.
BeiGene Ltd.

**LUSONG LUO**

SVP & Head of External Innovation

Dr. Lusong Luo is currently SVP & Head of External Innovation at BeiGene. Prior to taking this role, Dr. Luo is SVP & Head of Discovery Biology at BeiGene. Dr. Luo is one of the founding scientists of BeiGene. Before joining BeiGene, Dr. Luo held positions in BioDuro as Sr. Director and Director of Discovery Biology. Dr. Luo has also spent a number of years at GlaxoSmithkline Oncology CEDD, where he served as Group Manager, Research Investigator, and Principal Scientist.

Dr. Luo was a key member of a number of oncology drug discovery/development teams that have contributed to the discovery and development of around a dozen clinical compounds over the years.

Dr. Luo has published over 50 research papers, reviews, and book chapters. He was trained with Professo. Christopher T Walsh at Harvard Medical School and obtained his Ph.D. in Biochemistry from University of New Mexico.

STALICLA S.A.

**LYNN DURHAM**

Founder & CEO

Lynn has founded STALICLA on May 29th, 2017. STALICLA is a near clinical Swiss Biotech Company developing a unique approach to bring personalized medicine to patients with Autism Spectrum Disorder (ASD). Today, patients with ASD account for 1-1.5% of the world population. The condition remains a high unmet medical need.

Driven by her lifelong involvement with the autism community, Lynn Durham has initiated a paradigm shift in the field of neurodevelopmental disorder drug discovery. In founding STALICLA, she kick-started the creation of a unique corporate structure including an AI discovery platform and a drug development unit to bring personalized medicine to patients with Autism and other ill-defined conditions. In less than 3 years, the STALICLA platform has already proven successful in expediting and derisking drug development for a first group of patients with Autism. This first subgroup of patients has been biologically validated and the corresponding drug products identified by the STALICLA platform will be entering clinical trials in the US in early 2020. In parallel, Lynn has federated an exceptional network of research and clinical partners including top-tier US and European academic centers and hospitals.

Furthermore, Lynn raised CHF 10M in Series A and is securing an additional Circa CHF 8M to support STALICLA’s development.
IO Biotech ApS

MAI-BRITT ZOCCA
Founder & CEO

Mai-Britt Zocca is CEO of IO Biotech. She has participated in founding and co-founding of several biotech spinouts and has held several executive positions in the industry. Mrs. Zocca holds a PhD in tumor immunology and a Master Sc. in Biochemistry receiving her PhD from the Institute of Medical Microbiology and Immunology, University of Copenhagen, and the NIH, National Cancer Institute, Maryland, USA.

Mai-Britt Zocca has more than 15 years of experience in translational immunology (Immuno Oncology) and has published more than 25 articles in peer reviewed international journals. Furthermore, she is an inventor of several patents.

Mai-Britt Zocca has focused her work on translational immunology especially for the development of immunotherapies for cancer diseases. She has been involved in several clinical studies and is also focused on biomarker discovery in immunotherapy. Participates in a taskforce consisting of several EU and US clinical departments and the FDA.

Sosei Heptares

MALCOLM WEIR
Executive Vice President & Chief R&D Officer

Malcolm has extensive career experience and expertise in drug discovery and development. He was the Head of Biomolecular Structure and then the Molecular Sciences division of GlaxoWellcome with responsibility for 300 people engaged in target validation and lead discovery. During this time, he pioneered the application of structural biology and modelling to drug discovery, resulting in the advancement of clinical candidates to a wide range of diseases.

Malcolm joined the structural bioinformatics and drug discovery company Inpharmatica Ltd as CEO in 2000, growing it from the spin-out stage to a 100-person company which was sold to Galapagos NV in 2006. He then joined MRC Technology in 2006 to establish Heptares Therapeutics Ltd in July 2007, as Co-Founder and CEO.

Malcolm has been Visiting Professor of Biochemistry at Imperial College, London since 1997 and advises on translational sciences and structural biology at the same university. He served on the Council of the UK Biotechnology and Biological Sciences Research Council from 2004 to 2011, and continues to advise the UK Government periodically on biotechnology issues. He received the Malcolm Campbell Memorial Prize 2015, awarded by the UK Royal Society of Chemistry’s Biological and Medicinal Chemistry Sector, in recognition of his contribution to GPCR drug discovery. In 2016, he received an honorary DSc from the University of Hertfordshire for services to research, and is a Trustee of the Biochemical Society. He has published over 70 papers and patents.
Gain Therapeutics SA
MANOLO BELLOTTO
General Manager

As an international life sciences executive, he is devoted to science, medicine and market access in such a way that he values bringing together various stakeholders and functions in order to build value and give a sustainable and responsible access to innovation in healthcare.

He holds a Ph.D. in molecular developmental genetics from the University of Zurich after having studied at The Biocentre of the University of Basel and at the Fredrich Miescher Institute for Biomedical Research in Basel.

Among others, Manolo worked for Vifor Pharma, Helsinn Healthcare, DKSH and the European Society of Medical Oncology and has consulted for international projects for companies such as Abbott, Celgene, BMS, GSK, Loxo Oncology, Teva.

Manolo has an international Rx pharmaceutical experience encompassing product, medical and advocacy development, commercialization and international research collaborations in major and rare/orphan disease indications across various continents.

General Manager – Gain Therapeutics SA, Lugano - Switzerland

Senolytic Therapeutics, Inc.
MARC RAMIS CASTELLORT
Co-Founder & CEO

Marc is passionate about creating new ventures in the life sciences field. He is a co-founder and CEO at Senolytic Therapeutics Inc., a pharmaceutical company that develops a novel class of medicines by targeting senescence cells. He is also supporting investments and strategic partnerships at Life Biosciences Inc. in Europe. Currently, Marc is a strategic advisor at Ninevah Therapeutics, Cebiotex, Retinset Therapeutics and Origen Ventures. He is a co-founder and Partner at Chasing Science, an early-stage biomedical venture builder. Marc is also a founder and Advisor at Tech & Business Innovation (TBI), an academic firm focused on knowledge exchange and corporate-academic partnerships. Marc brings experience as advisor and board member for multiple organizations and as co-founder of several companies. Marc has implemented Entrepreneurs-in-Residence programs at several academic institutions such as IRB Barcelona. From 2010 to 2012, Marc was working for Isis Innovations/University of Oxford as an associate consultant in Spain and LATAM. From 2007 to 2011, Marc was working at Endor, a nanomedicine company based in Spain. During this period, he was R&D director (drug-delivery nano-systems for cancer therapy) and Business Development Director (launched several nanotechnology products to the cosmetic and textile markets).

Previously, Marc also worked in the pharmaceutical environment in Novartis. He also collaborated with other research institutions such as Cancer Research UK and Boston College during his academic career. Marc gained a DPhil in Biochemistry from the University of Oxford in 2006, and a Harvard Business School PLD Program in 2011. Marc also gained a M.Sc. in Chemical Engineering in 2001 and a B.Sc. in Chemistry from IQS (Barcelona) in 2000.
Maria Gabriella Camboni MD, is currently CEO of BiovelocITA, member of the Board of Director Mission Therapeutics, and Genenta Science. She was until 2013 the Chief Operating Officer of EOS, a start-up company devoted to translational research in oncology that she co-founded with Silvano Spinelli in 2006; EOS was sold to Clovis Inc. in 2013.

She previously held various positions in the pharma industry, starting as Clinical Project Leader at Sandoz (subsequently Novartis), Head of Clinical Oncology at Boehringer Mannheim, Head of Development at Novuspharma (a spin out company of Boheringer Mannheim she co-founded and that is now Cell Therapeutics), Head of Medical Affairs Europe at Novartis Oncology.

Prior to joining the industry, Gabriella was fellow («borsista») at the Istituto di Scienze Mediche at the University of Milan.

Gabriella obtained her MD from the University of Milan and she is a board-certified gastroenterologist and clinical pharmacologist.

Dr. Marietta Wu is Managing Director of Quan Capital, a life sciences venture fund with offices in China & US, and deep expertise in cross-border value creation and global investments. She is a founding member of Zai Lab and served as COO and Director of the company prior to Quan Capital. Zai Lab is a NASDAQ listed company widely recognized as a leader in bringing innovative and transformative medicines to China. Over the past decade, Dr. Wu has been active in cross-border ventures and value creation in the life sciences industry. She was Managing Director at Burrill & Company, leading Burrill's investments and operation in Greater China, focusing on venture capital investing in China and Taiwan related life sciences opportunities. She also served as acting COO of Waterstone, a specialty pharmaceutical company with key operations in China. Dr. Wu is a frequent speaker and author on China and Taiwan life sciences topics, and a founding member of the China Healthcare Investment Conference. Prior to her focus on healthcare investments and company building, Dr. Wu was Director of Strategy at Edwards Lifesciences. She also held various financial and business development positions at Eli Lilly & Company.

Dr. Wu received her medical degree from Shanghai Jiaotong University School of Medicine (formerly Shanghai Second Medical University), a Ph.D. in Medical Sciences from Medical College of Ohio, and an MBA from the University of Michigan Ross School of Business.

Dr. Wu serves on the board of Crescendo Biologics, Kira Pharmaceutical, Qiagen (Suzhou) Translational Medicine Co., Ltd. She was a board member of Zai Lab Limited (NASDAQ: ZLAB), Jing Medicine Technology, Taiwan Liposome Company (GTSM: 4152), JHL Biotech (TWEM: 6540), and General Biologics Corporation (TWEM: 4117).
BioMedPartners AG
MARKUS HOSANG
General Partner

Dr. Markus Hosang is a General Partner and Managing Director at the life sciences venture capital firm BioMedPartners in Basel. He has strong experience and broad knowledge in strategic and operational aspects of the VC business, as well as in pharmaceutical and diagnostics R&D. Before joining BioMedPartners, Dr. Hosang was a Venture Partner at MPM Capital, where he managed their European office and was co-responsible for their European deal flow. Previously, at Roche in Basel, he held several senior management positions of increasing importance in its global Pharma R&D organization, and was directly involved in major strategic transactions, including the acquisition of Genentech. Dr. Hosang obtained his Ph.D. in Biochemistry from the ETH Zurich. He serves on the boards of several biotech and medtech companies, many of which have already been exited highly successfully.

Dyadic International, Inc.
MATTHEW JONES
Chief Commercial Officer

A veteran of the life sciences industry with two decades of commercial leadership experience and deal-making, Mr. Jones has led and transformed commercial growth and M&A strategies for a diverse range of science businesses both in Europe and the US. Prior to joining Dyadic he served as Chief Commercial Officer for Concept Life Sciences from its formation until 2016 – prior to that, Mr. Jones was Vice President of Global Sales & Business Development at Lonza Biologics, where he implemented new income-generating streams alongside capturing enterprise and cross-divisional synergies in manufacturing, research and client/vendor relationships. From 2009-2012 Mr. Jones served as Executive Vice President of Business Development & Marketing at Ricerca BioSciences LLC where key responsibilities included strategic deal making, royalty and asset license optimisation and marketing effectiveness. From 2003-2009 Mr. Jones was Senior Vice President of Business Development at MDS Pharma Services Inc. where he led the BioPharmaceutical commercial growth platforms. Mr. Jones has also held senior level biologic and clinical leadership roles within the biopharmaceutical industry with Alkermes, Inc. and from 1998 with GlaxoSmithKline PLC.

Merck KGaA
MATTHIAS MÜLLENBECK
Executive Director & Head Global Licensing & BD Enabling Technologies

Dr. Matthias Müllenbeck is Executive Director & Head Global Licensing and Business Development Enabling Technologies at Merck Biopharma. In this role, Matthias leads a team of senior business developers that is responsible for designing and leading strategic partnering initiatives in the field of oncology, immuno-oncology, and immunology.

Matthias has a track record of leading strategic licensing-, co-development-, co-commercialization transactions and multi-asset portfolio acquisitions for various clinical- and pre-clinical-stage assets-, platform technologies-, and companion diagnostics.

Matthias holds a PhD in immunology from the Humboldt-University of Berlin and a MBA from Kellogg-School of Management Chicago. Prior to joining Merck, Matthias worked as a scientific project leader at the Max-Planck Institute for Infectionbiology Berlin, Germany, and the Albert-Schweitzer Hospital in Lambaréné, Gabon.
Swedbank Robur AB
MATTIAS HÄGGBLOM
Portfolio Manager Global Healthcare
Biologist by training, who let his colleagues down already at the university by adding some courses in economics to his degree. Ended up in the banking world by coincidence and never turned back. Think clients liked his honest way of describing events as he saw them unfold. Think companies liked his integrity and lengthy experience covering this industry. To say they liked him all. Meeting talented people he never thought he would have met, seeing science progress in a way he never thought he'd understand and getting to travel the world to places he did not know existed, is what keeps him going. 18 years as sell-side analyst with Aragon Securities, Alfred Berg ABN AMRO and most recently Danske Bank. 3+ years as portfolio manager at Swedbank Robur.

Swiss Biotech Association
MICHAEL ALTORFER
CEO
Dr. Michael Altorfer is the CEO of the Swiss Biotech Association. He has more than 20 years of experience in the life science industry comprising both big pharma and smaller biotech organizations. As a member of the Executive Committee he supported the build-up of Polyphor Ltd in Allschwil in many different roles (Head BD&L, CFO, COO and CEO). Michael started his career as a scientist in pharmaceutical research at Sandoz, Ciba-Geigy (Summit, NJ, USA), and Roche. From 1996 to 2001 he held program management and line management roles at the investment bank UBS Warburg.

Michael studied Natural Sciences at the ETH and he obtained his Ph.D. in Chemistry under the supervision of Prof. Dr. H.-J. Hansen (University of Zurich) and Prof. Dr. K. Müller (Roche) and holds an MBA degree from the University of Rochester, NY, USA.

Valor Management S.A.
MICHAEL FARLEY
Director
Michael has 32 years of experience in the biomedical field as corporate advisor, manager and investor. In the 1990s he managed S&T and investment programs for the Canadian Department of Foreign Affairs and International Trade. Among the achievements was the Connaught Biosciences-Pasteur Merieux vaccine merger, the largest pharmaceutical industry transaction in Canada up to that time. In 2003, Michael founded MRF Associates Inc. (Canada) and Valor Management SA (Switzerland) offering corporate and business development services to Biotech, Med-tech, Specialty Pharma and Nutraceutical companies in international markets. MRF Valor also acted as life sciences development advisor to the Quebec, Chile, Taiwan and Catalonia governments. His foray into cannabinoid medicine dates back to 2006 when he syndicated a $CAD 30 million financing for Phase 1b-2a trials for a CB inverse agonist API developed by Cervelo Pharmaceuticals in Toronto. Michael is active in the food and beverage industry as Founder of a natural food importing company (exited 2003) and is currently Director of a wine production and distribution company in California. He holds a PhD in the Philosophy of Science from the Université de Montréal (1986) and is fluent in several languages.
LyGenesis, Inc.

MICHAEL HUFFORD
Co-Founder & CEO

Michael Hufford, PhD is the Co-Founder and CEO of LyGenesis, Inc., an organ regeneration company using the lymph node as a bioreactor for organogenesis. An entrepreneur and drug developer, he has over 20 years of experience in the development and regulatory approval of small molecules (Cypress Bioscience), biologics (Amylin Pharmaceuticals), as well as drug delivery technologies (e-Nicotine Technology). He has helped to design clinical trials and drug development programs across a wide variety of therapeutic areas, from orphan metabolic diseases to psychiatry and oncology. His philanthropic work includes co-founding Harm Reduction Therapeutics, Inc., a nonprofit pharmaceutical company developing low-cost over-the-counter naloxone in the US.

Dr. Hufford earned his undergraduate degree with distinction from Purdue University, and his master’s and doctoral degrees in clinical psychology from the University of Pittsburgh before completing a Research and Clinical Fellowship in the Department of Psychiatry at Harvard Medical School.

Metys Pharmaceuticals AG

MICHAEL SCHERZ
Founder & CEO

Mike manages drug development and discovery activities at Metys Pharmaceuticals, and is spear-heading the company’s search for Series A investors. He is responsible for Metys’ development plans for MP-101, a newly-patented orally-active Phase 2-ready small molecule intended for prevention of chemotherapy-induced symptoms of peripheral neuropathy.

Mike previously held senior roles in drug development and drug discovery at Actelion. Prior to Actelion, Mike was section head of cardiac research at Procter & Gamble Pharmaceuticals in Cincinnati, Ohio, USA; and post-doctoral scientist in CNS chemistry drug discovery at Hoffman-La Roche AG in Basel, Switzerland.

Digital Networks Plc.

MICHELE MARZOLA
CEO

One of the most active private investor in Life Sciences in Europe, with a portfolio of more than 20 companies, founded and funded, spanning from surgical robotics to orthopaedics, diagnostics, biotechnology, oncology, neurodegenerative disorders, etc. Michele is now Chief Executive at Interceptin and Investor at Italian Angels for Growth. Previously General Manager IBM in Europe, Middle East & Africa and Principal Booz, Allen & Hamilton.
CoFeS China Ltd.
MIRKO SCHERER
CEO

Mirko holds an MBA from Harvard Business School, Boston. He also earned a Doctorate in Finance from the European Business School in Oestrich-Winkel/Germany and a degree in business administration from the University of Mannheim/Germany.

He has served on the Board of the Frankfurt Stock Exchange as well as Quantapore Inc. and is currently a board member of the Stichting Preferente Aandelen QIAGEN, and Aptorum Inc.

Prior to working in the VC and advisory business, Mirko co-founded GPC Biotech (Munich and Princeton, NJ) and served as its Chief Financial Officer for a decade. GPC Biotech engaged in numerous pharmaceutical alliances with companies such as Sanofi Aventis, Boehringer Ingelheim, Altana (now part of Takeda), Yakult and Pharmion (now part of Celgene). At GPC, Mirko was responsible for all financial, legal, corporate communication and governance topics. He was instrumental in numerous capital raisings (venture capital stage, IPO and follow on offerings in Germany as well as on NASDAQ), licensing transactions, mergers & acquisitions and other strategic transactions. Over the last 20 years Mirko has established an extensive network in the European, Chinese, and North American pharma, biotechnology and venture capital industries. Prior to his time at GPC Biotech Mirko worked as a consultant at the Boston Consulting Group.

Previously he consulted for MPM Capital focusing on deal sourcing for MPM in Europe. Mirko was also a co-founder and partner at KI Kapital which specialized in consulting in the life science industries.

Dr. Scherer is CEO of CoFeS China and CoFes France. CoFeS’ mission is to facilitate licensing, investments, and partnerships between innovative Western life science companies and Chinese investors and companies. Mirko is co-located in Hong Kong and Paris.
NATHALIE TER WENGEL
European Lead, Worldwide Business Development

Nathalie ter Wengel, a medical doctor, is the European Lead Worldwide Business Development at Pfizer, where she is responsible for establishing new collaborations and exploring licensing and other corporate development opportunities across all therapeutic areas. Previous to this role, she was the European Head for External Science & Innovation. Nathalie has an international background and a broad knowledge in the medical field, having worked in the hospital with extensive experience in internal medicine. Nathalie started her commercial career as European Medical Manager at Pfizer, where she successfully led ambitious international projects, combining a business perspective with her medical knowledge. It was this experience, coupled with her father’s illness that convinced her of the urgent need for change in the pharmaceutical industry. Consequently, she started up a company called myTomorrows focused on compassionate use, and served as Chief Medical Officer before joining Galapagos as Business Development Director, where she played a key role in the very successful NASDAQ IPO and in partnering filgotinib.

NEIL JOHNSTON
Global Head, BD & Licensing Pharma

Neil Johnston is the Global Head of Business Development & Licensing since December 2017 and a member of the Pharma Executive Committee (PEC). Neil has worked at Novartis since 2007.

During his time at Novartis, Neil has worked mainly as Head M&A, BD&L Finance in the Pharma Division and as Global Head Finance for the Development organisation. Prior to Novartis, Neil was Chief Executive Officer at Medical Solutions plc, Chief Financial Officer at Pharmagene plc (UK public diagnostic/biotech companies) and spent 9 years at PwC. He holds a Ph.D in Molecular Biology and is a qualified UK Chartered Accountant. Neil is married with two children.

NISSIM DARVISH
Senior Managing Director

Nissim Darvish, M.D., Ph.D., is a Senior Managing Director. Nissim is a veteran of the lifescience industry, with 15 years of experience covering medical technology development, corporate leadership and investment management.

Nissim spent eight years with Pitango, where he was a General Partner managing life sciences investments.

Previously, Nissim was the founder and CEO of Impulse Dynamics, which he led for six years, culminating in a $250 million realization event.

Nissim obtained his M.D. and Ph.D. in Biophysics and Physiology from the Technion in Israel, and subsequently conducted his postdoctoral research at the NIH. He has published over 100 patents, authored over 20 publications and received eight prizes and awards.
Mirabaud Securities Ltd.

OLAV ZILIAN
Senior Healthcare Analyst, VP

Senior Healthcare Analyst, Vice President - Business unit: Mirabaud Securities Ltd., institutional brokerage services, sell-side equity research.

Key responsibilities and duties: coverage of biotech, medtech and pharmaceutical companies; acquisition and execution of corporate finance deals (VC, PE & cross-over financing, IPOs and follow-ups); supporting corporate clients in such transactions by writing research reports, advising on business strategy and transaction, and identification of potential investors.

The Janssen Pharmaceutical Companies of Johnson & Johnson

PATRICK BENZ
Sr. Director Alliance Management

Patrick Benz, Senior Director Alliance Management, Janssen Business Development. In this role Patrick manages all global commercial and R&D key alliances for Neuroscience in all different global regions.

Patrick joined Johnson & Johnson Family of Companies in 1998 at Janssen Switzerland. He progressed through several commercial roles into the board of the Swiss Operating Company as Business Unit Director CNS, and then moved to Italy, holding several commercial roles at board level, advancing to EMEA Franchise Leader for Neurology, overseeing the entire EMEA Neurology Franchise. Since October 2008, Patrick has been a member of the Janssen Business Development team. In this group he was holding the position of Senior Director, Business Development & Licensing for the Neuroscience Franchise until 2013, where he was negotiating several transactions for commercial as well as R&D assets.

Patrick holds a Master Degree in Pharmacy and a PhD in Organic Chemistry. Before joining Janssen Switzerland in 1998, Patrick did work for Gebro Pharma AG, Switzerland, and for Boehringer Mannheim/Roche.

Bird & Bird LLP

PAUL HERMANT
Partner

Paul Hermant is a corporate & finance partner at Bird & Bird LLP, specialised in the life sciences sector and based in Brussels. He heads the firmwide corporate life sciences group. He assists clients in their corporate and financial transactions and provides the full range of advice in these fields. He has particular expertise in mergers and acquisitions, private equity, venture capital, joint ventures, strategic alliances, securities offerings, take-over bids, as well as project and acquisition finance. Paul also represents clients in corporate and financial litigation, including shareholders disputes, directors’ liability and cases relating to financial products and services.

He graduated from the University of Brussels (Master in Law 1988; Master in Business Law 1989) and from the Solvay Business School (Master in Business Administration 1992). He joined Bird & Bird LLP in 2000, coming from Loeff Claeys Verbeke (now Allen & Overy). He has written and spoken widely on corporate and financial law topics and teaches at the University of Brussels. He also serves on the Board of the Solvay Business School Alumni.
Marker Therapeutics, Inc.

**PETER HOANG**
President & CEO

Peter L. Hoang brings over twenty years of immuno-oncology, investment banking, venture capital, and public company executive management experience to Marker Therapeutics, Inc., serving most recently as President & CEO of TapImmune Inc. (Nasdaq: TPIV), one of the predecessor companies that merged to form Marker Therapeutics. He has also served as Senior Vice President of Business Development & Strategy at Bellicum Pharmaceuticals (Nasdaq: BLCM). Previously, as the Managing Director of Innovations at The University of Texas MD Anderson Cancer Center, he headed the new venture formation and development effort for the institution. There, he led the commercialization of MD Anderson’s Sleeping Beauty transposon-based CAR-T program, resulting in the largest public company-to-academic research institution upfront deal in history. Before joining MD Anderson, Mr. Hoang was a Managing Director and head of healthcare mergers & acquisitions advisory for CIT Group (NYSE: CIT). He also served as a senior investment banker in the M&A departments at Oppenheimer, J.P. Morgan, Merrill Lynch, and Deutsche Bank. He earned an M.B.A. with high honors distinction from the Anderson School of Management at UCLA and a B.A. from Yale University.

TargImmune Therapeutics AG

**PETER KASH**
Co-Founder & Vice-Chairman

Dr. Peter Kash Ed.D/MBA is a Co-founder and Vice-Chairman of TargImmune Therapeutics based in Switzerland. Dr. Kash worked on Wall Street for more than 30 years in the biotech sector. He has co-founded more than a dozen biotech companies and co-raised more than $2 billion in private financings. Seven drugs reached FDA approval from pre-clinical status.

Dr. Kash has been an Adjunct Professor of Entrepreneurship and Visiting Professor at: Wharton Business School (USA), Nihon University (Tokyo) and Hebrew University (Jerusalem). He has traveled and guest lectured in over 60 countries, lecturing on Cancer and Entrepreneurship.

In addition, he is a Director in Fire Brick Pharma Pty Ltd. and he has authored several books including the international best seller Make Your Own Luck (2001), Freedom from Disease (2007) and Take Two Tablets Medicine from the Bible (2014).

In 2019 he lectured at TEDx London on “Entrepreneurship in the Age of Millennials”.

MSD

**PHIL L’HUILIER**
Head of Business Development, Europe & Middle East

Phil is Head of Business Development, Europe & Middle East for Merck, Sharpe & Dohme (MSD), based in London. He is a seasoned business development professional with 15+ years’ experience in the biotech/pharma industry, in R&D, licensing/partnering, new company formation and M&A. Prior to joining MSD, Phil was an Executive Director at Cancer Research Technology Ltd.

Phil has previously been a director of numerous start-ups including Achilles Therapeutics, Artois Pharma, PsiOxus Therapeutics and BiINK BioMedical. Prior to CRT, Phil headed up global licensing at BioFocus Discovery Ltd, an AIM-listed integrated early stage drug discovery company. Phil holds an MBA, and a PhD in cellular and molecular biology.
Daiichi Sankyo Europe GmbH

PHILIPP HOFFMANN

Head of Business Development & Licensing

PhD in Biology

Research Scientist in Xerion Pharmaceuticals 2000-2001

Team leader & Alliance Manager in MorphoSys 2001-2008

BD & L. in Daiichi Sankyo EU 2008- to date

Imcyse SA

PIERRE VANDEPAPELIÈRE

CMO

Pierre Vandepapelière, MD, PhD (CEO and CMO): C-level executive leader with over 25 years global experience in development of immunotherapeutics and vaccines. Pierre joined Imcyse in February 2015 and over 4 years, he has built from an academic research group a performing Biotech company in terms of management & governance, organization, strategic prioritization, financing, partnering, preclinical and clinical development, etc. We have accomplished partnership with 2 leading pharma companies, successfully conducted a phase Ib in type 1 diabetes patients across 7 European countries, obtained multiple grants and completed a large series B round. Before joining Imcyse, Pierre was Vice-President, Chief Medical Officer, at Neovacs and Abivax, Paris, France. He is also Consultant for other Biotech companies and actively working in other start ups. Previously, Pierre has occupied during 18 years various management positions in development of prophylactic and therapeutic vaccines in GSK Vaccines, Belgium.

Life Length, S.L.

PILAR NAJARRO

COO

Life Length’s COO and CSO. Dr. Najarro possesses over 20 years’ international experience in life sciences industries. She obtained her Ph.D. in cellular biology from SUNY in New York, later expanding her research interests at Imperial College in London. She subsequently worked in both small innovative biotech companies focusing on anti-viral drug discovery and in large pharma (AstraZeneca). Dr. Najarro has also extensive experience in technology transfer and licensing acquired during her work as a consultant and in business development for one of Spain’s most important translational research initiatives, CIMA, before joining Life Length in 2014.

Atriva Therapeutics GmbH

RAINER LICHTENBERGER

President & CEO

30 years senior management in life science and biotech industry, 15 years CEO/COO/CFO experience in 4 SME, raised € 50 Mn.
F2G Ltd.
RALF SCHMID
CFO
Ralf has more than 20 years’ experience in M&A, licensing, public and private market transactions in various leading positions in the field of finance and administration in Biotech and at several multinational companies including Sandoz. He joined F2G in July 2016 from Nabriwa Therapeutics AG where he had served on the management board since the company’s spin-off from Sandoz in 2006. In his role as Chief Financial and Chief Operating Officer, Ralf was instrumental in taking the company public on NASDAQ in September 2015. He holds a Master’s degree in finance and economics from Otto-Friedrich-Universität Bamberg, Germany.

Anocca AB
REAGAN JARVIS
CEO
Reagan is an experienced scientist in fundamental research and translational science, and co-founded Anocca AB in 2014. He held the CSO post from founding until 2018, and has been CEO at Anocca since 2017.

Altitude Investment Management, LLC
ROD STEPHAN
Partner
Roderick Stephan is a founding partner of Altitude Investment Management LLC, a cannabis investment management company with investments in approximately 20 cannabis companies in North America and Europe. Altitude manages two global cannabis funds and recently opened a London office and European platform to focus on European CBD/wellness and medical cannabis investment opportunities. As a mentor and advisor to early-stage and growth cannabis companies, he sits on a number of corporate boards. He was previously a founding partner and CEO of Longacre Fund Management (UK) LLP, a London-based alternative investment adviser and also co-founder and head of research of the distressed and alternative investments group at Citadel Investment Group.

AbbVie Ventures
ROSS LEIMBERG
Director
Ross is a Director of AbbVie Ventures, the strategic venture capital arm of AbbVie, Inc., where he focuses on identifying and executing early stage investments in biotechnology on behalf of the parent organization. He draws from over a decade of business development, investing, and consulting experiences from within the life sciences industry.

Ross holds an MBA from Harvard Business School, a BS in Economics from the Wharton School, and a BAS in Bioengineering from the University of Pennsylvania.
Sam Fazeli is a senior analyst and the EMEA head of Bloomberg Intelligence, a dynamic platform for in-depth research available on the Bloomberg Professional service at BI.

Dr. Fazeli specializes in European pharmaceuticals and biotechnology.

Dr. Fazeli has over 20 years of experience conducting equity research as a pharmaceutical analyst, working at firms such as Nomura International and HSBC.

Prior to joining Bloomberg in 2010, Dr. Fazeli worked at Piper Jaffray, Ltd. as a pharmaceutical analyst and head of European research. Before transitioning to investment banking, Dr. Fazeli was a research scientist for seven years.

Dr. Fazeli has been ranked a top analyst by both the U.K. and Pan-European Extel surveys. He received a bachelor’s of science from Cardiff University, and a Ph.D. in pharmacology from the University of London.

Sandrine Cailleteau is Managing Director at Bryan Garnier Healthcare Corporate Finance team and has completed numerous crossborder M&A, Licensing and financing transactions throughout her 30y career first in the industry as M&A Director at Sanofi, head of BD&L of Hesperion (Actelion), Fournier Pharma and as CBO of AIM-listed Plethora Solutions, and then for the last 10 years as a Corporate Finance banker.

Dr. Sari Prutchi-Sagiv has over 15 years of experience in various aspects of pharmaceutical development including discovery, regulatory affairs, intellectual property and pre-clinical and clinical trials. Dr. Prutchi-Sagiv has lead scientific operations in multiple cannabis-based drug companies for the last 9 years, including Talent Biotechs, acquired by Kalytera, Stero Biotechs, BOL Pharma, CannaLean and Gynica. She also serves as Director of Tech Transfer at Mor Research Applications (Clalit Health Services commercializing arm), where she is responsible for managing the pharma inventions from Clalit physicians. Dr. Prutchi-Sagiv holds an M.Sc. in Human Genetics and a Ph.D. in Cell Biology and Immunology from Tel Aviv University. In addition, she studied Business Administration at the same University.
Johnson & Johnson

SIMON BLAKE
Senior Director, Scientific Licensing, Immunology

Simon is the Scientific Licensing lead for the Immunology Therapeutic Area (ITA) at Janssen Research and Development. In this role he scouts, identifies and leads due diligence activities on assets of high strategic interest to the ITA. Simon joined J&J in 2004 as head of the Cardiovascular and Metabolic Diseases group within the Centocor organization. He then transitioned to a role in the Biopharmaceuticals group leading the external innovation efforts for that area prior to joining the BD team.

Simon has spent over 20 years in various roles in drug discovery and development mainly focused on the role of cytokines in connective tissue disorders. Simon holds a BSc (Hons) from Oxford Polytechnic, UK and obtained his PhD in Biochemistry while working at the Kennedy Inst. of Rheumatology in London, UK.

Novo Holdings A/S

SØREN MØLLER
Managing Partner, Seed Investments

Søren serves on the Board of Directors of EpiTherapeutics (sold to Gilead), AMRA, Biosyntia, Reapplix and Northsea Therapeutics. Since 2008, Søren has been board member of Danish Biotech (the Association of Biotechnology Industries in Denmark) and DVCA (Danish Venture Capital Association).

Prior to joining Novo Seeds, Søren served as global manager of Genomics at Novozymes. Before Novozymes, Søren was CSO and Vice President of R&D at Exiqon A/S. During Søren’s tenure, Exiqon completed an IPO and the company was acquired by Qiagen in 2016. Previously, Søren worked in cancer drug development as head of Lead Identification at BioImage and as research scientist at Novo Nordisk.

Søren obtained his MSc degree from the Technical University of Denmark in 1993 and his PhD degree in molecular biology in 1997 from the Technical University of Denmark. In addition, Søren has academic training as postdoctoral fellow at Stanford University School of Medicine.

Søren joined Novo A/S in 2011 as Managing Investment Director of Novo Seeds.

Gilde Healthcare Partners

STEFAN LUZI
Partner

Stefan Luzi is a Partner at Gilde Healthcare, a transatlantic life sciences-focused investment firm with >1bn EUR under management. He is focusing on investments in European therapeutics companies. Prior to joining Gilde, Stefan worked at Merck KGaA and completed a PhD program with Nobel Laureate Sir Gregory Winter at the MRC Laboratory of Molecular Biology in Cambridge (UK).
EpimAb Biotherapeutics GmbH

**STEPHAN LENSKY**

COO & CBO

Stephan Lensky is Chief Operating and Chief Business Officer of EpimAb Biotherapeutics, Inc., a company based in Shanghai, China, developing highly novel and proprietary bispecific antibodies. He is responsible for the strategic, financing and BD efforts of EpimAb since its foundation in 2015. While EpimAb’s first is being investigated in a Phase I/II compound in 2018, the company already entered into collaborations in China as well as ex China under Stephan’s leadership, increasing the candidates of bispecific antibodies their platform can deliver. Stephan also raised over US$ 100 M in Series Seed, A and B for the company in and ex China to support EpimAb’s rapidly growing pipeline. Currently, he is initiating EpimAb’s US operations in the Boston area.

Stephan brings over 20 years of experience in Pharma companies to EpimAb - thereof 15 years in business development and 5 years in international leadership as Corporate Vice President at Boehringer Ingelheim. He also held leading positions in research as well as marketing & sales during his years at Boehringer Ingelheim and Bayer Health Care. Stephan holds a Ph.D. in Chemistry.

Torreya Partners (Europe) LLP

**STEPHANIE LÉOUZON**

Partner & Head

Stephanie Léouzon is Partner and Head of Europe for Torreya Partners, a life sciences boutique advisory firm which she joined in 2012. Previously she worked in healthcare investment banking in the US and Europe from 1989 to 2010, most recently at Credit Suisse in London as a Managing Director and Senior Advisor.

She has advised life sciences clients on more than 25 strategic transactions, valued at over $65 billion, and has been involved in over 45 financing transactions to provide over $10 billion to healthcare clients.

Stephanie earned an MBA degree from the Darden Graduate School of Business at the University of Virginia in 1989 and a BA degree, cum laude, from Mount Holyoke College in 1985.

Crescendo Biologics Ltd.

**STEWART KAY**

CBO

Stewart joined Crescendo in 2019 as Chief Business Officer and has over 20 years’ experience in business development. He previously worked at GSK as Senior Director, Transactions in GSK’s Worldwide Business Development team gaining significant experience in leading and closing a wide range of deals. Prior to that Stewart held the position of Vice President Commercial Development and member of the executive management team at Pharmagene plc and as Senior Vice President European Business Development at Evotec AG. Stewart started his career at Amersham International (now part of GE) where he held various roles in sales, marketing and business development. Stewart holds a BSc. in Biochemistry and a MBA from Warwick Business School.
Inkef Capital B.V.

THIJS COHEN TERVAERT
Director

Thijs Cohen Tervaert is a Director at INKEF Capital. Thijs currently serves on the board of ViCentra, Castor, Aidence, Audion Therapeutics and Rainier Therapeutics. Prior to INKEF, Thijs was a strategy consultant at the Boston Consulting Group with a focus on health care and technology. He worked on projects for pharmaceutical companies, hospitals and insurers. Thijs is a medical doctor and graduated at Leiden University. He has also co-authored several scientific papers.

INKEF Capital is an Amsterdam-based venture capital firm that focuses on long-term collaboration and active support of innovative healthcare and technology companies. With €500 million under management INKEF Capital is one of the largest venture capital funds in the Netherlands.

Bone Therapeutics SA

THOMAS LIENARD
CEO

Thomas Lienard has over 15 years of national and international sales and marketing experience in the pharmaceutical industry.

Prior to joining Bone Therapeutics, Thomas Lienard worked at Lundbeck, where he acted as Managing Director for Belgium and Luxemburg and was vital to the launch of several products. Before his position at Lundbeck, he worked at Eli Lilly and Company, where he held various positions in sales and marketing in Europe and the US. Thomas Lienard started his career in 1999 as consultant a McKinsey & Company. He graduated from Solvay Brussels School of Economics and Management as Master in Business Engineering in 1999 and obtained a Master of Business Administration (MBA) from Harvard Business School in Boston in 2004.

Thomas Lienard joined Bone Therapeutics in 2015 as Chief Business Officer in charge of activities regarding business development and strategic planning and was appointed CEO in October 2016.
Tim Opler, a Partner and Co-Founder of Torreya, manages client relationships and oversees the firm’s administrative activities.

Prior to his career in investment banking, Tim was a professor in the finance department at Ohio State University. He earned a B.S. in economics and philosophy from Florida State University, and a Ph.D. in economics from UCLA.

Other notable transactions on which Tim advised prior to starting Torreya include advising Pfizer on the sales of Heumann, Dorom, and NM Pharma; managing $11 billion in swaps and bond issues for Eli Lilly; managing $150 million in derivatives for Guidant; managing $850 million in bond issuance and swaps for Bristol-Myers Squibb; acting as a lead on Glaxo’s $1 billion bond issue; and leading a $600 million Eurobond issue for Pfizer. He has also led transactions and served as a strategic advisor for BHP, BMW, BP, Coca-Cola Enterprises, Daimler, Dell, Diageo, Dow, Ford, GE, GM, the State of Israel, Microsoft, Philip Morris, the State of Poland, and Royal Dutch Shell, among others.

Before co-founding Torreya, Tim was Vice President of Strategy at FibroGen, where he helped raise $117 million for the company and negotiated licensing deals. Previously, Tim was a Managing Director in Healthcare Investment Banking at Credit Suisse First Boston and held senior roles at W.R. Hambrecht, Deutsche Bank, and Merrill Lynch.

Tim has 24 years experience leading strategic and financing transactions across multiple sectors. For nearly 20 years, he has focused exclusively on life sciences advisory; he has completed more than 150 financing, licensing, and M&A transactions across the industry with a total value of over $100 billion. Highlights include running the largest share buyback in history for Pfizer, leading a $3.9 billion convertible bond exchange for Amgen, working on Chiron’s $5.1 billion sale to Novartis, and managing Genentech’s inaugural $2 billion bond issue.

Tim Luker leads Lilly’s external innovation process in Europe within Global Corporate Business Development. In this role Tim interacts with numerous external EU/USA VC funds targeting transformational early stage research across multiple therapy areas and supports general due diligence and search and evaluation initiatives which ensure the most exciting external science is prioritised.

Tim is an experienced drug hunter with 20 years’ experience and is an inventor / author on >60 patent applications and publications. Prior to Lilly he co-founded a successful spin out biotech (Polleo Pharma, acquired 2016); and performed senior roles at Shire pharmaceuticals and AstraZeneca, where he led multiple drug discovery projects through to candidate molecules, provided input into early development projects and managed multiple scientific teams. Many of these projects reached efficacy studies in human.

Tim has a PhD (1995) in chemistry from the University of Southampton, carried out post-doctoral research at Universiteit Van Amsterdam (1996-1999) and is also a Prince2 qualified project manager.

Torreya Partners, LLC

TIM OPLER

Co-Founder & Partner

Eli Lilly and Company

TIM LUKER

VP, Emerging Technology & Innovation, Corporate Business Development

Eli Lilly and Company

VP, Emerging Technology & Innovation, Corporate Business Development

Tim Luker leads Lilly’s external innovation process in Europe within Global Corporate Business Development. In this role Tim interacts with numerous external EU/USA VC funds targeting transformational early stage research across multiple therapy areas and supports general due diligence and search and evaluation initiatives which ensure the most exciting external science is prioritised.

Tim is an experienced drug hunter with 20 years’ experience and is an inventor / author on >60 patent applications and publications. Prior to Lilly he co-founded a successful spin out biotech (Polleo Pharma, acquired 2016); and performed senior roles at Shire pharmaceuticals and AstraZeneca, where he led multiple drug discovery projects through to candidate molecules, provided input into early development projects and managed multiple scientific teams. Many of these projects reached efficacy studies in human.

Tim has a PhD (1995) in chemistry from the University of Southampton, carried out post-doctoral research at Universiteit Van Amsterdam (1996-1999) and is also a Prince2 qualified project manager.

Torreya Partners, LLC

TIM OPLER

Co-Founder & Partner

Tim Opler, a Partner and Co-Founder of Torreya, manages client relationships and oversees the firm’s administrative activities.

Prior to his career in investment banking, Tim was a professor in the finance department at Ohio State University. He earned a B.S. in economics and philosophy from Florida State University, and a Ph.D. in economics from UCLA.

Other notable transactions on which Tim advised prior to starting Torreya include advising Pfizer on the sales of Heumann, Dorom, and NM Pharma; managing $11 billion in swaps and bond issues for Eli Lilly; managing $150 million in derivatives for Guidant; managing $850 million in bond issuance and swaps for Bristol-Myers Squibb; acting as a lead on Glaxo’s $1 billion bond issue; and leading a $600 million Eurobond issue for Pfizer. He has also led transactions and served as a strategic advisor for BHP, BMW, BP, Coca-Cola Enterprises, Daimler, Dell, Diageo, Dow, Ford, GE, GM, the State of Israel, Microsoft, Philip Morris, the State of Poland, and Royal Dutch Shell, among others.

Before co-founding Torreya, Tim was Vice President of Strategy at FibroGen, where he helped raise $117 million for the company and negotiated licensing deals. Previously, Tim was a Managing Director in Healthcare Investment Banking at Credit Suisse First Boston and held senior roles at W.R. Hambrecht, Deutsche Bank, and Merrill Lynch.

Tim has 24 years experience leading strategic and financing transactions across multiple sectors. For nearly 20 years, he has focused exclusively on life sciences advisory; he has completed more than 150 financing, licensing, and M&A transactions across the industry with a total value of over $100 billion. Highlights include running the largest share buyback in history for Pfizer, leading a $3.9 billion convertible bond exchange for Amgen, working on Chiron’s $5.1 billion sale to Novartis, and managing Genentech’s inaugural $2 billion bond issue.
**Sofinnova Partners SA**

**TOM BURT**

Partner - Crossover

Tom was involved in raising Sofinnova's first Crossover Fund and joined the firm in June 2017. His background is in life science investment banking and late-stage public/private investing. Tom joined from Peel Hunt where he was Senior Healthcare research analyst. Prior to this he was an Investment Director with Ares Life Sciences, a late-stage growth/private equity fund with c.EUR1.5bn AuM and backed by the Bertarelli [Serono] Family. Before this, he was based at Novo Growth Equity, an investment division of Novo Holdings, responsible for investing US$200m per year in late-stage public/private life science companies in US & Europe. Tom began his finance career in 2006 as a member of Piper Jaffray’s European Healthcare Investment Banking team working on financings and M&A for late-stage, European life science companies. Tom holds an EngD in Biochemical Engineering and worked in pharma at GSK’s Biopharmaceutical CEDD.

---

**NBE-Therapeutics Ltd.**

**ULF GRAWUNDER**

Founder & CEO

Ulf Grawunder is CEO of NBE-Therapeutics, a Swiss Biotech company that he founded in 2012 and which focuses on the development of “next-generation” antibody-drug conjugates for cancer therapy.

Prior to that, Ulf had co-founded 4-Antibody in 2004, a Swiss therapeutic antibody engineering company, where he initially served as CEO and later as CSO, until the company was sold to US-based Agenus. Ulf is a Biochemist who did his PhD in the area of B cell Immunology at the Basel Institute for Immunology. After this he did several years of post-doctoral research at Washington University School of Medicine, St. Louis, and the University of Southern California, Los Angeles. After that he returned to Europe to continue research as principal investigator at the Basel Institute for Immunology, and the University of Basel, Switzerland, before he started his first Biotech company, 4-Antibody.

Ulf also holds a Diploma of Technology Entrepreneurship from the University St. Gallen, School of Business, Switzerland (HSG, Hochschule St. Gallen), and he is part if the teaching faculty of the European Center for Pharmaceutical Medicine (ECPM) at the University of Basel, Switzerland.

Ulf is advisor of a number of national and international organizations, including the scientific advisory board of the Bavarian Immunotherapies Network, BayImmunNet, Germany (www.bayimmununet.de), the jury of Venturekick, Switzerland (http://www.venturekick.ch), and the Board of the Swiss Biotech Association (SBA, www.swissbiotech.org).

---

**Syneos Health**

**VANELA BUSHI**

Director

Vanela is Europe lead for Portfolio Strategy and Transactions at Syneos Health. She focuses on corporate strategy, deal support and investments. Vanela has extensive experience advising a number of leading life sciences organisations and investors. Prior to Syneos Health, Vanela worked for EY and PwC in London.
Abingworth LLP

VANESSA KING
Venture Partner

A geneticist by training, Dr. King has spent the last two decades pursuing her passion for turning innovative science into effective treatments.

Dr. King is a Venture Partner at Abingworth, LLP, and also CEO of Virion Biotherapeutics, a company focused on transforming the treatment of respiratory virus infections.

Prior to Virion, she served as CEO of Luc Therapeutics, where she led the company’s transformation into a clinical-stage precision medicine neuroscience company. Dedicated to building innovative life sciences companies globally, Dr. King led business development in the turnaround team for deCODE Genetics, taking the company from bankruptcy to a $415M acquisition by Amgen. Dr. King has also served as Executive Chairman of Tiaki Therapeutics, and served as an Entrepreneur in Residence at Atlas Venture.

Dr. King’s other roles have spanned business development, financing, strategy and operations at Novartis, Amgen, and the J. Craig Venter Institute. She obtained her Ph.D. in Molecular Genetics from Trinity College, Cambridge, UK and her AB Phi Beta Kappa in Molecular Biology from Princeton University.

Wellington Partners

VARUN GUPTA
Associate

Varun joined Wellington Partners in July 2018 as an Associate in the Life Sciences Team. Varun gained his MSc degree in Medical Biotechnology from the Post-Graduate Institute of Medical Education & Research, Chandigarh, India, and was awarded a PhD with Summa cum Laude in Neuroscience from the Freie University of Berlin for his work on polyamine-mediated suppression of age-associated memory impairment, culminating in articles published in Nature Neuroscience, PLOS Biology and Autophagy.

Subsequently, Varun obtained an MBA degree from IESE Business School in Barcelona. While pursuing his MBA, Varun supported the investment teams of Forbion Capital Partners, Amsterdam, as well as Ysios Capital, Barcelona.

MetrioPharm AG

WOLFGANG BRYSCHE
Founder & CEO

Many years of experience as Chief Scientific Officer, primarily in drug development Dr. Wolfgang Brysch has been Chief Executive Officer of MetrioPharm AG since 2016, before which he was Chairman of the Board of Directors and Chief Scientific Officer (2007-2016). In 2001, he co-founded BioMedion - a successful IT company specializing in solutions for the pharmaceutical industry. He was Managing Director there until 2007. Prior to that, he worked at Biognostik GmbH, where he was Managing Director and Chief Scientific Officer (CSO) from 1992 to 2001. At that time, Dr. Brysch was also responsible for the preclinical development of various antisense cancer drugs at Antisense Pharma. Until 1992, Dr. Brysch was head of a research group for molecular neurobiology and cancer research at the Max Planck Institute in Göttingen.
Affibody AB

XIAOLI HU

Director Business Development

Dr. Xiaoli Hu currently works as Director Business Development at Affibody AB, a clinical stage Swedish biotech which she joined in 2017. Her responsibilities range from in-house pipeline strategy to licensing negotiation for research collaboration and commercial partnership with pharma partners across Europe and USA. Most recently she led the partnership negotiation with Alexion on the company’s lead asset, the FcRn inhibitor ABY-039.

Prior to Affibody, Dr. Hu worked at HealthCap, a life science venture capital firm based in Stockholm. During her tenure at HealthCap from 2013 to 2017, she joined and completed investment transactions across various geographies and stages of development, and took interim development roles from various portfolio companies.

Dr. Hu holds a Ph.D. in Medicine, and an M.D. with two years of specialized training in general surgery. Since 2018, she has been selected by the European Commission as Expert for the revision of investment proposals in Horizon 2020 SME Instrument.

Yafo Capital

XIAOYANG (SEAN) JIANG

Founder & CEO

Mr. Jiang is a founding partner and CEO of Shanghai Yafo Capital. He has about 20 years’ experience in investment banking, M&A, and investment in both China and Wall Street. Yafo Capital is dedicated to bringing global life science technologies to the Chinese market through licensing or investment. He was the General Manager of ISI Group’s China division and the Managing Director of ISI research. Before that, he was a senior research analyst at Roth Capital where he was involved in multiple cross-border transactions. When at Xiangcai Securities, a leading investment bank in Shanghai, Sean was the executive director, responsible for advising foreign institutional investors in China’s stock markets.

Mr. Jiang is now a visiting professor at Concordia University (Wisconsin). He received his MBA from Pepperdine University, MA from Fudan University, and BA from Central South University of China. He is a CFA Charter holder.
Anima Biotech, Inc.

YOCHI SLONIM

Co-Founder & CEO

Yochi Slonim is a serial entrepreneur with a track record of over 30 years in software and biotech.

As a Co-founder and CEO, he is driving the company’s vision and strategy, fundraising, and partnering.

Prior to Anima, Yochi has built several companies from their early stage, through all stages of product development, marketing, and sales and eventually turned them into successful large exits.

He was a co-founder of Mercury Interactive. As CTO and VP R&D from the company’s early days, he created product vision and strategy and led a multi-product organization of 200 developers. After going public and reaching revenues of over $1B annually, Mercury was acquired by HP for $4.5B.

As Senior VP of products and marketing for Tecnomatix, a public NASDAQ company, he led a 500 people organization of 4 divisions that generated revenues of $100m until the company was acquired by UGS for $230m.

In 2000, Yochi was founder and CEO of Identify. The company reached revenues of $50m in less than 5 years and was acquired by BMC in 2006 for $150m in cash.

Yochi founded ffwd.me, a unique startup acceleration program where he led a team that worked with over 25 startups in diverse areas and technologies, developing strategy, products and go to market operations while raising multiple rounds of financing from VCs and private investors.

BOHE Angel Fund

YUWEN LIU

Founding Partner

She started her career as QA Engineer for Capsugel in 1997, then moved up to QC manager, QA/QC manager and BD manager. In 2003, she joined Perrigo as first Chief Representative to set up its China operation.

She graduated from China Pharmaceutical University with master degree in Pharmaceutics and Master of Management at Fudan University and Norwegian Management School BI. She is a licensed pharmacist.

Before she sets up this fund, she was Chairwoman & CEO then executive director of Suzhou Industrial Park Biotech Development Co. Ltd. (BioBAY) for 9 years, when she was also Investment Committee Member for BioVENTURE Fund, and Board Director of Innovent, Admera Health, Chiral Quest, GenePharma, Reproposing and BrightGene, and Chairwoman of Qiagen (Suzhou) Translational Medicine and Suzhou BioTOP Biotech. She joined the company as EVP in 2005, was instrumental in building BioBAY to be one of the fastest growing biotech clusters serving ~400 biotech startup companies.

Founding Partner of BOHE Angel Fund, a 200M RMB fund jointly invested by Wuxi Apptec, Hengrui, Simcere, TigerMed and BGI, etc. This is the first angel fund focusing on healthcare technology-driven start-ups in China, with Xiaodong Wang and Yigong Shi sitting on its scientific advisory board. It has invested into XinKangHe biological, Transcriptic, SmartNuclide, Athelas Therapeutics, CoolLing Biotech, and HighField BioPharmaceutical covering drug discovery, diagnostic and innovative service solutions.
SciCann Therapeutics, Inc.

ZOHAR KOREN
CEO

Dr. Koren is the founder and CEO of SciCann Therapeutics Inc., a Canadian-Israeli specialty pharmaceutical firm dedicated to the development of cutting-edge technologies and products that target the Human endocannabinoid system for the treatment of inflammatory diseases and cancer.

Previously, he served as VP BD of Mor Research Applications, the commercial and intellectual property unit of Clalit Healthcare Services - Israel’s largest medical healthcare provider with 14 full scale hospitals, 2000 community clinics and a $6B annual turnover - and as VP BD of Talent Biotechs, a developer of CBD based drugs for the treatment and prevention of GVHD (Graft Vs Host Disease).

Dr. Koren is a co-founder of Cannabics Pharmaceuticals Inc. (OTCQB:CNBX), a developer of cannabis based therapies for oncology patients, and served as its CEO.

Prior to that, he served as director of Business Development at Aposense Ltd (TASE:APOS), a developer of novel pharmaceutical products in the oncology, CNS and metabolic disease fields.

Dr. Koren holds a Ph.D. and M.Sc. in Protein science and computational biology from the University of Haifa, and a B.Sc. in Mathematics, Physics and Biology from the Hebrew University in Jerusalem. Dr. Koren is a veteran of the prestigious “Talpiyot” program of the Israeli Defence Forces, an elite unit designed to qualify the top technology officers of the IDF.
Actinium Pharmaceuticals, Inc.

PRESENTER
Mr. Sandesh Seth, Chairman & CEO

COMPANY DESCRIPTION

Actinium Pharmaceuticals Inc. is a clinical stage biotech focused on improving patient access and outcomes to cellular therapies such as bone marrow transplant (BMT) and CAR-T with its proprietary, chemotherapy free, targeted conditioning technology. Actinium is the only company with a late stage, multi-disease, multi-target, drug development pipeline focused on targeted conditioning. Its targeted conditioning technology is enabled by Antibody Radio-Conjugates (ARC) that combine the targeting ability of monoclonal antibodies with the cell killing ability of radioisotopes. Actinium is also developing its proprietary AWE (Antibody Warhead Enabling) technology platform which utilizes radioisotopes coupled with antibodies to target a variety of cancer antigens.

Iomab-B, Actinium’s lead product candidate is an anti-CD45 antibody labeled with iodine-131 that is currently enrolling patients in the pivotal Phase 3 SIERRA trial in patients age 55 or older with active, relapsed or refractory AML. Actinium’s Iomab-ACT program is an expansion of its CD45 program that is intended to be a universal, chemo-free solution for targeted lymphodepletion prior to CAR-T. The Iomab-ACT program is administered as a single outpatient infusion and is expected to improve CAR-T cell expansion, reduce CAR-T related toxicities and expand patient access to CAR-T treatment and other adoptive cell therapies.

Actinium’s pipeline also includes a potentially best-in-class CD33 program with its ARC comprised of the anti-CD33 antibody lintuzumab labeled with the alpha-particle emitter actinium-225. Its CD33 program is currently being studied in multiple Phase 2 and Phase 1 clinical trials for targeting conditioning and as a therapeutic in multiple hematological diseases and indications.

Actinium’s clinical programs are covered by a portfolio of over 100 patents covering composition of matter, formulations, methods of use, and methods of manufacturing the radioisotope Actinium-225.

MANAGEMENT TEAM
Sandesh Seth - CEO and Chairman of the Board
Mark Berger, M.D. - Chief Medical Officer
Dale L. Ludwik, Ph.D. - Chief Scientific Officer
Anil Kapur - Chief Commercial Officer
Steve O’Loughlin - Principal Financial and Accounting Officer
Cynthia Pussinen - Executive Vice President, Technical Operations and Supply Chain
David Gould, M.D. - Senior Vice President, Corporate Development and Affairs
Dr. Vijay Reddy, M.D., Ph.D. - Vice President, Clinical Development
Mamata Gokhale, Ph.D., RAC - Vice President, Global Head of Regulatory Affairs
Qing Liang, PhD, DABR - Vice President, Head of Radiation Sciences
Gary Siegel - Vice President, Controller, Finance
PRODUCT #1 NAME

Iomab-B / Phase 3

Product #1 Description

Iomab-B (I-131 apamistamab) is a radioimmunoconjugate consisting of BC8, a novel murine monoclonal antibody, and iodine-131 radioisotope. BC8 has been developed by Fred Hutchinson Cancer Research Center to target CD45, a pan-leukocyte antigen widely expressed on white blood cells. This antigen makes BC8 potentially useful in targeting white blood cells in preparation for hematopoietic stem cell transplantation in a number of blood cancer indications, including acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, Hodgkin’s disease, Non-Hodgkin lymphomas and multiple myeloma. When labeled with radioactive isotopes, BC8 carries radioactivity directly to the site of cancerous growth and bone marrow while avoiding effects of radiation on most healthy tissues. Iomab-B is in a Pivotal Phase 3 trial that is enrolling at 19 high transplant volume medical centers.

PRODUCT #2 NAME

Actimab-MDS / Phase 1

Product #2 Description

Actimab-MDS (Ac-225 lintuzumab) is its second pivotal program for targeted conditioning that will study the ARC comprised of the anti-CD33 monoclonal antibody lintuzumab linked to the radioisotope actinium-225 in patients with high-risk MDS in combination with RIC or Reduced Intensity Conditioning prior to a BMT.

PRODUCT #3 NAME

Iomab-ACT / Planned Phase 1

Product #3 Description

Iomab-ACT is a single dose, outpatient administered chemo-free lymphodepletive agent to be used prior to adoptive cell therapy treatment, such as CAR-T or TCR-based therapies.

Its ACT or Adoptive Cell Therapy program targets CD45 and utilizes a lower dose of iodine-131 than Iomab-B or lutetium-177 and is intended to be used for targeted conditioning or lymphodepletion prior to CAR-T and adoptive cell therapies as a replacement to non-optimized chemotherapies, such as Flu/Cy or udarabine and cyclophosphamide, that is used in standard practice today.

PIPELINE IMAGE
Adrenomed AG

PRESENTER

Dr. Frauke Hein, Chief Business Officer

COMPANY DESCRIPTION

Adrenomed AG is a German privately financed, clinical stage biopharmaceutical company. Adrenomed’s mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. Founded in 2009 by a management team with decades of in-depth experience in sepsis and deep knowledge in diagnostics and drug development, the Company’s lead product candidate is Adrecizumab, a clinical-stage, rist-in-class humanized monoclonal antibody. Adrecizumab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity. Adrecizumab is currently under clinical evaluation in a biomarker-guided, double-blinded, placebo-controlled, randomized, multicenter proof-of-concept Phase II study with 300 patients suffering septic shock. Excellent safety and tolerability were demonstrated in two Phase I trials.

MANAGEMENT TEAM

CEO - Dr. Gerry Moeller
CSO - Dr. Andreas Bergmann
CMO - Dr. Jens Zimmermann
CBO - Dr. Frauke Hein

FINANCIAL SUMMARY

Privately Funded

PRODUCT #1 NAME

Adrecizumab, Phase 2 in biomarker strati. ed septic shock

Product #1 Description

Adrecizumab is a clinical stage first-in-class humanized mab drug candidate for the causal treatment of endothelial barrier dysfunction to rescue vascular integrity. Adrecizumab is currently tested in a biomarker-selected Phase 2 study with 300 patients in early septic shock with TLR in Q1/2020 and in 150 cardiogenic shock patients.

PIPEDLINE IMAGE

Adrenomed Pipeline

- Septic Shock
- Cardiogenic Shock
- Acute Heart Failure
- undisclosed

July 2019
Affbody AB

PRESENTER

Dr. Xiaoli Hu, Director Business Development

COMPANY DESCRIPTION

Affibody is a clinical stage Swedish biotech company with a broad product pipeline focused on developing innovative next generation biopharmaceuticals based on its unique proprietary technology platforms: Abody® molecules and Albumod™. The company operates a focused experimental medicine model and currently has three clinical stage proprietary programs. The first two are therapeutic programs that targets psoriasis and B-cell driven autoimmune diseases, respectively. The third program is a diagnostic imaging program that is directed primarily towards metastatic breast cancer. In addition to the partnering opportunities to its proprietary pipeline, the company offers the half-life extension technology, Albumod™, for out licensing.

Affibody has ongoing commercial relationships with several companies such as AbClon, Alexion, Biotest, Daewoong, Daiichi Sankyo, GE Healthcare, and Swedish Orphan Biovitrum.

MANAGEMENT TEAM

David Bejker, CEO
Johan Stuart, CFO
Karin Nord, SVP Research Operations
Fredrik Frejd, CSO

FINANCIAL SUMMARY

Financial Highlights (Interim Report – January to March 2019)

- Revenue for the quarter amounted to SEK 30.0 (22.5) m
- Operating result for the quarter amounted to SEK -24.9 (-37.0) m
- Net result for the quarter amounted to SEK -24.7 (-37.0) m
- Cash flow for the quarter amounted to SEK 10.7 (8.6) m
- Cash and cash equivalents at the end of the period amounted to SEK 101.6 (249.9) m.

PIPELINE IMAGE

Pipeline Designed to Explore Unique Technology

<table>
<thead>
<tr>
<th>ABY-035 (IL-17) Psoriasis</th>
<th>Preclinical</th>
<th>IND Enabling</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABY-039 (FB01) IgG-mediated autoimmunity</td>
<td>Preclinical</td>
<td>IND Enabling</td>
<td>Phase I</td>
<td>Phase II</td>
<td>Phase III</td>
</tr>
<tr>
<td>Discovery Programs</td>
<td>Preclinical</td>
<td>IND Enabling</td>
<td>Phase I</td>
<td>Phase II</td>
<td>Phase III</td>
</tr>
<tr>
<td>Partnered Programs</td>
<td>Preclinical</td>
<td>IND Enabling</td>
<td>Phase I</td>
<td>Phase II</td>
<td>Phase III</td>
</tr>
</tbody>
</table>
Amryt Pharma Plc.

PRESENTER
Dr. Kieran Rooney VP, Strategic Alliances & Licensing

COMPANY DESCRIPTION
Amryt Pharma is a commercial-stage pharmaceutical company focused on acquiring, developing and commercializing innovative new treatments to help improve the lives of patients living with rare and orphan diseases. Founded in August 2015, Amryt has subsequently made 2 corporate acquisitions, licensed EU/MENA rights to a commercial-stage orphan asset (Lojuxta/lomitapide for the treatment of Homozygous Familial Hypercholesterolemia) and licensed a gene therapy platform technology from University College Dublin. The Company is traded on the London AIM market under the ticker AMYT. The Company remains highly transactional and continues to actively seek to identify assets (in particular commercial or late stage development assets) which present a good strategic fit.

MANAGEMENT TEAM
Dr Joe Wiley - CEO;
Rory Nealon - CFO;
Dr Mark Sumeray - CMO;
David Allmond - CCO;
Dr Kieran Rooney - VP, Strategic Alliances & Licensing

FINANCIAL SUMMARY
Publicly listed on AIM (London) and Euronext Growth (Dublin).

PRODUCT #1 NAME
Lojuxta (lomitapide) - marketed

Product #1 Description
Lojuxta (lomitapide) is approved in US, EU and Japan for the treatment of Homozygous Familial Hypercholesterolaemia. Amryt has rights to Lojuxta for EMEA, Russia and CIS.

PRODUCT #2 NAME
AP101 - Phase III

Product #2 Description
AP101 is currently in a global Phase III study for the treatment of the orphan dermatological condition, Epidermolysis bullosa.

PRODUCT #3 NAME
AP103 - preclinical

Product #3 Description
AP103 is a non-viral gene therapy in preclinical development for the treatment of Recessive Dystrophic Epidermolysis Bullosa.
<table>
<thead>
<tr>
<th>Product Candidate</th>
<th>Indication</th>
<th>Preclinical</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
<th>Approved</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lojuxta(^1) (lornilapide)(^1)</td>
<td>Adult HoFH</td>
<td></td>
<td>EU, MENA, Turkey, Russia &amp; CIS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Episalvan(^2)</td>
<td>Partial Thickness Wounds</td>
<td>EU</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AP101(^2)</td>
<td>Epidermolysis Bullosa</td>
<td>Global</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lojuxta(^*) (lornilapide)(^*)</td>
<td>Paediatric HoFH</td>
<td>EU, MENA, Turkey, Russia &amp; CIS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lojuxta(^*) (lornilapide)(^*)</td>
<td>FCS</td>
<td>EU, MENA, Turkey, Russia &amp; CIS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AP101(^2)</td>
<td>TENS / SIS</td>
<td>Global</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AP101(^2)</td>
<td>Radiation Induced Dermatitis</td>
<td>Global</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AP103 (Gene Therapy)</td>
<td>Epidermolysis Bullosa</td>
<td>Global</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1. The European Commission (EC) granted authorization to lornilapide under the tradename Lojuxta\(^\*\) in July 2019.
Anagenesis Biotechnologies

PRESENTER
Dr. Jean-Yves Bonnefoy, CEO

COMPANY DESCRIPTION
A start-up dedicated to developing treatments for muscle dystrophies and T2D through two complementary, cutting-edge approaches:

a) NCE from cell-based in vitro HTS based on stem cell-derived normal and disease in vitro models

b) Cell therapy in vivo using stem cell-derived satellite cells or brown adipocytes

Exclusive rights to know-how and patents generated by Prof. Olivier Pourqui (Strasbourgh/Harvard) for the high-yield, high-abundance generation of paraxial mesodermal cells in vitro.

Partnership opportunities for pharma companies to develop customized in vitro assays for compound testing (e.g. Boehringer Ingelheim) and develop cell-based therapies.

First investors in 2013 (AFM, French Muscular Dystrophy Association) 2015, Cap Innov'Est and Boehringer Ingelheim Venture Fund in 2018. Now seeking new co-investors (8 M€) for 2 programs up to IND in 3 years.

MANAGEMENT TEAM
Jean-Yves Bonnefoy, President & CEO
Aurore Hick, Lab Head
Cécile Jacques, Head of Operations

FINANCIAL SUMMARY
Raised 4.2 M€ in equity, 5.5 M€ in non-dilutive funding, seeking to complete a 15 M€ round, 8 M€ sought from 2 investors.
Anima Biotech, Inc.

PRESENTER
Mr. Yochi Slonim, Co-Founder & CEO

COMPANY DESCRIPTION
Anima Biotech is advancing Translation Control Therapeutics, the first and only platform for the discovery of small molecule drugs that specifically control mRNA translation as a new strategy against hard and undruggable targets in many diseases.

Anima’s proprietary technology enables visualization and monitoring of target protein translation via pulses of light emitted by ribosomes. The fully automated high-throughput screening system discovers small molecules that modulate the light, as they decrease or increase the target protein’s production. The platform integrates proprietary technologies in biology, bioinformatics, image analysis, big data analysis and artificial intelligence algorithms in a cloud computing software architecture.

Anima is developing an internal pipeline across multiple therapeutic areas with high unmet need and hard targets. Current programs are in Fibrosis (inhibiting the synthesis of Collagen type I), Viral infections (Respiratory Syncytial Virus – interfering with viral protein synthesis), Oncology (C-Myc translation inhibitors) and Huntington’s disease (monitoring mutant Huntingtin translation pausing).

Anima’s Translation Control Therapeutics platform is strategically designed for partnering with Pharma. The power of Anima’s approach was solidified with a $1B+ collaboration with Lilly for the discovery and development of translation inhibitors of several targets. Anima’s technology has been further validated by 5 granted patents, 14 peer reviewed publications and 17 scientific collaborations.

MANAGEMENT TEAM
Yochi Slonim, Co-founder & CEO, Board member
Zeev Smilansky, Ph.D., Co-founder & Chief Science O. cer
Iris Alroy, Ph.D., Vice President, R&D
Avi Eliassaf, Chief Operating Officer
Kevin Pong, Ph.D., Vice President, Business Development
Yossi Oulu, Vice President, Digital Technologies

PRODUCT #1 NAME
Lung Fibrosis - Collagen I translation inhibitors

Product #1 Description
By using our platform, we identified lung-selective Collagen I translation inhibitors small molecules active in reducing the production of Collagen I.

PRODUCT #2 NAME
C-Myc translation inhibitors

Product #2 Description
A novel approach to target the undruggable Myc oncogene in Cancer – reducing Myc protein translation. Compounds were identified which markedly reduced Myc protein levels in lung tumor cell line.
Several compound clusters identified as reducing RSV translation and viral load in target cells. A new strategy for the discovery of anti-viral drugs: instead of targeting viral proteins, we focus on intervention in host protein interactions with viral proteins, targeting cellular targets that viruses

**Product #3 Description**

PRODUCT #3 NAME
RSV Viral Translation Inhibitors

PIPELINE IMAGE
Anocca AB

PRESENTER
Dr. Reagan Jarvis, CEO

COMPANY DESCRIPTION
Anocca is a biotechnology company developing next-generation immunotherapies via individualisation of therapeutic products to precisely leverage the immune system of each patient.

Due to both the immense complexity of immunity and the significant differences in the composition of the immune system between individuals, there is a need to individualise targeted immunotherapeutics. Anocca’s unique technology platform captures key information from the immune system of each individual to deliver a range of immunotherapies specifically tailored to target the disease attributes of each patient, and to work safely within the constraints of each patient’s immune system.

Anocca’s first clinical programs aim to deliver cellular therapies equipped either with targeting receptors from our receptor libraries that are tailored for defined groups of individuals, or equipped with targeting receptors that are created for each patient in a fully individualised manner.

MANAGEMENT TEAM
Reagan Jarvis - CEO
Hugh Salter - CSO
Hassan Aly - CMO
Viktor Arnkil - COO

Company Address
Forskargatan 20G
Sodertalje, 15136
Sweden

Company Website
www.anocca.com

Contact Email
bd@anocca.com

Company Type
Private

Company Sector
Biotechnology

Years Founded
2014
Ares Genetics GmbH

**PRESENTER**
Dr. Andreas Posch, CEO

**COMPANY DESCRIPTION**
Ares Genetics (ARES), a Vienna-based digital diagnostics start-up is revolutionizing infectious disease diagnostics and therapeutics by artificial intelligence based DNA testing to improve patient outcomes at reduced costs. To achieve this, ARES makes use of high-resolution next generation sequencing (NGS) technology in combination with a proprietary pathogen and antibiotic resistance reference database, ARESdb for result interpretation.

Founded in March 2017, ARES makes revenue from services as well as IP licensing and its customers and strategic partners include leading anti-infectives manufacturers (e.g. Sandoz), a prime supplier of biological data applications (QIAGEN) as well as one of the world’s largest NGS providers (BGI/MGI). As of September 2019, ARES has entered into a multi-phase partnership with an undisclosed leading global in vitro diagnostics corporation to jointly advance human diagnostic solutions based on ARESdb and the company is currently fundraising to rapidly scale its business in EU and US.

**MANAGEMENT TEAM**
Dr. Andreas Posch, CEO
Dr. Achim Plum, Managing Director
Dr. Stephan Beisken, Head of Bioinformatics & Analytics
Dr. Johannes Weinberger, Head of NGS Laboratory
Faranak Atrzadeh, Head of Market Access USA

**FINANCIAL SUMMARY**
Founded in March 2017 and seed-financed by the German molecular diagnostic company Curetis GmbH, ARES projects seven figures revenues from services and licensing for 2019. ARES’ customers and strategic partners include leading anti-infectives manufacturers (e.g. Sandoz), a prime supplier of biological data applications (QIAGEN) as well as one of the world’s largest NGS providers (BGI/MGI). As of September 2019, ARES has entered into a multi-phase partnership with an undisclosed leading global in vitro diagnostics corporation to jointly advance human diagnostic solutions based on ARESdb. Additionally, current ARES’ R&D programs with a total volume of approx. €3 million are largely co-funded by competitive non-dilutive grants.

**PRODUCT #1 NAME**
ARESupa - Universal Pathogenome Assay

**Product #1 Description**
The ARESupa – Universal Pathogenome Assay represents Ares Genetics’ first commercial offering for next-generation molecular antimicrobial resistance (AMR) testing services with an initial focus on infection control, AMR epidemiology and surveillance, clinical research and pharmaceutical anti-infectives R&D.

Under the ARESupa, the company provides whole genome sequencing of bacterial isolates for pathogen identification, typing, and drug resistance detection. Using Ares Genetics’ cloud-based data analytics platform, customers can interactively explore detailed information on the identity of pathogens as well as their genetic mechanisms of resistance, the prevalence of such mechanisms and the accuracy with which they predict resistance to specific antibiotics.
ARES UNIVERSAL PATHOGENOME ASSAY: MOLECULAR DRUG RESPONSE DETECTION BY NGS

Our Pipeline From Public Health And Pharma Services To Diagnostic Services And IVD Products

Offer | Customer | Need | Timeline
--- | --- | --- | ---
IVD & SaaS Products | Healthcare Provider | Early informed decision by rapid real-time testing for hospital acquired infections | Q2 2022 (TBC)
| Diagnostic Testing Services | Healthcare Provider | Informed decision in <3 days for patient care | Under development (confidential)
| Public Health & Pharma Services | Public Health Lab | Infectious disease control | Launched 2010
| | Phoenix Companies | Accelerated drug development & improved drug positioning | (Revenue generating in 2019)

©2019 Ares Genetics GmbH - All rights reserved - www.ares-genetics.com
Athira Pharma, Inc.

PRESENTER
Dr. Leen Kawas, President & CEO

COMPANY DESCRIPTION
Athira Pharma, Inc. is a drug development company striving to improve human health by advancing new therapies for neurodegenerative diseases like Alzheimer’s and Parkinson’s. Our approach is “first-in-class” with the potential to halt or even reverse degeneration of the nervous system. We are committed to advancing novel and innovative research, developing products that are affordable and accessible in alignment with our strategy focused on the people that we ultimately aim to serve with our therapies. We are mission-driven to restore lives by advancing bold therapies, thoughtfully and urgently.

MANAGEMENT TEAM
Leen Kawas, PhD - President and Chief Executive Officer
Mark Litton, PhD, MBA - Chief Operating Officer;
Hans Moebius, MD, PhD, ECPM, FAAN - Chief Medical Officer; Glenna Mileson - Chief Financial Officer
Christina Thomson, JD - General Counsel

FINANCIAL SUMMARY
Successfully raised two oversubscribed financing rounds totaling approximately $20M USD. Currently active in Series B fundraising to support Phase 2 clinical trials for lead product and additional product and corporate development.

PRODUCT #1 NAME
NDX-1017

Product #1 Description
NDX-1017 is a small molecule therapeutic specifically designed to impact neurodegeneration and regenerate brain tissue. Unlike other drugs approved or in development, NDX-1017 is novel because of its regenerative potential and is designed to slow, halt or potentially reverse the effects of Alzheimer’s disease, rather than just alleviate symptoms.

PIPELINE IMAGE
Atriva Therapeutics GmbH

PRESENTER
Dr. Rainer Lichtenberger, President & CEO

COMPANY DESCRIPTION
Atriva Therapeutics, quantum leap in antiviral therapies: Atriva is the first clinical stage company, successfully targeting host-cell factors. Replication of RNA viruses like Hantavirus, Influenzavirus, Coronaviruses (SARS, MERS), Flaviviruses (Dengue, West-Nile, Zika) depends on the RAF / MEK / ERK signaling cascade. ATRIVA discovered that blocking this pathway effectively impairs viral replication and favorably modulates the immune system of the host (dual mode of action).

ATRIVA ATR-002, a selective non-competitive MEK1/2 inhibitor, is first-in-class for tackling influenza, Hantavirus, and influenza-like-illness. Viruses depend on MEK function for their replication and spreading. ATR-002, a small molecule in one-daily oral presentation successfully finished phase 1 clinical study in doses up to 1 g/d. For severe influenza best-in-class benefits are proven in preclinical studies:

• Therapeutic activity 4 days after infection against all known influenza strains
• Uniquely beneficial for patients with severe influenza at risk developing serious complications, due to dual mode of action.
• Resistance formation hardly possible: virus cannot replace missing cellular function (shown with Baloxavir-resistant virus strain).

MANAGEMENT TEAM
Rainer Lichtenberger, Ph.D., MBA, President and CEO
Sebastian Canisius, MD, Ph.D., Chief Medical Officer
Prof. Oliver Planz, Ph.D., Chief Scientific Officer
Christian Wallasch, Ph.D., Chief Operations/Development Officer

FINANCIAL SUMMARY
Atriva has raised € 4.5 Mn seed round in 2017 and made initial closing of € 6 Mn of the series A/B round in early 2019. The series A/B of € 32 Mn total closed by December 2019 shall advance the ATR-002 lead in influenza to confirmatory phase 2b study ) and ATR-004 to initial clinical PoC in 2023.
PRODUCT #1 NAME
ATR-002 Clinical Phase 2

Product #1 Description
ATR-002, a small molecule in a one-daily oral presentation successfully finished phase 1 clinical study in doses up to 1 g/d. For lead indication severe influenza best-in-class benefits are proven in preclinical studies:

• Therapeutic activity up to 4 days after infection against all known influenza strains
• Uniquely beneficial for patients with severe influenza and those at risk developing serious complications, due to dual mode of action.
• Resistance formation hardly possible: Virus cannot replace the missing cellular function (shown with Baloxavir-resistant virus strain)

The lead project ATR-002 is entering phase 2 for influenza in high-risk patients with co-morbidities.

PRODUCT #2 NAME
ATR-004 Hantavirus Pulmonary Syndrome

Product #2 Description
The pipeline project ATR-004 is developed for Hantavirus Pulmonary Syndrome (HPS) and Hanta Fever Renal Syndrome (HFRS). After the preclinical PoC obtained in Q3 2019, Atriva will submit an Orphan Drug Designation (ODD) in USA still in Q4 2019. ATR-004 is first-in-class for Hantavirus, as neither a vaccination nor a cure exists to-date, with up to 150,000 cases a year in the Americas, Asia and Europe and fatalities up to 40% (HPS). ATR-004 will enter clinical development in 2020.
BioEcho Life Sciences GmbH

PRESENTER
Mr. Frank Schaefer, Managing Director

COMPANY DESCRIPTION
BioEcho is a Biotech start-up developing disruptive technologies and products for molecular diagnostics, molecular breeding and genome research.

The company has developed revolutionary single-step technologies for dramatically accelerated and simplified genomic Sample Preparation (DNA and RNA isolation processes). We apply these technologies in the development of more convenient Liquid Biopsy procedures (isolation of circulating nucleic acids), high-throughput automation and Point-of-Care diagnostics applications.

Molecular diagnoses workflows consist of 2 general steps, i) Sample Preparation (DNA/RNA isolation) followed by ii) Sample Analysis. Our technologies will allow to bring genomic Sample Preparation to the performance level required to keep pace with the pacemaker technologies in Sample Analysis, e.g., Next Generation Sequencing, PCR.

BioEcho technologies speed up the isolation processes 10-fold, reduce process steps at least 5-fold and improve downstream Sample Analysis performance and robustness by significant increase in DNA quality. Moreover, BioEcho products and processes are sustainable in avoiding toxic materials and by saving of 70% plastics waste.

BioEcho has been founded by an experienced team of experts in the field of genomic Sample Preparation with formerly leading positions at Qiagen and other companies. The organization has 15 employees, is fully digitalized and set up to meet the increasing demand from the market. We are engaged in deals with major players in the life sciences field. We look for a major investment in order to support our growth plans.

MANAGEMENT TEAM
Dr. Frank Schäfer, Managing Director
Dr. Markus Müller, Managing Director

FINANCIAL SUMMARY
BioEcho has been founded with a seed investment by the founders and by private investors of 1.4 Mio €. Since 2016, two more smaller rounds have been realized with the current group of private investors.

After market entry early 2018, revenues of 0.3 Mio € are expected for 2019 and a strong growth to 2 Mio € for 2020, supported by the start of a global distribution agreement with a top 3 world-wide player in the life sciences field. We plan with revenues of 50 Mio € by 2025, corresponding to 1% market share. Break Even is targeted for 2021.

BioEcho targets an investment round of 5 Mio € by Q1-2020. Potential partners have been identified for this round and we now look for suitable co-investors to join our journey.
PRODUCT #1 NAME
EchoLUTION Plant DNA 96 Kit

Product #1 Description
The kit product is used for single-step 96-well high-throughput purification of genomic DNA from plant tissue. It is applied by plant breeding companies and academic institutions and provides up to 80% time savings compared to traditional products.

PRODUCT #2 NAME
EchoLUTION Tissue DNA Micro Kit

Product #2 Description
The kit product is used for single-step spin purification of genomic DNA from small human or animal tissue samples. The process provides high DNA yield from small samples with nearly 100% recovery and no loss of precious samples. The process is convenient and very fast: complete in less than 40 min, no tedious bind-wash-elute procedure. Furthermore, EchoLUTION products are sustainable in generating 70% less plastic than with Silica-based methods and no longer make use of hazardous liquids.

PIPELINE IMAGE
Bone Therapeutics SA

PRESENTER
Mr. Thomas Lienard, CEO

COMPANY DESCRIPTION
Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopaedics and bone diseases. Based in Gosselies, Belgium, the Company has a broad, diversified portfolio of bone cell therapy and an innovative biological product in later-stage clinical development across a number of disease areas, which target markets with large unmet medical needs and limited innovation.

Bone Therapeutics’ core technology is based on its allogeneic cell therapy platform (ALLOB) which uses a unique, proprietary approach to bone regeneration, which turns undifferentiated stem cells from healthy donors into bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery, and are produced via a proprietary, cutting-edge manufacturing process.

The Company’s ALLOB product pipeline includes a cell therapy product candidate that is expected to enter Phase II/III clinical development for the treatment of delayed-union fractures and a Phase II asset in patients undergoing a spinal fusion procedure. In addition, the Company is also developing an enhanced viscosupplement, JTA-004, which is expected to enter Phase III development for the treatment of pain in knee osteoarthritis.

Bone Therapeutics’ cell therapy products are manufactured to the highest GMP (Good Manufacturing Practices) standards and are protected by a broad IP (Intellectual Property) portfolio as well as knowhow.

MANAGEMENT TEAM
Thomas Lienard, MBA – Chief Executive Officer
Jean-Luc Vandebroek – Chief Financial Officer
Olivier Godeaux, MD – Chief Medical Officer
Benoit Moreaux, PhD – Chief Technology and Manufacturing
Officer Linda Lebon – Chief Regulatory Affairs Officer

FINANCIAL SUMMARY
- 2018 revenues and operating income of €5.1 million, up 20.5%
- 2018 operating loss for the period amounted to €11.5 million
- 2018 year-end cash position of €8.2 million
- The net cash burn for the full year 2019 is expected to be in the range of €12-13 million
- Successfully raised €8.5 million through private placement of new shares and non-dilutive subordinated bonds.
PRODUCT #1 NAME
The allogeneic bone-cell therapy platform, ALLOB - Expected to enter phase II/III clinical development for the treatment of delayed union fracture and successfully completed a Phase IIa study in patients undergoing a spinal fusion procedure.

Product #1 Description
ALLOB is company’s allogeneic bone-cell therapy platform which turns undifferentiated stem cells from healthy donors into bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery, and are produced via a proprietary, cutting-edge manufacturing process.

PRODUCT #2 NAME
The enhanced viscosupplement, JTA-004 - Expected to enter phase III development for the treatment of pain in knee osteoarthritis.

Product #2 Description
JTA-004 is Company’s patented, enhanced viscosupplement product for the treatment of knee osteoarthritis (KOA), with a demonstrated better pain relief compared to the current market leader.

PIPELINE IMAGE

Company Address
Rue Auguste Piccard 37
Gosselies, 6041
Belgium

Company Website
www.bonetherapeutics.com

Contact Email
info@bonetherapeutics.com

Company Type
Listed/Public

Stock Ticker
[EBR: BOTHE]

Company Sector
Biotechnology

Years Founded
2006
Boston Pharmaceuticals

PRESENTER

Mr. Ed Zhang, VP Corporate Development

COMPANY DESCRIPTION

Boston Pharmaceuticals is a translational drug development company. It was founded in 2016 by Chris Viehbacher, ex-CEO of Sanofi and Rob Armstrong, ex-R&D Executive from Eli Lilly. With $600M committed capital from Gurnet Point Capital, Boston Pharma’s business model is focused on partnering and developing therapeutics from late pre-clinical to clinical POC. In the past 3 years, we have built an experienced clinical development team and acquired a diverse portfolio of fifteen programs in oncology, autoimmune, cardiovascular, dermatology, anti-infective, gastrointestinal, and metabolic, including recent deals with GSK, Novartis, and other Pharma and biotech partners. In principle, we are agnostic with regards to indication or molecular modality. During this conference, we are seeking in licensing and out licensing partnering discussions.
Cantargia AB

PRESENTER
Dr. Göran Forsberg, CEO

COMPANY DESCRIPTION
Cantargia is a Swedish biotechnology company that specialises in the development of antibodies for various types of cancer diseases and autoimmune/inflammatory diseases. Our development programme includes the product candidate CAN04, which is currently in phase IIa clinical studies for treatment of non-small cell lung cancer and pancreatic cancer, as well as our discovery project CANxx. The company is listed on OMX Stockholm’s Main List (Small Cap).

MANAGEMENT TEAM
Dr Göran Forsberg, CEO
Bengt Jöndell, CFO
Dr Liselotte Larsson, VP Operations
Dr Lars Thorsson, VP Clinical Development
Dr David Liberg, VP Cancer Research

PRODUCT #1 NAME
CAN04 Phase IIa clinical development (cancer)

Product #1 Description
CAN04: Antibody against IL1RAP found on tumor cells and in tumor microenvironment. Phase I data presented orally at ASCO, phase IIa for ongoing at approximately 20 centres in Europe. The trial is investigating both monotherapy and combination therapy in patients with non-small cell lung cancer or pancreatic cancer.

PRODUCT #2 NAME
CANxx Preclinical stage to be developed in autoimmunity/inflammatory disease.

Product #2 Description
CANxx: Antibody against IL1RAP designed to potently block signalling of IL1/IL33/IL36. Preclinical stage to be developed in autoimmunity/inflammatory disease.

PIPELINE IMAGE

<table>
<thead>
<tr>
<th>Project</th>
<th>Discovery phase</th>
<th>Preclinical phase</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
<th>Commercial phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAN04</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-small cell lung cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pancreatic cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leukemia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CANxx</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Autoimmune and inflammatory diseases</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
CanVirex AG

PRESENTER
Dr. Tobias Speck, Scientific Project Manager

COMPANY DESCRIPTION
CanVirex is a Swiss biotech company developing oncolytic viruses as a multiplexed immune-modulating platform for cancer therapy.

The company is a spin-off from the Heidelberg University Hospital in Germany and participates in the Heidelberg network for clinical development of proprietary virus constructs. CanVirex’s virus constructs are based on 15 years of academic research with a focus on safety, immune modulation and commercialization.

CanVirex implements a translational program that combines clinical testing with scientific research. The translational approach will allow for a personalized therapeutic approach by rational selection of cancer patients.

MANAGEMENT TEAM
Dr. Werner Tschollar, founder and chairman of the board, holds degrees in medicine, clinical pharmacology (PhD), and has an MBA. Werner held senior executive positions at BMS, Schering Plough and Novartis and was founder of several successful biotech companies.

Prof. Guy Ungerechts, co-founder and CMO/CSO is deputy director of the department Medical Oncology at the NCT, Heidelberg, Germany. Guy is an experienced leading investigator of phase I/II/III clinical trials with different oncolytic viruses and head of the division Virotherapy at the DKFZ, Heidelberg.

Dr. Urs Breitenstein, CFO previously worked for Basler Kantonalbank, PwC and was partner at Deloitte Switzerland.

FINANCIAL SUMMARY
The initial funding of several million CHF was recruited from a single private investor in the field. CanVirex is currently offering investment opportunities. The funding will be dedicated to clinical trial preparation, including toxicity studies, GMP development, manufacturing scale-up and cGMP vector manufacturing. A second offering will be available in 12 months, dedicated to conduct a phase I/IIa clinical trial with CanVirex’s lead candidate.

PIPELINE IMAGE
Cardior Pharmaceuticals GmbH

PRESENTER
Mrs. Claudia Ulbrich, CEO

COMPANY DESCRIPTION
Cardior Pharmaceuticals GmbH (Cardior) was founded 2016 by Prof. Thomas Thum as a spin-off from Hannover Medical School. A Series A financing round of 15 Mio. € was successfully closed in May 2017 with five international leading venture capital funds including LSP, BioMedPartners, Boehringer Ingelheim Venture Fund, Bristol-Myers Squibb and High-Tech Gründerfonds.

The company is dedicated to becoming a world-leader in design, research and development of non-coding RNA based therapeutics and diagnostics for cardiovascular diseases. These non-coding RNAs are a novel class of regulatory RNAs and have huge therapeutic potential. As its lead compound “CDR” Cardior is developing an anti-sense oligonucleotide as therapeutic to inhibit a specific non-coding RNA in the heart controlling cardiac growth, autophagy and contractility. Its inhibition reverses cardiac remodeling, restores normal cardiac function and can revolutionize the treatment of patients with myocardial infarction-induced as well as chronic heart failure. New innovative treatments of heart failure are scarce. But with this novel approach Cardior’s clear advantage is having a well-characterized target with convincing preclinical efficacy and safety data leading to a superior approach for the treatment of patients with heart failure.

Within only two years Cardior has advanced from research to clinical stage. The company’s lead compound started a clinical phase 1b trial in June 2019. After proof-of-concept (POC) data and clinical validation Cardior seeks to market its lead compound in collaboration with a big pharma partner. Besides the patent protected lead compound Cardior has access to a large patent portfolio consisting of several candidates for heart failure therapy and other indications, e.g. kidney fibrosis.

MANAGEMENT TEAM
Dr. Claudia Ulbrich - CEO,
Prof. Dr. Dr. Thomas Thum - CSO,
Dr. Wilfried Hauke - CMO

FINANCIAL SUMMARY

PRODUCT #1 NAME
CDR - clinical phase 1b

Product #1 Description
Cardior is developing the anti-sense oligonucleotide "CDR" as therapeutic to inhibit a specific non-coding RNA in the heart controlling cardiac growth, autophagy and contractility. Its inhibition reverses cardiac remodeling, restores normal cardiac function and can revolutionize the treatment of patients with myocardial infarction-induced as well as chronic heart failure.
**Therapeutics**

<table>
<thead>
<tr>
<th>Company candidate</th>
<th>Product</th>
<th>Target class</th>
<th>Indication</th>
<th>Discovery</th>
<th>Preclinical</th>
<th>Safety/Tox</th>
<th>Clinical Phase 1</th>
<th>Clinical Phase 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>CDR</td>
<td>Therapeutic</td>
<td>mRNA</td>
<td>Subacute/Chronic Heart Failure</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CDR426D</td>
<td>Therapeutic</td>
<td>Targeted delivery</td>
<td>Chronic Heart Failure</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CDR080L</td>
<td>Therapeutic</td>
<td>mRNA</td>
<td>I/R kidney disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CDR180L</td>
<td>Therapeutic</td>
<td>mRNA</td>
<td>Refr. Angina Pectoris</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CDR088D</td>
<td>Therapeutic</td>
<td>Targeted delivery</td>
<td>Refr. Angina Pectoris</td>
<td>I/R kidney disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CDR6411L</td>
<td>Therapeutic</td>
<td>lncRNA</td>
<td>Heart Failure</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CDR546T</td>
<td>Therapeutic</td>
<td>lncRNA</td>
<td>Supportive LVAD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CDR076L</td>
<td>Therapeutic</td>
<td>mRNA</td>
<td>Cardiac Inflammation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CDR265L</td>
<td>Therapeutic</td>
<td>mRNA</td>
<td>Pathol. hypertrophy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CDR586L</td>
<td>Therapeutic</td>
<td>mRNA</td>
<td>I/R injury heart</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Diagnostics**

<table>
<thead>
<tr>
<th>Company candidate</th>
<th>Product</th>
<th>Target class</th>
<th>Indication</th>
<th>Discovery</th>
<th>Prototype</th>
<th>RUO</th>
<th>CE/IVD</th>
</tr>
</thead>
<tbody>
<tr>
<td>CDR022B</td>
<td>Diagnostic</td>
<td>lncRNA</td>
<td>Heart Failure</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CDR426B</td>
<td>Biomarker</td>
<td>mRNA</td>
<td>Heart Failure</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CDR088B</td>
<td>Biomarker</td>
<td>mRNA</td>
<td>I/R Kidney Heart Failure</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
CUTISS AG

PRESENTER
Mrs. Daniela Marino, CEO

COMPANY DESCRIPTION
Every year more than 50 million people suffer from skin defects and need skin transplantation to restore skin function. Unfortunately, standard of care is often scarce and non effective leaving these patients with scars. Scars are disfiguring but also highly comforting, they can impair growth and movement and require serial surgeries and intense homecare. Often, psych-social rehabilitation too. CUTISS can now offer a solution: personalized, bioengineered skin grafts that can be produced in large quantities from a small biopsy and that due their biological characteristics will minimally scar after transplantation. Burn victim, burn survivors and all patients in need for skin could now finally have an option. Skin though is our largest organ. It takes more than clinical validation (ongoing phase II) to reach out to patients. This is why we are working on the the scale up already and trying to convert the actual manual production process into an automated one. denovoSkin, our first-in-line product, is envisioned to be the first-in-class automatically produces personalized skin tissue therapy: safe, effective and accessible.

MANAGEMENT TEAM
CEO, CCO (Dr. F. Hartmann), CIO (Dr. Vincent Ronfard), COO (Kathi Mujinya)

FINANCIAL SUMMARY
raised 13.3 M CHF since incorporation plus 4M CHF in EU and CH grants. Round B in Q4 2019.

PRODUCT #1 NAME
denovoSkin

Product #1 Description
Personalized, bio-engineered skin tissue therapy.

PIPELINE IMAGE
Cyxone AB

PRESENTER
Dr. Kjell Stenberg, CEO

COMPANY DESCRIPTION

Cyxone develops novel drugs to improve quality of life for patients suffering from autoimmune diseases. Cyxone AB is a clinical biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). The company's drug portfolio is based on two technological pillars in the form of oral molecules and cyclotide-based drugs that inhibit key processes in the body's cells that are typically associated with various immune-related disorders.

Cyxone’s technologies have the potential to address an unmet need to develop new effective and safe medicines that can improve the quality of life for patients affected by autoimmune diseases. The company's development portfolio comprises Rabeximod in a clinical phase II program for RA and T20K that has successfully completed phase I infusion study.

MANAGEMENT TEAM

- Ola Skanung – CFO
- Bert Junno – Chairman of the Board
- Theresa Comiskey Olsen – Board Member
- Saad Gilani – Board Member
- Mikael Lindstam – Board Member

PRODUCT #1 NAME

T20K (Lead candidate for multiple sclerosis), Phase 1 candidate.

Product #1 Description
T20K is Cyxone’s main candidate for prophylactic treatment for the autoimmune disease multiple sclerosis (MS). T20K is a unique substance derived from natural plant protein that scientists at the Medical University in Vienna, Austria, and the university clinic in Freiburg, Germany, first showed inhibiting pro-inflammatory cytokines such as IL-2 and effectively reduce clinical symptoms in an animal model for MS after oral administration. No signs of toxicity has been observed at therapeutic dosages.

PRODUCT #2 NAME

Rabeximod (Lead candidate for rheumatoid arthritis), Phase 2-b candidate.

Product #2 Description
Rabeximod is Cyxone’s drug candidate for the severe autoimmune disease rheumatoid arthritis (RA). It is an oral drug candidate for patients with moderate to severe active RA, who have previously been treated with methotrexate with inadequate response. Rabeximod’s efficacy is based on inhibiting differentiation of monocytes to pro-inflammatory macrophages, without affecting the anti-inflammatory macrophages. Previous clinical phase II-data in RA have proven a beneficial safety profile, confirmed optimal dosage and preliminary therapeutic efficacy.
DCPrime B.V.

PRESENTER
Dr. Erik Manting CEO

COMPANY DESCRIPTION
DCprime focuses on relapse vaccines, a novel class of cancer vaccines aimed at supporting immune control over residual disease, in order to prevent or delay tumour recurrence.

The company is currently testing its lead product DCP-001 in an international Phase II trial in AML. The study focuses on patients in clinical remission but with measurable residual disease (MRD) and who are not eligible for stem cell transplantation, posing a high risk of relapse.

DCprime is developing a broader relapse vaccine pipeline in both haematological cancers and solid tumour indications.

MANAGEMENT TEAM
Erik Manting, PdH - CEO
Jeroen Rovers, MD PhD - CMO

FINANCIAL SUMMARY
DCprime is supported by Van Herk Ventures

PRODUCT #1 NAME
DCP-001

Product #1 Description
DCP-001 is an off-the-shelf, cell-based relapse vaccine. DCP-001 is based on DCprime’s proprietary DCOne® leukemic cell line and is produced by transforming these tumour cells into a mature dendritic cell phenotype. In contrast to tumour cells, DCP-001 is highly immunogenic and efficiently processed by endogenous antigen-presenting cells.

PIPELINE IMAGE

<table>
<thead>
<tr>
<th>Indication</th>
<th>Product</th>
<th>Research</th>
<th>Preclinical</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>AML</td>
<td>DCP-001</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ADVANCE-II study monotherapy</td>
</tr>
<tr>
<td>AML / MDS</td>
<td>DCP-001</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>In combination with HMA's</td>
</tr>
<tr>
<td>Multiple Myeloma</td>
<td>DCP-001</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Post-ASCT in combination with lenalidomide</td>
</tr>
<tr>
<td>Solid tumours</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Various preclinical programs</td>
</tr>
</tbody>
</table>
Dyadic International, Inc.

PRESENTER
Mr. Matthew Jones, COO

COMPANY DESCRIPTION
Dyadic International, Inc. (NASDAQ: DYAI) – We are a global biotechnology company focused on further improving and leveraging the patented and proprietary C1 expression system to help bring biologic vaccines and drugs to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers to improve access and cost to patients and the healthcare system – but most importantly to save lives.

MANAGEMENT TEAM
Mark Emalfarb - CEO
Ronen Tchelet - CSO
Ping Rawson - CFO

FINANCIAL SUMMARY
Shares Outstanding (as of 7/8/2019): ~26.7M
Stock Price (as of 7/8/2019): $5.82
Market Capitalization (as of 7/8/2019): ~$155.7M
Cash & Liquid Investments (as of 3/31/2019): ~$40.1M
EpimAb Biotherapeutics GmbH

PRESENTER
Dr. Stephan Lensky, COO & CBO

COMPANY DESCRIPTION
EpimAb Biotherapeutics was founded in mid-2015 and is a privately-owned biopharmaceutical R&D company based in Shanghai with a proprietary unique and efficient technology called FIT-Ig® (Fabs-In-Tandem Immunoglobulin) to generate bispecific molecules with antibody-like properties. With this platform, EpimAb is creating a pipeline of its own novel bispecific antibody therapeutics focused around oncology and other areas of high value to patients. EpimAb’s frontrunning program, EMB01, is a dual cMet and EGFR inhibitor and is currently being investigated in a Phase I/II trial for treatment of solid tumors. Its differentiated mechanism called co-degradation, enabled EMB01 in preclinical models to prolong tumor regression many days beyond dosing. EpimAb’s pipeline also contains highly innovative immune-oncology assets entering preclinical development, including EMB02, a dual checkpoint inhibitor with a unique efficacy profile in preclinical models, that is expected to enter clinical studies in 2020. Furthermore, EMB06, a T-cell engaging bispecific with a unique safety profile.

EpimAb is diversifying its pipeline through selective licensing of its platform and pipeline assets to partners worldwide. The partnering models range from straightforward technology licenses, research collaborations, cross-licenses, co-development as well as outlicensing.

MANAGEMENT TEAM
CEO, Dr. Chengbin Wu, former CSO of Shanghai CP Guojian, former SVP of Biologics at Shangpharma ChemPartner, former Executive Director at AbbVie (inventor of DVD-Ig)
CBO/COO, Dr. Stephan Lensky, former Corporate VP of Business Development at Boehringer Ingelheim, former Regional BD Head at Bayer
CMO, Dr. Bin Peng, former Head of Global Translational Oncology at Novartis/Shanghai (Gleevec), former Clinical Director at GSK

FINANCIAL SUMMARY
2.5 M USD Seed
25 M USD Series A
74 M USD Series B

PRODUCT #1 NAME
EMB01

Product #1 Description
EMB01 is a bispecific cMET/EGFR antibody with a unique mechanism of action called co-degradation. By saturating all four of its binding sites it clusters 4 receptors forcing the tumor cell to internalize and degrade the entire complex including EMB01. It is currently being investigated in a clinical Phase I/II study.
PRODUCT #2 NAME
EMB02

Product #2 Description
EMB02 is a dual checkpoint inhibitor that has a unique efficacy profile in animal models differentiating the bispecific from its corresponding monoclonal antibodies. EpimAb is currently generating material for IND enabling studies.

PRODUCT #3 NAME
EMB06

Product #3 Description
EMB06 is a unique T-Cell engaging bispecific with an unexpectedly preferable safety profile. EpimAb has generated its own proprietary CD3 binders for this candidate. The profile has been tested in cynomolgous monkeys.
Faron Pharmaceuticals Ltd.

PRESENTER
Dr. Juho Jalkanen, Chief Development Officer

COMPANY DESCRIPTION
Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet need. "Small, but tough." That’s the best description of this outstanding Finnish biotech company looking to conquer some of the hardest diseases on the planet, e.g. ARDS, pancreatic cancer, glioblastoma, as well as tuberculosis. The Company currently has a pipeline focusing on vascular damage, leucocyte migration and immunotherapy. Faron’s pipeline is based on endothelial receptors involved in regulation of immune responses. Faron has mastered control of this response in both directions; slowing down immune escalation, and removal of immune suppression.

MANAGEMENT TEAM
Markku Jalkanen, CEO
Matti Karvonen, CMO
Toni Hänninen, CFO
Juho Jalkanen, CDO
Jami Mandelin, Head of R&D
Maria Lahtinen, Head of Supplies
Yrjö Wichman, VP Investor Relations and Finance

FINANCIAL SUMMARY
Faron is listed on the London Stock Exchange on the AIM market. Up to date it has gathered approximately € 70 mill in private and public placement, grants and governments loans.

PRODUCT #1 NAME
Traumakine, Phase II/III

Product #1 Description
Traumakine (i.v. interferon beta-1a) induces endothelial CD73 expression, which is the rate limiting enzyme in producing extracellular adenosine. This pathway is key in protecting organs under acute ischemic and inflammatory insult. Adenosine enhances the endothelial barrier, prevents capillary leak and enables organs to stand hypoxia.

PRODUCT #2 NAME
Clevegen (bexmarilimab), Phase I/II

Product #2 Description
Clevegen (FP-1305 or bexmarilimab) is humanized anti-Clever-1 antibody that turns immunosuppressive M2 macrophages into pro-inflammatory M1 macrophages. It is a first-in-class macrophage checkpoint for cancer immunotherapy and hard to treat infectious diseases.

PRODUCT #3 NAME
AOC3/SSAO inhibitors, pre-clinical

Product #3 Description
AOC3/SSAO inhibitors are small molecules targeting vascular adhesion protein-1 (VAP-1) for inflammatory conditions. We are developing 2nd generation AOC3/SSAO inhibitors and are currently in lead identification.
Gain Therapeutics SA

PRESENTER
Dr. Manolo Bellotto, General Manager

COMPANY DESCRIPTION
Gain Therapeutics SA is a Swiss biotech company specializing in the discovery of new drugs for rare and CNS diseases. The company targets lysosomal enzymes to develop innovative drugs for rare pediatric genetic disorders and selected CNS diseases with high unmet medical needs: Gaucher, MPS1, Krabbe, GM1, Parkinson and alpha-synucleopathies. Gain Therapeutics SA is developing a new class of compounds: structurally targeted allosteric regulators, identified through its pioneering proprietary platform – SEE-Tx.

MANAGEMENT TEAM
Gain Therapeutics management team is composed by international drug discovery, drug development, scientific affairs, market access and financial managers with a proven track record of out-licensing products for over $1mio deals values.

FINANCIAL SUMMARY
Currently, Gain Therapeutics collected €2.5mio initial investments.

PRODUCT #1 NAME
Parkinson and alpha-synucleopathies Program

Product #1 Description
We are targeting misfolded beta-glucosidase lysosomal enzyme to recover enzyme function via Gain Therapeutics Structurally Targeted Allosteric Regulators so as to reduce alpha-synuclein in Parkinson patients

PRODUCT #2 NAME
Gaucher Disease Program

Product #2 Description
We are targeting misfolded beta-glucosidase lysosomal enzyme to recover enzyme function via Gain Therapeutics Structurally Targeted Allosteric Regulators so as to reduce sphingolipids in Gaucher Disease patients

PRODUCT #3 NAME
GM1 Gangliosidosis Program

Product #3 Description
We are targeting misfolded beta-galactosidase lysosomal enzyme to recover enzyme function via Gain Therapeutics Structurally Targeted Allosteric Regulators so as to reduce GM1 gangliosides in GM+ Gangliosidosis patients
Genclis SA

PRESENTER

Prof. Bernard Bihain, CEO

COMPANY DESCRIPTION

Genclis commercializes pre-clinical and cellular models in allergy and autoimmunity to evaluate novel therapeutic, probiotic and nutritional solutions.

Genclis assists commercial partners in:
Evaluating intrinsic allergenicity of pharmaceutical, food and cosmetic ingredients;
Establishing industrial procedures to control or suppress ingredient’s allergenicity;

Genclis engages in exclusive industrial partnerships for co-development of Transcription Indelity Assisted Sequential Immunization programs for infectious and immune diseases.

Genclis manufactures and commercializes cutting edge reagents for diagnostic and preclinical use.
GeNeuro SA

PRESENTER
Mr. Jesús Martín García, CEO

COMPANY DESCRIPTION
GeNeuro’s mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases such as multiple sclerosis (MS) and type 1 diabetes (T1D) by neutralizing potential causal factors expressed by human endogenous retroviruses (HERV), which represent 8% of the human DNA. This new approach focused on HERVs is based on more than 25 years of R&D, including 15 within Institut Mérieux and INSERM before the creation of GeNeuro in 2006. GeNeuro’s lead drug candidate, temelimab, is a humanized monoclonal antibody targeting the pathogenic protein HERV-W Env to block key neurodegenerative mechanisms of multiple sclerosis, through reducing microglial activation and through the rescue of the myelin repair process, independently of the immune pathways used by existing drugs. GeNeuro’s recent Phase IIb and its extension have shown its impact on key neuroprotection markers known to be linked to disease progression. These results confirm the potential of temelimab to act against disease progression, the largest unmet medical need in MS.

This is also the first time that the benefit of a treatment targeting endogenous retrovirus protein has been observed in a clinical trial, opening a field led by GeNeuro to tackle other areas of unmet medical needs such as T1D or amyotrophic lateral sclerosis.
GlyCardial Diagnostics is focused on the development of a novel in vitro diagnostic device for myocardial ischemia. The technology is based on the detection of Apo J-Glyc in blood as a biomarker for the early diagnosis of cardiac ischemia and the prediction of patient's evolution after an ischemic event. The quantification of circulating ApoJ-Glyc levels as a biomarker of ischemia will represent a clinical advantage compared to the available methodologies as it would: allow the early diagnosis of an ischemic event in the absence of the irreversible necrosis of the tissue; speed up the triage of patients with acute chest pain; and improve the risk stratification and prognosis of patients with ischemia. All these points would be finally translated into a reduction in the elapsed time between event onset and decision making by the physicians, leading to a significant reduction of the social impact of the disease and its associated economic costs.

**FINANCIAL SUMMARY**
Series A (2.4M€) raised in October 2017 with two local investors specialized in healthcare: Caixa Capital Risc and Healthequity. Public funding raised until today 2.88M€ (including a SME Instrument phase 2). Development covered until Q1 2021

**PRODUCT #1 NAME**
Novel test for the early diagnosis of ischemia
HOOKIPA Pharma, Inc.

PRESENTER
Mr. Daniel Pinschewer, CSO

COMPANY DESCRIPTION
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body’s immune system.

HOOKIPA’s proprietary arenavirus-based technologies, VaxWave®, a replication-deficient viral vector, and TheraT®, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8+ T cells and pathogen-neutralizing antibodies. Both, VaxWave® and TheraT®, are designed to allow for repeat administration while maintaining an immune response. TheraT® has the potential to induce CD8+ T cell response levels previously not achieved by other published immuno-therapy approaches. HOOKIPA’s “off-the-shelf” viral vectors target dendritic cells in vivo to activate the immune system.

HOOKIPA has successfully completed a Phase 1 trial of a VaxWave®-based prophylactic vaccine to protect against cytomegalovirus infection and has started dosing patients in a Phase 2 trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. To expand its infectious disease portfolio, HOOKIPA has entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to jointly research and develop functional cures for HIV and Hepatitis B infections. HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens.

TheraT® and VaxWave® are not approved anywhere globally and their safety and efficacy have not been established.

Find out more about HOOKIPA online at www.hookipapharma.com.

*Registered in Europe; Pending in the US.

MANAGEMENT TEAM
Joern Aldag, CEO
Reinhard Kandera, CFO
Daniel Pinschewer, CSO
Igor Matushansky, CMO
IGEM Therapeutics Ltd.

PRESENTER

Dr. Tim Wilson, CEO

COMPANY DESCRIPTION

IGEM is a UK Immuno-Oncology company developing novel IgE antibodies to treat cancer. Unlike IgG, IgE has evolved to kill tissue-dwelling multicellular parasites endowing it with several key features that make it ideal for the treatment of solid tumours. IgE antibodies bind to their cognate receptors around 10,000 times tighter than IgG and this makes it an anticipatory receptor ideal for allowing macrophages, monocytes, basophils, mast cells and other immune effector cells to seek and destroy cancer cells.

Pre-clinical in vivo Proof of Concept has been obtained with two different IgE antibodies showing significantly greater efficacy versus IgG comparators in a variety of rodent cancer models. IGEM’s pipeline comprises of IgE antibodies against folate receptor alpha, HER2 and CSPG-4. IGEM has an exclusive option to in-license IGEM-F, an anti-folate receptor alpha IgE currently in a phase I trial in ovarian cancer patients. This trial is being conducted by Cancer Research UK who co-own the asset with King’s College London. This is the world's first IgE antibody to enter the clinic.

MANAGEMENT TEAM

Vivienne Cox, Director, Research Operations
Kevin FitzGerald, Chief Scientific Officer
Ian Ardill, Chief Financial Officer

FINANCIAL SUMMARY

IGEM raised £5M in Series A finance from Epidarex Capital, ALSA Holdings and UCL Technology Fund.
IKU

PRESENTER
Mr. Gregory Rigano, CEO

COMPANY DESCRIPTION
A decentralized research organization (DRO) for staking and monetizing open science. IKU changes the status quo with decentralized contracts by distributing the risk, cost, and ownership of bio r&d, while simultaneously capturing the commercial value of relevant data via blockchain-based licensing. All participants (nodes) are economically aligned to build a progressively better intelligence. IKU's mission is to tear down walled gardens, eliminate research secrecy, and accelerate bio-innovation.

Proposed projects will satisfy 100x key value experiment criteria, a strategy vetted with Stanford SPARK Translational Research Program, to exponentially speed up the cycle in which actionable bio-information emerges for investors, scientists, and most importantly human longevity. The criteria being i) 100x efficiency when compared to the current market, ii) direct to Phase II/III human trial, iii) costs less than $3M, iv) biomarker established and v) support from trusted institution(s).

Current DRO pipeline includes neurodegeneration (alz.iku.network), antimicrobial resistance (www.antibx.com), and HPV.

IKU’s first project, the NeuroDRO, aims to deliver a breakthrough - plasmalogen supplementation - addressing neurodegeneration with research supported by University of Pennsylvania, Alzheimer’s Association, Duke University, and the NIH. The plasmalogen hypothesis was uncovered by emerging technology: non-targeted metabolomics using ultra-high-resolution mass spectrometry, capable of generating 100x more data points than traditional systems. This will be the rst Є decentralized offering of its kind where anyone can have skin in the game.

MANAGEMENT TEAM
Gregory Rigano, Esq. - CEO & Founder
Stanford SPARK Advisor
Chadbourne & Park LLP Associate

Dr. Mitch Kling - Chief Science Officer, NeuroDRO
MD, Harvard Medical School
Associate Professor of Psychiatry at the University of Pennsylvania
NIH Fellow

Dr. Dayan Goodenowe - Chief Science Officer, NeuroDRO
PhD Medicine, University of Alberta
Duke Alzheimer’s Disease Metabolomics Consortium

Dr. Kevin Perrot - Chief Science Officer, NeuroDRO
PhD Biomedical Engineering, University of Alberta
Co-Founder SENS Research Foundation
CEO OpenOme

Michael Kisselgof - Project Lead & CoFounder
MSc Economics (Finance)
Credit Suisse Private Banking, SAP Global Marketing
1) $1.5M for the PH III Plasmalogen NeuroTrial to evaluate the effects of plasmalogen precursor supplementation on neurodegeneration, and to collect comprehensive clinical and biochemical data on neurodegeneration and aging on a representative North American population.

2) $500K for the buildout of the IKU Network.

We primarily seek strategic parties who have something high-value and unique to offer to IKU. We want contributors who will share their skills, their knowledge, and their networks to achieve our success.

PRODUCT #1 NAME
Supplement: Plasmalogen

Product #1 Description
Plasmalogen - a lipid in your brain required for normal functioning - is a key causative factor in neurodegeneration and that plasmalogen supplementation can prevent neurodegeneration. The plasmalogen hypothesis targets neurodegeneration by addressing the core structural integrity of neurons that declines with age and disease - their membranes.

PRODUCT #2 NAME
IKU NeuroDRO

Product #2 Description
The IKU NeuroDRO is the first decentralized offering to distribute the cost, risk, and ownership of a scientific breakthrough addressing neurodegeneration. Its purpose is to prevent neurodegeneration and create a licensable research library of over 10,000,000 data points for aging and neurodegenerative disorders.
Imcyse SA

PRESENTER

Mr. Pierre Vandepapelière, CMO

COMPANY DESCRIPTION

Imcyse develops active targeted immunotherapies to treat and prevent severe chronic diseases caused by disruptions of the immune system. The company’s unique active immunotherapy technology platform allows it to destroy locally the immune cells involved in the destruction of the diseased organ. This platform is based on the administration of Imotopes™, which are specific modified peptides, allowing for the generation of a new type of T-cell, called cytolytic CD4. Imcyse’s approach, sustained over time, helps to prevent and treat diseases with no current therapeutic alternative and to cure the patient without impairing immune defenses.

The company has established proof of concept and has completed its first clinical trial in type 1 diabetes in seven European countries. Results will be announced in September 2019. Other projects, which address multiple sclerosis, rheumatoid arthritis and neuromyelitis optica, are at preclinical and proof-of-concept research stages, respectively.

Founded in 2010, Imcyse is a spin-off from the KU Leuven university, Belgium. The company is based near the Belgian city of Liège. It is managed by a group of former pharmaceutical industry executives.

MANAGEMENT TEAM

→ Jean Smal, PhD, Senior Advisor, Development and Manufacturing.
→ Marcelle Van Mechelen, PhD, Senior Scientific Advisor in immunology, biotechnology and vaccinology.
→ Vincent Carlier, PhD, Head of Immunology.
→ Yves Lobet, PhD, Portfolio Director.
→ Luc Vander Elst, PhD, Head of Preclinical and Imotope Development.
→ Marie Gérard: Corporate governance, Finances and HR Director
→ Geoffrey Gloire, PhD, IP Director.
→ Jean Van Rampelbergh, PhD, Clinical & Regulatory Director
→ Guillaume de Viron, CFO.

Closed series B of €35M in June 2019

PRODUCT #1 NAME

Imotope-T1D

Product #1 Description

Imotope-T1D is a peptide derived from a pro insulin epitope and modified by addition of a thioferredox motif. Injection of the Imotope induce cytolytic CD4 T cells that will specifically destroy APCs and T cells involved in the destruction of the pancreatic beta cells and stop the disease process.
Imotope-RA is a peptide derived from epitopes of auto antigens involved in the disease pathogenesis and modified by addition of a thioredox motif. Injection of the Imotope induce cytolytic CD4 T cells that will specifically destroy APCs and T cells involved in the destruction of the joint cells.

Imotope-MS is a peptide derived from an epitope issued from a myelin antigen and modified by addition of a thioredox motif. Injection of the Imotope induce cytolytic CD4 T cells that will specifically destroy APCs and T cells involved in the destruction of the myelin sheath and stop disease.

Imotope-RA is a peptide derived from epitopes of auto antigens involved in the disease pathogenesis and modified by addition of a thioredox motif. Injection of the Imotope induce cytolytic CD4 T cells that will specifically destroy APCs and T cells involved in the destruction of the joint cells.

**Pipeline & Status**

- **Product 1**: Imotope Diabetes
  - ND Partnership Pharma
  - Results Q3 2019
  - Clinical start Q1-2 2020

- **Product 2**: Imotope MS
  - Ongoing project

- **Product 3**: Imotope RA
  - Planned project
  - ND 2020

- **Product 4**: Imotope MS
  - Planned project

Company Address
1 Avenue de l’Hôpital
Lige, 4000
Belgium

Company Website
www.imcyse.com

Contact Email
info@imcyse.com

Company Type
Private

Company Sector
Biotechnology

Years Founded
2010
Immunicum AB

PRESENTER

Mr. Carlos de Sousa, Chief Executive Officer

COMPANY DESCRIPTION

Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient’s own immune system to fight cancer. The company’s lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm.

MANAGEMENT TEAM

• Carlos de Sousa - Chief Executive Officer
• Michaela Gertz - Chief Financial Officer
• Alex Karlsson-Parra - Chief Scientific Officer
• Peter Suenaert - Chief Medical Officer
• Sharon Longhurst - Head of CMC
• Margareth Jorvid - Head of Regulatory and QA
• Sijme Zeilemaker - Senior Director Business Development

FINANCIAL SUMMARY

In November 2018, Immunicum raised $39 million on Nasdaq Stockholm before issue costs for continued clinical development of ilixadencel through a directed issue and a rights issue.

PRODUCT #1 NAME

Ilixadencel

Product #1 Description

Immunicum’s lead product ilixadencel is an immune primer containing allogeneic cells specially treated to become inflammatory dendritic cells. The use of allogeneic cells makes the need for patient-specific cells obsolete which allows for the manufacturing of an off-the-shelf product that can be used for injectable, solid tumors.

PIPELINE IMAGE

![Pipeline Image](image-url)
Innovate Biopharmaceuticals, Inc.

PRESENTER
Mr. Jay Madan, Founder, President & CBO

COMPANY DESCRIPTION
Innovate is a publicly traded (Nasdaq: INNT) clinical stage biotechnology company focused on developing novel medicines for autoimmune and inflammatory diseases with unmet needs. Our pipeline includes drug candidates for celiac disease, NASH, Crohn’s, and ulcerative colitis. Innovate is led by a strong management team with extensive drug development experience and a history of bringing novel therapeutics to market. All global rights to the products, which are backed by more than 150 patents worldwide, are owned by the company.

MANAGEMENT TEAM
Sandeep Laumas, M.D. - Executive Chairman and Chief Executive Officer
Jay P. Madan, M.S. - Founder, President and Chief Business Officer
Edward J. Sitar, CPA - Chief Financial Officer
Patrick H. Griffin, M.D. FACP. - Chief Medical Officer
Kendyle Woodard, MBA - Co-founder and Executive Vice President, Corporate Affairs

FINANCIAL SUMMARY
Innovate is a publicly traded company on Nasdaq: INNT
$18.1 M raised Jan 2018
$9.7 M raised March 2019
$8.7 M raised April 2019
http://ir.innovatebiopharma.com/financial-information/sec-filings

PRODUCT #1 NAME
Larazotide acetate INN-202 for celiac disease Phase 3

Product #1 Description
INN-202 is a tight junction regulator, restoring “leaky” or open junctions to a normal state. The open junctions cause an inflammatory cascade within the intestinal epithelium that eventually destroys the intestinal villi leading to a variety of diseases.

PRODUCT #2 NAME
INN-217 for NASH Phase 1/2

Product #2 Description
Nonalcoholic steatohepatitis (NASH) is a smaller subset of liver disease stemming from the most common liver disease in the world, fatty liver disease, which affects about a quarter of the adults in the United States. Our drug works on both steatosis and brosis of NASH.
PRODUCT #3 NAME
INN-329 for MRCP in Phase 3

Product #3 Description
Resolution of baseline MRCP is poor for pancreatic ducts because of their small diameter; visualization can be improved substantially by intravenous administration of secretin, which stimulates the release of pancreatic juice from acinar cells in the exocrine pancreas into the pancreatic ducts.

PIPELINE IMAGE

<table>
<thead>
<tr>
<th>DISEASE</th>
<th>CELIAC DISEASE</th>
<th>NASPH</th>
<th>CROHN'S DISEASE</th>
<th>ADULT ORPHAN</th>
<th>ULCERATIVE COLITIS</th>
<th>S-MRPC</th>
</tr>
</thead>
<tbody>
<tr>
<td>INN</td>
<td>329</td>
<td>217</td>
<td>289</td>
<td>204</td>
<td>316</td>
<td>519</td>
</tr>
<tr>
<td>PHASE 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHASE 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHASE 3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FDA FILED</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Karyopharm Therapeutics, Inc.

PRESENTER

Mr. Chris Robillard, Senior Director, Business Development & Strategy

COMPANY DESCRIPTION

Karyopharm is a commercial pharmaceutical company focused on the discovery, development and subsequent commercialization of novel, first-in-class drugs for the treatment of cancer and other major diseases. Our lead drug candidate, Xpovio, as an oral agent in cancer indications with significant unmet clinical need, was approved by the FDA in June 2019 For the treatment of refractory Multiple Myeloma. We are also advancing the clinical development of Xpovio in Diffuse Large B-Cell Lymphoma and multiple solid tumor indications. To date, Xpovio has been administered to nearly 3,000 patients, some chronically for over two years.

We also have a non-oncology program including two other SINE compounds, verdinexor and eltanexor. Verdinexor has strong anti-inflammatory and neuroprotective properties and is being developed for the treatment of autoimmune and inflammatory indications (including viral infections) with promising pre-clinical results in Systemic Lupus Erythematosus (SLE). Furthermore, verdinexor has completed a phase 1 study in healthy volunteers where it was found to be generally safe and well tolerated at pharmacologically relevant doses. Eltanexor is focused on autoimmune indications such as irritable bowel disease, with promising preclinical data.

MANAGEMENT TEAM

CEO - Michael Kauffman
CSO/Founder - Sharon Shacham
CBO - Chris Primiano
CMO - Jatin Shah

FINANCIAL SUMMARY

Karyopharm just launched Xpovio in refractory multiple myeloma and has not yet publicly reported revenue (Q3 2019 earnings will be first time).

PRODUCT #1 NAME

Xpovio (selinexor)

Product #1 Description

Xpovio (selinexor) was approved by the FDA in July 2019 For the treatment of refractory Multiple Myeloma. We are also advancing the clinical development of Xpovio in Diffuse Large B-Cell Lymphoma and multiple solid tumor indications. Xpovio has been administered to nearly 3,000 patients, some chronically for over two years.

PRODUCT #2 NAME

verdinexor

Product #2 Description

verdinexor has strong anti-inflammatory and neuroprotective properties and is being developed for the treatment of autoimmune and inflammatory indications with promising pre-clinical results in Systemic Lupus Erythematosus (SLE). Furthermore, verdinexor has completed a phase 1 study in healthy volunteers where it was found to be safe and well tolerated.
PIPELINE IMAGE

All Oral Pipeline

Company Address
85 Wells Ave
Newton, 02459
United States

Company Website
www.karyopharm.com

Contact Email
crobillard@karyopharm.com

Company Type
Listed/Public

Stock Ticker
[NASDAQ: KPTI]

Company Sector
Biotechnology

Years Founded
2008
Kupando GmbH

PRESENTER
Dr. Johanna Holldack, CEO

COMPANY DESCRIPTION
Issue: Cancer is still one of the leading causes of death in the Western world, and metastasis—the spread of cancer to distant sites—and drug resistance represent the most critical attribute for therapy failure. Infiltrating distant tissue, evading immune defences, adapting to supportive niches, surviving as latent tumour-initiating seeds are key factors in the process of metastasis. Solution: Development of safe, efficacious small molecule drugs that are affordable and based on the understanding of the biology of the innate immunity, metastasis and drug resistance

MANAGEMENT TEAM
Johanna Holldack, CEO
Nick Rogerson, NED

FINANCIAL SUMMARY
Seed Stage

PRODUCT #1 NAME
KUP 101, TLR4/7 agonist for the treatment of solid tumors

Product #1 Description
Small molecule TLR 4/7 agonist in a liposomal formulation. In primates, TLR7 is expressed mainly by plasmacytoid dendritic cells and B cells. Active TLR4 is expressed by many more cell types, including endothelial cells and macrophages. The purpose of an innate immune stimulator is to initiate an adaptive immune response. Adding a TLR4 agonist causes local cytokine and chemokine release, especially from the endothelial cells that line the abundant micro vessels that penetrate tumors. Then more dendritic cells and B cells will be recruited to the tumor, initiating a CD8 cytotoxic immune response.

PRODUCT #2 NAME
MACC1 repurposing project

Product #2 Description
MACC1 (Metastasis Associated in Colon Cancer 1) is both a key driver and prognostic biomarker for cancer progression and metastasis of all solid tumors, and down regulation of its activity might be a powerful therapeutic approach. Two marketed compounds have been identified by screening to be able to reduce MACC1 mRNA expression and MACC1 protein, and are able to reduce cellular motility when applied in a wound healing assay. The combinatorial synergy with Wnt-signaling inhibitors also represents an unexpected finding. The IND enabling work will take about 8 months and PoC can be established within 2 to 3 years.
Company Address
Kurfuerstendamm 194
Berlin, 10707
Germany

Company Website
www.kupando.com

Contact Email
jholldack@kupando.com

Company Type
Emerging

Company Sector
Biotechnology

Years Founded
2018
Kuros Biosciences AG

PRESENTER
Mr. Michael Grau, Chief Financial Officer

COMPANY DESCRIPTION
Kuros is a Swiss listed biotech company with three locations in Schlieren (Switzerland), Bilthoven (The Netherlands) and Burlington, MA (USA). Kuros Biosciences AG focuses on the development and commercialization of innovative products for bone repair and regeneration. The two key products are (1) MagnetOs, a marketed synthetic bone graft substitute with a unique surface topography, and (2) KUR-113, a novel orthobiologics candidate for use in spinal fusion scheduled to enter Phase II development in the second half of 2019. MagnetOs has a patent-protected surface topography that was shown to promote and direct bone formation. MagnetOs is CE-marked and 510k cleared and available in two formulations (granules and putty). Product launch was in June 2018 in the US and in the UK.

KUR 113 is an innovative growth factor. Kuros is currently preparing for a Phase II study in spinal fusion. The technology is de-risked with two Phase II programs completed in trauma indications (400 patients).

MANAGEMENT TEAM
Prof. Joost de Bruijn, CEO
Michael Grau, CFO
Dr. Alistair Irvine, Chief Business Officer
Dr. Pascal Longlade, Chief Medical Officer
Dr. Philippe Saudan, Chief Development Officer
Frank-Jan van der Velden, Head of Business Affairs
LimmaTech Biologics AG

PRESENTER
Dr. Veronica Gambillara, CEO

COMPANY DESCRIPTION
LimmaTech Biologics AG applies its proprietary CustomGlycan Platform to develop novel therapeutic biologics like monoclonal antibodies with tailored and homogenous glycosylation for maximal and novel effector functions. The platform is applicable to all protein formats and carries the potential to be a game changer in robustness, speed, and cost-efficiency of biologics production. It serves the need for cheaper, reproducible glycosylated biologics production in all indications.

MANAGEMENT TEAM
https://lmtbio.com/management/
LS CancerDiag Oy

PRESENTER
Mr. Philippe Arnez, Chief Business Officer

COMPANY DESCRIPTION
LS CancerDiag has developed DiagMMR®, a novel predictive diagnostic test to detect the most common inherited cancer predisposition in the world, Lynch syndrome. Unlike the current array of tests, DiagMMR® provides easily interpretable and highly accurate results even before the cancer develops, enabling preventive and personalized care.

Lynch syndrome (previously known as hereditary nonpolyposis colorectal cancer; HNPCC) is the most common hereditary cancer syndrome in the world and the affected individuals have an over 80% lifetime risk of developing cancer. The threshold for testing is very high due to the costs, ambiguity and low awareness of Lynch syndrome diagnostics. As a result, only 5% of affected people are diagnosed and the care remains largely reactive.

We want to become the global standard test for detecting Lynch Syndrome. By using our breakthrough functional test to detect Lynch Syndrome, we can help prevent cancer development through early and reliable diagnosis, enabling personalized care saving and improving millions of lives.

MANAGEMENT TEAM
Niklas Lahti, Chief Financial Officer;
Philippe Arnez, Chief Business Officer;
Minttu Kansikas, R&D Director;
Jukka Kantelinen, Laboratory Director;
Prof. Minna Nyström, Founder and Chairman

FINANCIAL SUMMARY
Since the creation of the company in 2013 we have raised seed money in 5 rounds, and with that have also secured grants and loans from the public business agency (Tekes/Business Finland). We anticipate to run a Series A funding round in the next 12 months to raise around €5 million.

PRODUCT #1 NAME
DiagMMR® / CE-marked

Product #1 Description
DiagMMR® detects LS in healthy individuals, allowing an early diagnosis, enabling cancer prediction and preventive treatment, while unaffected family members can be relieved from regular follow-up. For cancer patients it complements current tests. DiagMMR® detects genetic markers underlying LS without hereditary information. This makes testing people at risk before developing cancer easier and thanks to the proactive test lives are being saved and improved while decreasing healthcare costs. Unlike current methods requiring tumour tissue, our test is carried out on a small skin biopsy of healthy tissue, typically taken from the arm of an individual. Cells are cultured and the characteristic DNA repair function (mismatch repair, MMR) is tested and quantified at the protein level. The validation of our test has shown an exceptional accuracy for the industry, with a specificity of 100% and sensitivity of 92%.
**Company Address**
c/o Terkko Health Hub,
Haartmaninkatu 4
Building 14 Helsinki, 00290
Finland

**Company Website**
www.lscancerdiag.com

**Contact Email**
info@lscancerdiag.com

**Company Type**
Emerging

**Company Sector**
Biotechnology
Diagnostics
Medical Devices
Pharmaceuticals/Licensing

**Years Founded**
2006

---

**PIPELINE IMAGE**

**LYNCH SYNDROME:**
The most common cancer syndrome (1/270) in the world

**INHERITED MMR DEFECT:**
LS is inherited with 50% probability

**INDIVIDUAL RISK:**
Individuals with inherited mismatch repair (MMR) deficiency have 80% risk of developing colorectal cancer

**DiagMMR® TEST:**
Detects inherited MMR deficiency, enables preventive care and saves lives

---

1. Sample
2. Cells
3. Proteins
4. Repair

---

**WELCOM**

**19TH ANNUAL BIOTECH IN EUROPE FORUM**
FOR GLOBAL PARTNERING & INVESTMENT

---

www.sachsforum.com
Macrophage Pharma

PRESENTER
Mr. Søren Bregenholt, CEO

COMPANY DESCRIPTION
Macrophage Pharma is developing a novel class of small molecule therapeutics which modulate macrophage plasticity and function to treat human disease. We leverage our proprietary Esterase Motif Technology™ (ESM™) platform. ESM™ to deliver small molecule inhibitors of key intracellular targets in a highly selective manner to, monocytes, macrophages and dendritic cells. We are progressing our lead molecules to the clinic, initially utilising ESM™ to deliver inhibitors to tumour associated macrophages and tolerogenic dendritic cells in the tumour microenvironment as cancer therapies. Macrophage involvement in a broad range of diseases means selective targeting with ESM™ also holds great promise in the treatment of inflammation, fibrosis and metabolic diseases.

The company’s management team has track record of success in the pharma industry ranging from early discovery to commercialisation. The Scientific Advisory Board is comprised of world-leading immunologists and cancer researchers who will help shape the future development of our unique approach in immunotherapy.

MANAGEMENT TEAM
Dr Søren Bregenholt, PhD, CEO
Dr David Moffat, PhD, Director of Chemistry
Dr Jo Bedwell-Garner, PhD, Director of Development
Dr Martin Perry, PhD, Director of Biology
Dr Elisabeth Parker, PhD, Director of Business Development

FINANCIAL SUMMARY
The company has raised approximately 15 MGBP in Series A financing.

PRODUCT #1 NAME
MPL-5821 - ESM p38 MAPK inhibitor

Product #1 Description
MPL-5821 is a macrophage-targeted specific p38 MAP kinase inhibitor. MPL-5821 repolarizes M2 macrophages into a M1 functional phenotype. The molecule is currently in late stage pre-clinical development for oncology as other indications that are driven by M2 macrophages. Macrophage Pharma retains all right to the molecule.

PRODUCT #2 NAME
PI3 kinase inhibitor

Product #2 Description
Macrophage Pharma is developing a macrophage-targeted, specific PI3 kinase inhibitor. Macrophage targeting is believed to mitigate known off-macrophage toxicities associated with conventional PI3K inhibitors. The project is in late stage discovery with final lead selection scheduled for end Q4 2019. The PI3 kinase inhibitor will be developed for immune oncology and fibrotic diseases. Macrophage pharma retains all right to the molecule.
Marinomed Biotech AG

PRESENTER
Mr. Andreas Grassauer, CEO

COMPANY DESCRIPTION
Marinomed Biotech AG is a biopharmaceutical company. It specializes in the development of innovative products based on patent protected technology platforms in the field of respiratory and ophthalmic diseases.

Marinomed has developed two platforms to date: the Marinosolv® technology platform and the Carragelose® platform.

The Marinosolv® technology platform enhances the efficacy of hardly soluble compounds. This innovative technology has the potential to sustainably change a number of therapies for allergies and auto-immune diseases. The flagship product Budesolv has recently been tested successfully in a pivotal Phase III approval study.

The Carragelose® platform is already used in six different products to treat viral infections of the respiratory tract, which are sold globally via the company’s partners.

MANAGEMENT TEAM
Andreas Grassauer, CEO
Pascal Schmidt, CFO
Eva Prieschl-Grassauer, CSO

FINANCIAL SUMMARY
The successful IPO on the prime market of the Vienna Stock Exchange in February 2019 created a strong financial basis, which was further strengthened by a loan commitment from the European Investment Bank of up to EUR 15 million. This puts Marinomed in a strong position to realise its R&D goals, to fully exploit the potential of the two platforms Marinosolv® and Carragelose® and to create sustainable value.

Marinomed Biotech AG’s shares have been listed on the Vienna Stock Exchange since February 1, 2019. The shares are listed in the prime market segment and included in the ATX Prime Index.
**PRODUCT #1 NAME**
**BUDESVOLV**

**Product #1 Description**
Budesolv is a new formulation of the non-halogenic glucocorticoid budesonide for intranasal treatment of allergic rhinitis that intents to achieve:

- Faster onset of action
- Immediate relief
- Reduced dose

The company has just successfully completed a pivotal phase III clinical study supporting a subsequent application for marketing authorization. This study will be used two-fold: Supporting Marinosolv® technology and being used for supporting the registration of Budesolv in Europe and other countries.

---

**PRODUCT #2 NAME**
**TACROSOLV**

**Product #2 Description**
Tacrolimus is a macrolide immunosuppressant with proven efficacy with a biological activity approximately 100-fold higher than the currently used Cyclosporine A. Until today, the use of Tacrolimus in ophthalmology was hampered by its insolubility and stability issues. Tacrosolv goes one step beyond: Marinosolv® enables a broader ophthalmological use of Tacrolimus due to a significant increase in solubility and stability. The company plans to initiate a clinical phase II trial with Tacrosovl in the next 6 months.

---

**Company Address**
Veterinaerplatz 1
Vienna, A-1210
Austria

**Company Website**
www.marinomed.com

**Contact Email**
office@marinomed.com

**Company Type**
Listed/Public

**Stock Ticker**
[VIE: MARI]
[ISIN: ATMARINOMED6]

**Company Sector**
Drug Delivery
Pharmaceuticals/Licensing

**Years Founded**
2006
Marker Therapeutics, Inc.

PRESENTER
Mr. Peter Hoang, President & CEO

COMPANY DESCRIPTION
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker’s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient’s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells therapies, we believe that our product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies. Marker is also advancing a number of innovative peptide- and gene-based immunotherapeutics for the treatment of metastatic solid tumors, including the Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and the HER2/neu program (TPIV100/110) for breast cancer, currently in Phase 2 clinical trials.

MANAGEMENT TEAM
Peter Hoang - President & Chief Executive Officer;
Anthony Kim - Chief Financial Officer;
Juan Vera - Chief Development Officer;
Ann Leen - Chief Scientific Officer;
Michael Loiacono - Chief Accounting Officer;
Ken Moseley - Senior Vice President & General Counsel;
Mythili Koneru - Senior Vice President, Clinical Development;
Gerald Garrett - Vice President, Clinical Operations;
Tsvetelina Hoang - Vice President, Research & Development;
Sheila Sterr - Director of Human Resources & Finance

PRODUCT #1 NAME
Multi Tumor-Associated Antigen Approach

Product #1 Description
Marker’s MultiTAA platform is a novel, non-genetically modified cell therapy approach that selectively expands tumor-specific T cells from a patient’s blood capable of recognizing a broad range of tumor antigens.

PRODUCT #2 NAME
TPIV 200: Folate Receptor Alpha T cell vaccine

Product #2 Description
TPIV200 is a T cell vaccine that consists of five naturally processed peptide antigens derived from the highly prevalent tumor cell surface molecule, Folate Receptor Alpha (FRα). FRα is overexpressed by ~90% of ovarian cancer cells and 80% of triple-negative breast cancer cells.
Marker’s novel T cell vaccine targeting HER2/neu consists of five HER2/neu antigens. The antigens were selected for binding to both MHC class I and class II. Because this vaccine utilizes multiple class II-restricted peptides, it can target a portion of the population unlike conventional class I-restricted single peptide vaccines.
MedinCell

PRESENTER

Mr. Gaël L’Hévéder, Chief Business Development Officer

COMPANY DESCRIPTION

MedinCell is a clinical stage pharmaceutical company developing long-acting injectables based on BEPO®, its game-changing technology platform enabling controlled, localized and sustained drug delivery. Independently and in partnership with other pharma or NGOs MedinCell develop a portfolio of best-in-class medicines incorporating additional benefits related to therapeutic compliance, targeted action and ease of use.

BEPO® physicochemical properties make it an ideal vehicle for a broad variety of compounds such as peptides, proteins and small molecules. BEPO® applications cover a wide range of unmet medical needs in neurology, cardiology, urology, gastroenterology, oncology, metabolic and immune diseases, pain management, and inflammation. In many situations, such as life cycle management, we can develop multiple duration prototypes to provide partners with greater strategic flexibility and competitive advantage.

MedinCell is dedicated to delivering innovative medical treatments to all global markets, mature and emerging alike. Via its active Global Health strategy, MedinCell aims to engage like-minded stakeholders where we can make a difference.

MedinCell is based in Montpellier, France, and employs more than 130 people representing over 25 different nationalities.

MANAGEMENT TEAM

Christophe Douat - CEO
Nicolas Heuzé - Director Corporate Development & Corporate Finance
Jaime Arango - CFO
Joël Richard - Head of Technical and Pharmaceutical Operations
Gaël L’Hévéder - Chief Business Development Officer

FINANCIAL SUMMARY

Medincell is listed on Euronext Paris since October 2018 [MEDCL]

PIPELINE IMAGE

Long-acting injectables portfolio as of July 31, 2019

Products in development

<table>
<thead>
<tr>
<th>Product</th>
<th>Indication</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>mdc-TJK</td>
<td>Pain</td>
<td>Clinical Phase 1</td>
</tr>
<tr>
<td>mdc-ANG</td>
<td>Cancer</td>
<td>Preclinical</td>
</tr>
<tr>
<td>mdc-CNV</td>
<td>Autoimmunity</td>
<td>Preclinical</td>
</tr>
</tbody>
</table>

Products in lead formulation selection

<table>
<thead>
<tr>
<th>Product</th>
<th>Indication</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>mdc-NAK</td>
<td>Chronic pain</td>
<td>Formulation</td>
</tr>
<tr>
<td>mdc-AN-BC</td>
<td>Transplantation</td>
<td>Formulation</td>
</tr>
<tr>
<td>mdc-BOR</td>
<td>Neurology</td>
<td>Formulation</td>
</tr>
</tbody>
</table>
Metys Pharmaceuticals AG

PRESENTER

Mr. Michael Scherz, Founder & CEO

COMPANY DESCRIPTION

Metys Pharmaceuticals AG is developing MP-101 for the prevention and treatment of sensory symptoms of peripheral neuropathy. No therapy is indicated to treat or prevent chemotherapy-induced symptoms of peripheral neuropathy; these lead to premature interruption of cancer therapy and linger to reduce patients’ quality of life and increase health care costs.

We seek Series A investors to finance the Phase 2 clinical trial of MP-101 in this indication. Our development plans have been discussed and agreed with FDA in a face-to-face pre-IND meeting in February this year. MP-101 is an orally active allosteric modulator of spinal and brain glutamate signalling. It is a patent-pending non-racemic mixture of the dimiracetam enantiomers. Metys Pharmaceuticals AG holds exclusive world-wide rights to the existing IND of racemic dimiracetam from two prior independent development efforts, and will use these data to support - without prior clinical or toxicological bridging data - the Phase 2 trial of MP-101.

Metys Pharmaceuticals AG is privately-held Swiss corporation, financed by private seed investors.

MANAGEMENT TEAM

Michael Scherz, PhD - Founder & CEO
Elisabet Lindberg, MD - Chief Medical Officer
Carlo Farina, PhD - Head of Chemistry and Patents

FINANCIAL SUMMARY

Michael Scherz, PhD, is the sole founder of Metys Pharmaceuticals AG. The company has been financed through a series of seed investments totalling CHF 3 million. These seed investments are structured as convertible loans, repayable in shares of Metys Pharmaceuticals AG at an average 20% discount to the pre-money valuation agreed with Series A investors.

Metys Pharmaceuticals AG seeks a CHF 25 million Series A transaction to finance the Phase 2 clinical trials of MP-101 for prevention of chemotherapy-induced symptoms of peripheral neuropathy and for the treatment of painful diabetic peripheral neuropathy.

PRODUCT #1 NAME

MP-101 - Phase 2

Product #1 Description

MP-211 is a non-racemic mixture of levetiracetam (UCB's Keppra®) and its enantiomeric anti-pode, R-etiracetam. MP-211 is the subject of the patent application filed by Metys Pharmaceuticals AG on 07 November 2018. MP-211 is substantially more potent in vivo than levetiracetam alone.

PRODUCT #2 NAME
MP-121 - preclinical development

Product #2 Description
MP-121 is non-racemic mixture of NT-24336 and its enantiomer NT-24337. It is covered in the patent application filed by Metys Pharmaceuticals AG on 07 November 2018. NT-24336 is a single enantiomer, previously selected for pre-clinical development, of a novel bicyclic pyrrolidinone derivative, belonging to the chemical class of hexahydropyrrolo[1,2-a]pyrazin-6(7H)-ones.

PRODUCT #3 NAME
MP-211 - preclinical

Product #3 Description
MP-211 is a non-racemic mixture of levetiracetam (UCB's Keppra®) and its enantiomeric anti-pode, R-etiracetam. MP-211 is the subject of the patent application filed by Metys Pharmaceuticals AG on 07 November 2018. MP-211 is substantially more potent in vivo than levetiracetam alone.
Omnix Medical Ltd.

PRESENTER
Dr. Niv Bachnoff, Co-Founder & CSO

COMPANY DESCRIPTION
Omnix Medical is a pre-clinical company developing an arsenal of novel antibiotic-agents targeting Multi-Drug-Resistant bacteria. Our technology is inspired by the innate immune system of insects, employing a strategy that has been proven very efficient for 250 million years. Insects combat pathogenic bacteria using a unique family of Antimicrobial-Peptides that physically damage bacterial membranes with no toxic effects. The rapid-bactericidal Mechanism of Action employed by these peptides is active regardless of any existing antibiotic-resistance. Omnix’s proprietary technology utilizes biochemical engineering to enable the synthesis of soluble, stable, safe and highly-potent Antimicrobial-Peptides. Our unique patented technology allows for a vast array of peptides to be designed for further therapeutic applications.

The company’s lead molecule, OMN6, targets Superbugs. Omnix is focused on Gram(-) Multi-Drug-Resistant pathogens, the ESKAPE bacteria: K. pneumonia spp, A. baumannii, P. aeruginosa and Enterobacter spp. These bacteria are the most serious and urgent threats to public-health while the drugs intended to fight them become ineffective. High mortality-rates and limited therapeutic solutions make it an immediate unmet need. Omnix medical’s molecules are developed for the treatment of life-threatening hospital-acquired infections via systemic IV-administration. Omnix technology will save lives of millions suffering from infections involving antibiotic-resistant bacteria.

Omnix Medical was founded in 2015, and now Omnix team boasts 8 employees advancing R&D and directing studies with top-tier CROs.

Our patented platform technology offers a pipeline of peptides at various stages of development.

OMN6 demonstrates high efficacy and presented a significant reduction in blood and lung bacterial-burden, in animal models. OMN6 presents a favorable PK/PD profile and has been designated QIDP by the FDA.

Omnix Medical technology can tilt the odds in the battle against Antimicrobial Resistance.

MANAGEMENT TEAM
Dr. Moshik Cohen-Kutner – Co-Founder & CEO. PhD. biochemistry, expert in peptide design
Dr. Niv Bachnoff – Co-Founder & CSO. PhD. biochemistry, microbiology and biomimetics
Rom Lakritz – Co-Founder, CFO. Finance and Operations

FINANCIAL SUMMARY
Omnix has raised over $5M from private and public investors in addition to Israeli-government grants.

PRODUCT #1 NAME
OMN6 - Pre-Clinical

Product #1 Description
OMN6 is an biochemically engineered antimicrobial peptide
Orexo AB

PRESENTER
Mr. Nikolaj Sørensen, CEO

COMPANY DESCRIPTION
Orexo develops improved pharmaceuticals based on innovative drug delivery technologies. The focus is primarily on opioid addiction and pain but the aim is to address therapeutic areas where our competence and technologies can create value. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo sells the product Zubsolv®. Total net sales for 2018 amounted to SEK 783.1 million and the number of employees was 129.

Our drug delivery technologies improve pharmaceuticals:
Orexo develops improved products by combining well-known and well-documented substances with in-house innovative drug delivery technologies.

Developed 4 products approved worldwide:
Orexo has developed four products from concept to patient. The products have been approved in multiple markets and helped patients benefit from improved drugs worldwide.

Strategic focus on product expansion:
One of Orexo’s objectives for long-term growth is to broaden the US commercial platform, by M&A transactions, to leverage scale and expand sales.

Key market characterized by strong growth:
In the US the #opioidcrisis is accelerating and in 2017 70,200 Americans died of an overdose, mainly caused by use of opioids. There is a great need for treatment and the buprenorphine/naloxone market grew by more than 14 percent in 2018.

Embracing all aspects of opioid addiction:
Orexo’s pipeline contains development projects with a primary therapeutic focus around opioid addiction in all phases, from prevention to treatment.

MANAGEMENT TEAM
Nikolaj Sørensen, President and CEO
Joseph DeFeo, EVP and Chief Financial Officer
Johannes Doll, EVP and Head of Corporate Development
Cecilia Coupland, VP and Head of Operations
Robert Rönn, VP and Head of R&D
Robert A. DeLuca, President of Orexo US
Michael Sumner, Chief Medical Officer

FINANCIAL SUMMARY
Record-breaking performance in 2018 further improved in Q219

Group Net Revenues, 12 mth Jul 2018- Jun 2019, SEK 819 m, Growth vs last period, 18 %
Group EBITDA, 12 mth Jul 2018- Jun 2019, SEK 155 m, Growth vs last period, 35 %
US EBIT, 12 mth Jul 2018- Jun 2019, SEK 277 m, Growth vs last period, 110 %
Cash position, Jun 30 2019, SEK 697 m
Net Cash position, Jun 30 2019, SEK 376 m
PRODUCT #1 NAME
Zubsolv, Launched US and Approved Europe

Product #1 Description
Zubsolv is a product for the treatment of opioid dependence. Zubsolv has comparable efficacy and safety as well as the same active components as previously approved buprenorphine/naloxone sublingual formulations. The broad choice of six different strengths offers the potential for finer titration and individualized dosing with potentially fewer tablets compared with existing substitution treatments.

In July 2013, Zubsolv was approved for the maintenance treatment of opioid dependence by the US Food and Drug Administration, FDA, and in August 2015 the product also received approval for induction treatment of the same patient population.

PRODUCT #2 NAME
Abstral, Approved/Launched US, Europe and RoW

Product #2 Description
Abstral is a rapidly disintegrating sublingual tablet for management of breakthrough cancer pain in patients already being treated with opioids. The product contains the pain-relieving substance fentanyl. Abstral allows doses to be customized according to individual requirements, which is essential for achieving optimal pain relief.

The product was initially approved for sales in Europe in 2008. Approval and launch in other major territories has followed, and Abstral is currently available in key markets such as US, Japan, Australia, South-Korea and the EU.

PRODUCT #3 NAME
Edluar, Approved/Launched US, Europe and RoW

Product #3 Description
Edluar is based on Orexo’s sublingual tablet technology and the active substance zolpidem. The product offers treatment for short-term insomnia. Zolpidem is a well-documented substance that has been used in the treatment of insomnia for a long time. The Edluar tablet is placed under the tongue, where it rapidly dissolves and the active ingredient is absorbed through the mucous membrane.

Edluar was approved by the US Food and Drug Administration, FDA, in March 2009. In June 2012 Edluar was approved for registration in Europe.

PIPELINE IMAGE

Company Address
Box 303
Uppsala, 751 05
Sweden

Company Website
www.orexo.com

Contact Email
zillur.rahman@orexo.com

Company Type
Listed/Public

Stock Ticker
[STO: ORX]

Company Sector
Drug Delivery

Years Founded
1995

Company Address
Box 303
Uppsala, 751 05
Sweden

Contact Email
zillur.rahman@orexo.com

Company Type
Listed/Public

Stock Ticker
[STO: ORX]

Company Sector
Drug Delivery

Years Founded
1995

Company Address
Box 303
Uppsala, 751 05
Sweden

Contact Email
zillur.rahman@orexo.com

Company Type
Listed/Public

Stock Ticker
[STO: ORX]

Company Sector
Drug Delivery

Years Founded
1995
Oryzon Genomics S.A.

PRESENTER
Carlos Buesa, Founder & CEO

COMPANY DESCRIPTION
Oryzon is a public clinical stage biopharmaceutical company listed on the Madrid stock exchange and a European leader in the development of epigenetics-based therapies. Oryzon has programs in clinical phase:

CNS - Vafidemstat (ORY-2001), a dual LSD1-MAOB inhibitor, currently in three Phase IIA:
- "ETHERAL": in mild to moderate AD
- "REIMAGINE": aggression in adult population with Alzheimer’s Disease (AD), Adult attention deficit hyperactivity disorder (ADHD), Borderline Personality Disorder (BPD), and Autism Spectrum Disorder (ASD)
- "SA TEE N": in relapse-remitting and secondary progressive forms of MS.

Oncology – Iadademstat (ORY-1001), a selective LSD1 inhibitor, currently in two Phase IIA:
- "ALICE": in AML
- "CLEPSIDRA": in SCLC

A third epigenetic compound (ORY-3001), also against LSD1, has completed the preclinical development, for a yet undisclosed non-oncological indication.

MANAGEMENT TEAM
- Carlos Buesa: Chief Executive Officer (CEO)
- Tamara Maes: Chief Scientific Officer (CSO)
- Enric Rello: Chief Operating Officer (COO), Chief Financial Officer in Spain (CFO)
- Neus Virgili: Chief Intellectual Property Officer (CIPO)
- Roger Bullock: Chief Medical Officer (CMO)
- Michael Ropacki: Vice President of Clinical and Product Development
- Sonia Gutierrez: Chief of Clinical Operations
- Emili Torrell: Chief Business Development Officer (CBDO)

FINANCIAL SUMMARY
Oryzon is listed on the Spanish Stock Exchange since December 2015 (ORY, ISIN Code: ES0167733015). In the period 2015-2016, the company raised €32M, with additional Pipe in 2017 (€18.2M) and 2018 (€13M) where the company incorporated specialized investors from US and Europe.

From 2014 to 2017 the company had a collaboration with Roche relating to our lead oncology program, iadademstat, and received +$23M. This asset is now being developed by Oryzon. The company has also obtained competitive US and European grants in the amount of €8M to support the development of vademstat since the start of our CNS research.
ORYZON’s Epigenetic Platform has also delivered an additional program ORY-3001, a third epigenetic compound, also against LSD1, currently ready to start Phase I in a yet undisclosed indication.

PRODUCT #2 NAME
Iadademstat (ORY-1001) – Oncology program

Product #2 Description
Iadademstat is a highly selective LSD1 inhibitor. It has finalized a First in Man Safety Phase I/IIA in acute leukemia. Two Phase IIA trials in Acute Myeloid Leukemia (AML) and Small Cell Lung Cancer (SCLC) are currently ongoing.

PRODUCT #3 NAME
ORY-3001

Product #3 Description
Oryzon’s Epigenetic Platform has also delivered an additional program ORY-3001, a third epigenetic compound, also against LSD1, currently ready to start Phase I in a yet undisclosed indication.
PDC*line Pharma SA

PRESENTER
Mr. Eric Halioua, President & CEO

COMPANY DESCRIPTION
Founded in 2014 as a spin-off of the French Blood Bank (EFS), PDC*line Pharma is a Belgian-French clinical-stage biotech company that develops an innovative class of active immunotherapies for cancers, based on a GMP-grade allogeneic therapeutic cell line of plasmacytoid dendritic cells (PDC*line). PDC*line is much more potent than conventional Dendritic Cell-based vaccines in priming and boosting antitumor antigen-specific cytotoxic T-cells, including T-cells specific for neoantigens, and is synergistic with checkpoint inhibitors. The technology can be applied to any type of cancer. Following a first-in-human phase I feasibility study in melanoma, PDC*line Pharma focuses on the development of PDC*lung01, a candidate for non-small-cell lung cancer (NSCLC) and neoantigens (PDC*Neo). The company has a staff of 20 people, with an experienced management team. The company has so far raised €17M ($19.3M) including €7.6M ($8.6M) in equity and loans from Belgian investors (MeusInvest, Innodem3, InvestSud and SFPI) and several business angels, in addition to €9.3M ($10.5M) of non-dilutive funding (including grants from the Walloon region, Belgium, French entities and the European Commission).

In March 2019, the company granted an exclusive license to LG Chem Life Sciences Company in South Korea and an exclusive option in other Asian countries, for the development and commercialization of the PDC*lung01 cancer vaccine for lung cancer. The total deal value is €108M ($123M) plus tiered royalties on net sales in Asia.

MANAGEMENT TEAM
M. Eric Halioua (MS, MBA), President & CEO.
M. Laurent LEVY (MS, MBA), co-founder & COO.
Dr. Joel PLUMAS (PhD), co-founder & CSO.
M. Claude Dedry (Industrial Pharmacist), Vice-President of Pharmaceutical operations & Quality. Dr. Channa Debruyne, Medical Director.

PRODUCT #1 NAME
PDC*lung

Product #1 Description
PDC*lung is our leading product for non-small-cell lung cancer (NSCLC). PDC*lung consists of PDC*line loaded with HLA-A*02:01-restricted peptides derived from 6 antigens matching with shared NSCLC tumor antigens. PDC*lung is primarily intended to treat HLA-A*02:01 advanced-stage NSCLC patients who are candidates for anti-PD-1 in first-line settings.

PRODUCT #2 NAME
PDC*Neo

PIPEDLINE IMAGE

Company Address
CHU - Tour 5 (B34) - GIGA,
Avenue de l'Hôpital 11
LIEGE, 4000
Belgium

Company Website
www.pdc-line-pharma.com

Contact Email
e.halioua@pdc-line-pharma.com

Company Type
Private

Company Sector
Biotechnology

Years Founded
2014
Perseo Pharma AG

PRESENTER
Dr. Yves Dudal, CEO

COMPANY DESCRIPTION
Perseo pharma takes its name from Perseus, the hero of Greek mythology who, by wearing the Cap of Invisibility, was able to slay the Gorgon Medusa whose gaze was turning onlookers into stone. Perseo pharma’s therapeutic enzymes, with their stealth coating, are able to invisibly reach their targets so as to slay the disease.

Over the past 30 years and the first development of biologics, 30 therapeutic enzymes have been approved by EMA and FDA (1/4 of all approved biologics). Therapeutic enzymes address a wide variety of indications, ranging from rare genetic diseases (enzyme replacement therapies) to oncology (key tumor-element depletion therapies). However, existing therapeutic enzymes exhibit both efficacy issues (lack of systemic stability, low residence time) and toxicity issues (up to 80% anti-drug reactions, immunogenicity).

Our platform technology has proved successful in addressing both these issues for non-therapeutic enzymes (see related company INOFEA AG).

MANAGEMENT TEAM
Dr. Yves Dудal, CEO
Dr. Emilie Laprévotte, CDO
Prof. Dr. Patrick Shahgaldian, CSO

FINANCIAL SUMMARY
Perseo pharma is raising its seed round of CHF3m in equity. CHF 0.7m has already been invested in the form of a convertible loan form business angels.

PRODUCT #1 NAME
PER001 - enzzen(R)-asparaginase
PharmaKrysto Ltd.

PRESENTER
Julian Howell, Co-Founder & CEO

COMPANY DESCRIPTION
Our vision is to save kidneys and prevent pain in children and adults with cystinuria. This genetic, orphan condition causes kidneys to leak amino acids - these crystalise, blocking urine flow. We are a start-up biopharma company developing a novel, patented product to prevent crystal build-up in people with cystinuria. Our product is a patented small molecule with a unique mechanism of action and robust preclinical data. This is a very underserved market and we are projecting peak sales of $450M.

Our experienced team has established orphan status and a clear development pathway with US and EU regulators and we have opened our Series A raise to get us to Phase 1 ready.

MANAGEMENT TEAM
Julian Howell - CEO
Jackie Mitchell - Regulatory and PreClinical Expert
Carl Sterritt - Non-Executive Chairman

FINANCIAL SUMMARY
PharmaKrysto has been supported through seed funding from the co-founders and non-dilutive funding from Scottish Enterprise. We are raising $3M Series A through sale of equity to get us to Phase 1 ready. The whole development programme will be completed with around $30M investment and we have projected $450M peak sales. This figure is supported by market research.

PRODUCT #1 NAME
PK10

Product #1 Description
PK10 is our lead small molecule being developed for the prevention of renal failure and pain in children and adults with cystinuria.
Phi Pharma SA

PRESENTER
Dr. Franco Merckling, CEO

COMPANY DESCRIPTION
Phi Pharma SA is a private Swiss-based biotech company founded by well-known figures of the Swiss Biotech industry. It specializes in the development of drug conjugates with a first focus on liquid tumors.

Phi Pharma technology allows the development of a powerful new class of peptide drug conjugates which have the potential to overcome the limitations of Antibody Drug Conjugates.

Phi Pharma’s technology is based on the groundbreaking discovery of HIV using TAT peptide to penetrate white blood cells to deliver its deadly cargo. Naturally occurring TAT peptide has a very short half-life in blood as it is being instantly degraded by respective enzymes.

By super-computer assisted modelling Phi Pharma was able to identify, synthesize and patent protect “semi-synthetic” TAT derived peptide with dramatically improved stability and affinity, hence targeting properties.

After extensive in-vitro work showing the expected biological activity, Phi Pharma is completing the pre-clinical development of the lead compounds to move into IND and the implementation of a first in human PoC phase 1/2a clinical trial.

MANAGEMENT TEAM
Franco Merckling, PhD, CEO
Christophe Bonney, PhD, acting CSO
Dirk Weber, MD, CMO
Luc Otten, MD, COO

FINANCIAL SUMMARY
Phi Pharma has been financed to this point by its founders and educated private investors.

The company is now securing its second round of financing to complete the pre-clinical development of the lead compounds and move into IND readiness required toxicology, CMC process development as well the implementation of a first in human PoC phase 1/2a clinical trial.
Primex Pharmaceuticals AG

PRESENTER

Mr. Alan Knox, CEO

COMPANY DESCRIPTION

Primex Pharmaceuticals is a leading global innovative anaesthesia company, expanding in paediatric pharmaceuticals.

Primex brings a broad portfolio of anaesthesia products helping patients undergo a wide range of medical procedures, including a novel, oral solution for paediatric sedation now approved in several markets in the European Union.

Primex Pharmaceuticals will continue to identify and bring to the market new medications that complete the Triad of Anaesthesia.

Primex Pharmaceuticals is headquartered in Switzerland.

MANAGEMENT TEAM

Alan Knox - Group CEO
Ernesto Alegria - CFO
Linda Liitola - Head of Legal affairs
Tomaso Dameno - Head of Operations

PRODUCT #1 NAME

OZALIN - EU approved

Product #1 Description

OZALIN® is indicated in children from 6 months to 17 years old for moderate sedation before a therapeutic or diagnostic procedure or as a premedication before anaesthesia.

OZALIN® is the 1st oral paediatric sedative licensed in EU.
RhoVac AB

PRESENTER
Mr. Anders Månsson, Chief Business Officer & Deputy CEO

COMPANY DESCRIPTION
RhoVac is a biotech company with an asset, RV001, in clinical phase 2b. RV001 is an antigen mediated immuno-therapy that triggers the immune system to target and destroy metastatic cells, and metastatic cells only, on the basis of their unique over-expression of the protein RhoC, a protein that lends to metastatic cells their lethal ability to migrate and infiltrate other tissues. In its phase 2b (ca. 175 patients) trial, RV001 is being studied for its ability to prevent cancer recurrence (measured as PSA rise) after radical prostatectomy in prostate cancer. But the RhoC targeting principle is probably generally applicable to other metastatic cancers too. As such, RhoVac is looking for a licensee or an acquirer among large oncology focused pharmas after the phase 2b study. Phase 2b results will be at hand mid 2021. We might consider an option deal prior to that.

MANAGEMENT TEAM
CEO Anders Ljungqvist
CBO & Deputy CEO Anders Månsson
CFO Henrik Stage

All have a solid track record of deal making with large pharma companies.

FINANCIAL SUMMARY
The company is fully financed for three years. Results of the phase 2b study will be at hand in two years (mid 2021), and we are looking to have a number of companies inventoried for their interest and ready for final negotiation by that time. We might also consider an option deal or a right-to-first-negotiation deal prior to that. We anticipate a robust clinical efficacy read-out after the 175 patient strong phase 2b trial (prostate cancer) that finalizes in mid 2021. A third-party (Edison Group) financial analysis of the asset and of our company is available at our website.

PRODUCT #1 NAME
RV001

Product #1 Description
RV001 is an antigen mediated immuno-therapy that triggers the immune system to destroy metastatic cancer cells, and metastatic cancer cells only, on the basis of their unique over-expression of a protein called RhoC. Currently this asset is in phase 2b (in prostate cancer). Potentially broadly applicable in all metastatic cancers.
STALICLA S.A.

PRESENTER
Ms. Lynn Durham, Founder & CEO

COMPANY DESCRIPTION

STALICLA is a near clinical Swiss Biotech Company developing a unique approach to bring personalized medicine to patients with Autism Spectrum Disorder (ASD). Today, patients with ASD account for 1-1.5% of the world population. The condition remains a high unmet medical need. In its Geneva and Barcelona units, STALICLA has assembled world class teams of experienced drug developers and computational biologists. The company is recognized as a disruptive player, using its systems biology DEPI platform to identify subgroups of patients with ASD and candidate repurposed and rescued drugs. Patients are then characterized through biomarker preclinical and clinical investigations. This translates into a derisked drug development process bringing the vision of ASD personalized medicine to reality.

STALICLA’s first therapeutic package - STP1 - addresses a distinct sub-group of ASD patients estimated to 1.5-2M people in the EU and North America.

To support STP1 development and create strong value for all stakeholders, STALICLA has developed a network of top tier research and clinical partners and established IP as a strategic priority.

STALICLA is currently applying its DEPI discovery model to advance new pipelines for additional groups of patients. Applicability of the DEPI platform goes beyond ASD and has potential for drug discovery in other complex ill-defined diseases.

Q1 2019 – Three new modules have been added to the DEPI v.III platform, exponentially increasing its capacities for single and combination drug repositioning and for identification of clinical trial stage drug high responder patients in complex neurodisorders.
Themis Bioscience GmbH

**PRESENTER**

Mr. Alexander Kort, SVP Corporate Development

**COMPANY DESCRIPTION**

Themis is developing immune-modulation therapies for infectious diseases and cancer. The company’s lead asset maintains its front-runner position worldwide and is currently in final preparations for a pivotal global Phase 3 clinical trial.

The company has built a sophisticated and versatile technology platform, and a robust commercial-scale manufacturing process for the discovery, development and production of vaccines as well as other immune system activation approaches, based on the advanced understanding of immune system mechanisms.

Initially focused on preventing infectious diseases, the Company has demonstrated the potential of its versatile platform through the rapid progression into Phase 3 clinical development for a vaccine against Chikungunya, a debilitating disease with global outbreak potential.

Themis launched an immunotherapy franchise in the second half of 2018 to further exploit the potential of its platform in oncolytic virotherapy and is rapidly moving the lead asset into a Phase 1 study in 2019 to treat gastrointestinal cancer.

Funded to date by high profile EU- and US-based VCs, Themis has also gained prestigious non-dilutive funding for emerging infectious disease indications, including two partnerships with the Coalition for Epidemic Preparedness Innovations (CEPI).

The company will apply its platform and manufacturing capabilities to diseases with high market potential both alone and for its partners.

**MANAGEMENT TEAM**

- Dr. Erich Tauber - Chief Executive Officer Co-Founder
- Dr. Philippe Dro - Chief Business Officer
- Dr. Katrin Ramsauer - Chief Scientific Officer
- Dr. Jochen Stritzker - Senior Vice President Immunotherapy
- Dr. Lee Smith - Chief Technical Officer
- Alexander Kort - Senior Vice President, Corporate Development
- David A. Maier - Chief Financial Officer
- Dr. Matthias Müllner - Senior Vice President, Technical Operations
- Dr. Christian Mandl - Chairman, Scientific Advisory Board
PRODUCT #1 NAME

Product #1 Description
Our clinical pipeline of immune-modulation therapeutics focuses on infectious disease and cancer indications, addressing the need for novel vaccines to prevent both emerging and large market diseases.

We have several programs in our infectious disease portfolio. These include vaccine candidates for Chikungunya (Phase 3-ready), Zika (Phase 1), Lassa Fever (Phase 1, partnered program), Noro/RSV/CMV (all three programs, pre-clinical proof-of-concept completed), MERS (pre-clinical, partnered program).

We are advancing programs in immuno-oncology based on the intrinsic oncolytic capabilities of our measles vaccine vector demonstrated in several pre-clinical studies. The first program is in gastrointestinal cancer (Phase 1 to be initiated, 2019).
TOLREMO Therapeutics AG

PRESENTER
Dr. Stefanie Flückiger-Mangual, Co-founder and CEO

COMPANY DESCRIPTION
TOLREMO therapeutics AG is a spin-off of the ETH Zurich. The company was founded in 2017 by ETH scientists and experienced executives from the pharmaceutical industry. It has since raised almost $12 million to beat drug resistance in cancer therapy.

TOLREMO uses a proprietary drug resistance screening platform to identify novel drug targets and develop resistance-preventing small molecules. The company’s compounds can be combined with existing cancer drugs to prevent resistance development and increase patient survival.

PRODUCT #1 NAME
TT125 (preclinical)

Product #1 Description
TT125 is a novel epigenetic inhibitor. TT125 suppresses transcriptional escape mechanisms that give rise to drug resistant cancer cells. When combined with EGFR inhibitors, TT125 prevents drug resistance development in NSCLC to increase patient survival. Other resistance-preventing combinations under investigation.

PRODUCT #2 NAME
TT5180 (preclinical)

Product #2 Description
TT5180 is a novel kinase inhibitor. TT5180 specifically eliminates hypoxic and/or nutrient-starved cancer cells. It potentiates anti-angiogenic therapies and chemotherapies to increase patient survival.
Topadur Pharma AG

COMPANY DESCRIPTION
Topadur Pharma AG is a biopharmaceutical start-up company based at the Bio-Technopark in Schlieren-Zürich, Switzerland. The company was established in April 2015 and is a successor of Topadur GmbH founded in 2009. It was qualified as SME by EMA on May 22, 2017. Topadur is also a CTI-certified company. The company focuses on research and development for diseases with highly unmet medical needs. Topadur invented a new type of drugs, small molecular weight drugs with dual mode of action resulting in a rich pipeline of innovative drug candidates to enable healing of chronic wounds, avoid scar formations after burn wounds, treat major eye and aging diseases and improve patients quality of live. The leading development drug for is foreseen to enter this year the clinical development phase in diabetic foot ulcer and in a rare ulcer indication.

- Topadur’s leading drug, TOP-N53 enables the healing of chronic wounds such as diabetic foot ulcers (DFU) and orphan ulcers. It is entering clinical trials end of 2019.
- TOP-N53 has the potential for a breakthrough medication in a disease with very high unmet medical need, saving more than one million foot amputations every year and prevent patients from dying.
- TOP-V122 and TOP-T5 are drug candidates in pre-clinical stage, predicted to increase ocular microcirculation and neuroprotection. It addresses glaucoma conditions and has the potential to become a breakthrough drug preventing blindness in several ophthalmic diseases.
- TOP-N44 is a drug candidate in preclinical development, which we expect based on preclinical data to inhibit scar formation after burn wounds.
- TOP-M119 is a very potent hair growth promoter. Since loss of sensory hair cells in the inner ear is the main reason for age dependent hearing loss it is foreseen to evaluate the potential of this drug candidate in relevant animal models.

MANAGEMENT TEAM
Dr. Reto Naef, CEO
Dr. Guido Koch, COO
Dr. Hermann Tenor CSO
Dr. Christian Ludin CDO
Christina Attaalla CFO

FINANCIAL SUMMARY
Seed Financing 2015
Ser A 2016
Ser B 2017
total equity 12 Mio CHF
non diluting grants 3.5 Mio CHF
next equity round: 2019 12 Mio CHF
PRODUCT #1 NAME
TOP-N53

Product #1 Description
• Topadur’s leading drug, TOP-N53 enables the healing of chronic wounds such as diabetic foot ulcers (DFU) and orphan ulcers. It is entering clinical trials end of this year.
• TOP-N53 has the potential for a breakthrough medication saving more than one million foot amputations every year.

PRODUCT #2 NAME
TOP-V122; TOP-T5

Product #2 Description
• TOP-V122 and TOP-T5 are drug candidates in pre-clinical stage, predicted to increase ocular microcirculation and neuroprotection. It addresses glaucoma conditions and has the potential to become a breakthrough drug preventing blindness in several ophthalmic diseases.

PRODUCT #3 NAME
TOP-M119

Product #3 Description
TOP-M119 is a very potent hair growth promoter. Since loss of sensory hair cells in the inner ear is the main reason for age dependent hearing loss POC in animal models are planned to evaluate the drugs potential in for hearing loss treatment.
Tubulis GmbH

PRESENTER
Dr. Dominik Schumacher, CEO

COMPANY DESCRIPTION
Tubulis generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients.

We will advance a range of conjugates, unlimited by indication, using our own discovery capabilities and by solving development challenges for partners with both antibody and chemical assets.

MANAGEMENT TEAM
Dr. Dominik Schumacher, CEO
Dr. Jonas Helma-Smets, CSO
Dr. Ingo Lehrke, CBO

FINANCIAL SUMMARY
We are currently raising 3 Million € Seed-Investment. First Investor is committed.

PRODUCT #1 NAME
TUB-010

Product #1 Description
With our preclinical TUB-010 we have developed a CD30 ADC with improved stability and efficacy compared to the state of the art that has the potential to reach the so-far unattained goal of facilitating broad first-line therapy with a significant patient benefit.

PRODUCT #2 NAME
TUB-020

Product #2 Description
With our preclinical TUB-020, we tackle AML from a completely new angle with a novel, transformative ADC with a novel mode of action. TUB-020 is designed with:

1. our proprietary Tub-tag® technology to provide unique ADC homogeneity and stability.
2. a unique payload with intrinsic specificity for leukemic cells. In consequence, the payload in use adds a new level of selectivity for leukemia, widening the therapeutic window.
UGA Biopharma GmbH

PRESENTER

Mr. Lars Kober, CEO

COMPANY DESCRIPTION

The expertise of UGA Biopharma is the development of biologics and biosimilars. This high speed contract development involves all the necessary steps from cell line development and bioprocess development to the development of purification processes and analytics. Furthermore, First CHOice® high-performance cell culture media and feeds are supplied in order to optimize the quality and product concentration of biologics and biosimilars. In addition, UGA Biopharma offers to customers ready-to-use biosimilar cell lines. The company supplies its customers in Germany and abroad from its headquarters in Hennigsdorf and already has several clients with UGA products in clinical trials or who have already received a market approval.

PRODUCT #1 NAME

Several therapeutic antibodies, bispecific antibodies, fusion proteins, enzymes and hormones are in the pipeline.
Versameb Ltd.

PRESENTER
Prof. Friedrich Metzger, CEO

COMPANY DESCRIPTION
Versameb Ltd. is a biopharmaceutical company located in Basel, Switzerland, fully operating since 2018. It was founded after many years of research for superior results of novel therapies for the local and efficacious delivery of therapeutic proteins to accelerate tissue regeneration and improve maintenance. The company’s VERSagile mRNA technology platform rapidly revealed various options for a broad range of therapeutic applications, thus providing multiple new drug development opportunities for both Versameb as well as potential partners.

MANAGEMENT TEAM
Prof. Dr. Friedrich Metzger - CEO;
Dr. Urs Breitenstein - CFO;
Dr. Isabel Ferreira - CBO;
Roger Meier - Delegate of the Board

PIPELINE IMAGE

<table>
<thead>
<tr>
<th>Compound</th>
<th>Indication</th>
<th>RESEARCH</th>
<th>DEVELOPMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>NME 1</td>
<td>Muscle</td>
<td>Discovery</td>
<td>Phase 1</td>
</tr>
<tr>
<td>NME 2</td>
<td>Neuromuscular</td>
<td></td>
<td>Phase 2</td>
</tr>
<tr>
<td>NME 3</td>
<td>Cartilage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NME 4</td>
<td>Tendon</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Undisclosed</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Undisclosed</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

www.sachsforum.com
Zmed Laser Ltd.

PRESENTER
Dr. Ziv Karni, Founder & President

COMPANY DESCRIPTION
Following the success of Alma Laser, Dr. Ziv Karni and his team are offering a full line of unique and unmatched innovative solutions based on minimally invasive laser technologies for Surgical & Professional Aesthetic Applications. A Zmed solutions are setting a new gold standard with maximum results and patients’ comfort, for out-patient/in-clinic procedures in Professional Aesthetics, Gynecology, Proctology, Plastic Surgery and more.

MANAGEMENT TEAM
Dr. Ziv Karni – President, Co-Founder & CEO at Alma Lasers, Ltd.
Ronen Lazarovitch – CEO
Yair Leopold – Executive VP

FINANCIAL SUMMARY
Zmed is in a Pre-Commercial stage. Up to date about 2M USD were invested in cash and equivalents. Looking for 10M USD for the series A funding for:
Entering the main markets starting from US & Europe
Establish global AAA distribution system with multiple launching events and training
Broaden application through clinical and R&D
Enhance & support IP portfolio
Clinical validation and publications
Regulatory approvals mainly for proprietary accessories
Operational cost – building up team and G&A.

PRODUCT #1 NAME
ZL-1000 is a 1470 ber laser platform

Product #1 Description
The ZL-1000 Platform is a unique ber laser system with proprietary and patented accessories, which makes it the new gold standard for various indications in Medical Aesthetics, Gynecology, Proctology, and more.
For hundreds of years, Basel has been an attractive location for successful trade fairs, congresses and major international events. The Basel Autumn Fair, for example, which dates back to 1471, is the oldest and biggest funfair in Switzerland. And Baselworld, global trade fair for watches and jewellery, as well as Art Basel, the most important art fair in the world, attract major international players and numerous visitors every year. You’ll be very welcome!
For hundreds of years, Basel has been an attractive location for successful trade fairs, congresses and major international events. The Basel Autumn Fair, for example, which dates back to 1471, is the oldest and biggest funfair in Switzerland. And Baselworld, global trade fair for watches and jewellery, as well as Art Basel, the most important art fair in the world, attract major international players and numerous visitors every year. You'll be very welcome!

www.basel.ch
SILVER SPONSORS

BeiGene Ltd.

www.beigene.com

BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 1,100 employees in China, the United States, and Australia, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeiGene markets ABRAXANE® (nanoparticle albumin-bound paclitaxel), REVLIMID® (lenalidomide), and VIDAZA® (azacitidine) in China under a license from Celgene Corporation.

Bristol-Myers Squibb

www.bms.com

Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing and delivering innovative medicines for patients with serious diseases. Our medicines are helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience, fibrosis and others. We have built a sustainable pipeline of potential therapies, and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient at the right time to achieve the best outcome.

Through the Bristol-Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions, giving new hope to some of the world’s most vulnerable people. Each day, our employees around the world work together for patients – it drives everything we do.

EIT Health e.V.

www.eihealth.eu/web/internet-eithealth

EIT Health is a network of best-in-class health innovators backed by the EU. We deliver solutions to enable European citizens to live longer, healthier lives by promoting innovation. We connect the right people and the right topics across European borders, so that innovation can happen at the intersection of research, education and business.
**Italian Trade Agency (ITA)**

www.ice.it/en/

Italian Trade Agency (ITA) is a governmental body promoting the connectivity between Italian tech-clusters and international partners. In the field of Health-Biotech, ITA promotes transnational cooperation in manufacturing and R&D. This is achieved by supporting match-making in Italy, and through ITA’s 80 world-wide offices also internationally. ITA serves as a one-stop window for international companies requiring support in doing business in Italy.

---

**Torreya Partners LLP**

www.torreya.com

Torreya is a global investment banking boutique serving companies in the life sciences industry. Since our inception in 2007, we have advised clients on more than $100 billion worth of deals for biotechnology, branded pharmaceutical, generic pharmaceutical, and life sciences companies. Our partners are senior industry bankers and executives, with deep experience, knowledge, and networks. We are a partner of choice for companies seeking discreet, conflict-free, and knowledgeable advice on M&A, pharmaceutical asset sale, capital markets, and licensing transactions. Torreya is differentiated from most other life sciences advisory practices by the breadth of its global presence. Over half the transactions on which we advise are cross-border. Torreya has offices in London, Mumbai, and New York, and affiliate offices on six continents.
Abingworth LLP
www.abingworth.com

Abingworth is an international investment group dedicated exclusively to the life sciences and healthcare sectors. We invest across all stages of company development including early and late-stage venture financing, growth equity and public companies.

Founded in 1973, Abingworth has a lengthy track record of building market leading companies. Our specialist team of over 20 professionals has a broad range of skills, including scientific and business expertise as well as investment banking, recruitment and legal knowledge. These resources are made available to portfolio companies. Abingworth has funds under management of over $1 billion and offices in London, Menlo Park (California) and Boston.

BioMedPartners AG
www.biomedvc.com

BioMedPartners AG is a Basel-based Life Science Venture Capital Firm that invests in innovative private early- to mid-stage human Life Science companies in Switzerland and surrounding EU countries. It has recently raised a new fund, BioMedInvest-III LP, at CHF 100 million, and has now a total of CHF 350 million under management.

Locust Walk
www.locustwalk.com

Locust Walk is a global life science transaction firm. Our integrated team-based approach across capabilities, geographies, and industry segments delivers the right products, the right partners, and the most attractive sources of capital to get the right deals done for biopharma and medtech companies.

- Capabilities – cohesive strategy, market analytics, and transaction capabilities
- Geographies – global footprint across all key life science geographies
- Industry Segments – comprehensive coverage across biopharma and medtech segments

Novo Holdings A/S
www.novoholdings.dk

Novo Seeds is the early stage investment arm of Novo Holdings. Novo Holdings is the holding company in the Novo Group, responsible for the management of the assets of the Novo Nordisk Foundation, which are currently valued at more than USD 30 billion. Novo A/S is a private limited liability company fully owned by the Novo Nordisk Foundation. Besides being the major shareholder in Novo Nordisk A/S and Novozymes A/S, Novo A/S provides seed and venture capital to development stage companies and takes significant ownership positions in well-established companies, within life science and biotechnology, as well as manages a broad portfolio of financial assets.
Staatz Business Development & Strategy

www.staatz.biz

Staatz Business Development & Strategy is a consulting firm with two complementary fields of expertise: business development and market access.

Our Senior Consultant team identifies and secures on a global basis for our international clients strategic partnering options on the buy and the sell side, applying our scientific and commercial expertise, vast network and profound process management. Our deals range from worldwide to national agreements and cover all deal structures customary in our industry, including M&A. Our track-record, comprising successful transactions in many indication areas with a transaction value to date exceeding US$ 3 bn in total is based on our successful preparation, our efficient and structured operational management and skilled negotiation.

We also advise clients from the international industry on market access and pricing & reimbursement strategies and processes for European markets. We have successfully developed and implemented Market Access Strategies including the development and testing of value messages, preparation of value dossiers, provision of pricing and reimbursement assessment and negotiation support.

Syneos Health

www.syneoshealth.com

Syneos Health™ is an end-to-end, fully integrated biopharmaceutical solutions company that works differently. At Syneos Health, all the disciplines involved in bringing new therapies to market, from clinical to commercial, work together to create customer success. Our unique Biopharmaceutical Acceleration Model (BAM) delivers value across the small to mid-size to large customer continuum. Syneos Health is the only company in the biopharmaceutical services industry purpose-built to create greater success for our customers. At Syneos Health, clinical and commercial live under the same roof and constantly share real world knowledge and insights that lead to getting the job done better, smarter and faster.
SUPPORTERS

Berlin Partner for Business and Technology

www.berlin-partner.de

Business and technology support for companies, investors and scientific institutions in Berlin – this is the Berlin Partner für Wirtschaft und Technologie GmbH mission. With customized services and an excellent science and research network, our many experts provide an outstanding range of programs to help companies launch, innovate, expand and secure their economic future in Berlin.

BioPartner

www.biopartner.co.uk

BioPartner is an independent, government-accredited trade organisation, promoting international partnering for trade, investment and collaborations with UK Life Science companies. BioPartner’s delegations promote the UK presence at major international biopharma conferences, and companies are assisted with access to government grants and heavily discounted entry fees. Through the BioPartner Programme, members receive extra benefits and support to effectively trade overseas.

Biotechgate

www.biotechgate.com

Biotechgate is the global Business Development Database for the Biotech, Pharma and Medtech industries.

- Over 500,000 clinical trials
- 50,000 company database
- Over 20,000 Biotech, Pharma and Medtech assets available for licensing
- Detailed search functions with Excel download options
- Over 240,000 management contact details
- Product pipelines
- Dedicated investor database
Citigate Dewe Rogerson

www.citigatedr.co.uk

Citigate Dewe Rogerson is one of the world’s leading strategic communications consultancies.

Our Life Sciences team has established a reputation for excellence spanning financial, corporate and scientific communications; this has enabled us to become trusted advisors and to build a broad portfolio including some of the most innovative and exciting international life sciences companies. Our clients are at all stages of development, from start-up to multinationals, and our activities are focused on delivering campaigns that support corporate objectives. As a result, we have been involved in major corporate transactions and events in the life sciences sector over the past decade such as IPOs, other public and private fundraisings, and M&As.

Recent IPO transactions: ABIVAX (Euronext Paris - €60m), OSE Pharma (Euronext Paris - €21m), Nordic Nanovector (Oslo - NOK575m), Midatech Pharma (London AIM - £32m), Abzena (London AIM - £20m), arGEN-X (Brussels - €42m), Pixium Vision (Euronext Paris - €39.5m), Crossject (Euronext Paris - €17m). Other recent financings: Abingworth (£225m ABV VI), Rigontec (€14.25m Series A), Calcivis (£4.5m fundraising), ViraTherapeutics ($3.6m - Series A). Recent M&A: Heptares (up to $400m acquisition by Sosei), Prosonix (up to £100m acquisition by Circassia), bioquell (Sale of subsidiary for £44.5m).

Economic & Trade Office of Israel in Geneva, Switzerland

https://itrade.gov.il/switzerland/about/

The Government of Israel’s Economic and Trade Office in Geneva, Switzerland, is a branch of the Foreign Trade Administration of the Ministry of Economy and Industry. The Trade Office in Geneva has two main responsibilities: World Trade Organization (WTO) affairs, and trade & investment promotion* (Switzerland-Israel).

*Trade and export promotion, investments and technological collaboration between Swiss and Israeli companies.


The Trade Office facilitates introductions between Swiss and Israeli companies, arranges meetings, organizes local conferences and assist Swiss and Israeli business delegations visiting the respective country, amongst other things.
Edison Group

www.edisongroup.com

Edison is an international advisory firm with around 450 corporate clients and 110 people working from offices in London, New York, Frankfurt, Sydney and Wellington. The team consists of 80 analysts, investment and logistics professionals with experience in capital markets, investor roadshows and communications. Healthcare is Edison’s largest sector, with 16 analysts covering over 100 biotech and medtech stocks across the UK, continental Europe, North America and Asia-Pacific.

FreeMind Group

www.freemindconsultants.com

FreeMind is a consulting group whose goal is to assist in maximizing potential to receive funding from non-dilutive sources. Established in 1999, FreeMind is the largest consulting group of its kind working with academics and industry alike. FreeMind’s proven long-term strategic approach has garnered its clients over 1.5 billion dollars to date.

Our expertise in applying for grants and contracts extends throughout every government mechanism open to funding the life sciences including all NIH institutes, DoD, NSF, FDA, CDC, BARDA, etc., as well as private foundations. FreeMind’s knowledgeable and experienced team of Client Strategists and Project Managers are dedicated to guiding non-dilutive funding efforts from identification of the most suitable opportunity through to submission and subsequent award. Our team of experts will assist in making non-dilutive funding a key tool in a long-term financial strategy.

IATI (Israel Advanced Technology Industries)

www.iati.co.il

IATI is Israel’s umbrella organization of the high-tech, life science and other advanced technology industries, with hundreds of paying members from every level and aspect of the ecosystem - including Venture Capital Funds, R&D Centers, Multinational Companies, Israeli Start-Ups and Large Companies, Incubators, Tech Transfer Organization, Academic Institutions, Innovation Centers, Hospitals, Municipalities, Leading Stock Exchanges, Service Providers and more. Through this broad range of members, IATI connects Israel’s tech ecosystem, provides solutions and support at all levels, and integrates the various sectors of the industry with strategic and ongoing governmental goals.
Instinctif Partners

www.lifesciences.instinctif.com

Instinctif Partners is an international business communications consultancy. With a track record of delivering truly creative programmes, the Life Sciences practice focuses on enhancing the value proposition for companies seeking investment, partnerships or customers. Our core skill is working with clients to communicate the value of their science and innovation to key stakeholders through the most relevant channels: crafting communications solutions that showcase each company, product or technology. Specifically, we are unique in offering specialist expertise seamlessly across corporate, financial, healthcare and marketing communications with outreach programmes to media, industry, professional, public, financial and investment communities. Our service offering covers all communications disciplines including strategic counsel, PR, IR, media relations, public affairs, crisis communications, internal communications, marketing, advertising, copywriting, design, research and event management. Our globally integrated and dedicated life sciences team serves clients around the world from our headquarters in London, and bases across Europe, AsiaPac and the USA.

Labiotech.eu

www.labiotech.eu

Labiotech.eu is the leading digital media covering the European Biotech industry. Over 150,000 monthly visitors use it to keep an eye on the business and innovations in biotechnology. Hope you’ll enjoy reading our stories!

Life Science Austria (LISA)

www.lifescienceaustria.at

Austria Wirtschaftsservice (aws) has established Life Science Austria (LISA) as a one-stop shop that spans the entire value-added chain of startups in the life sciences. LISA provides customised support at every stage of a startup’s development. Furthermore LISA promotes the life science sector in Austria on the international stage and is the first point of call for enquiries relating to it.

Organised through the regional life science clusters, LISA represents companies in the therapeutic, medical technology and diagnostic sectors as well as providers of enabling technologies and related service companies located in the following Austrian regions:

- ecoplus (Lower Austria)
- human.technology Styria (Styria)
- LISAvienna (Vienna)
- MedTech-Cluster (Upper Austria)
- Standortagentur Tirol/Cluster Life Sciences Tirol (Tyrol)
Ontario Bioscience Innovation Organization

www.obio.ca

The Ontario Bioscience Innovation Organization (OBIO®) founded in 2009, is a not-for-profit, membership based organization engaged in strategy, programming, policy development and advocacy to further the commercialization of Ontario’s human health science companies positioning Ontario as a leader in the international marketplace. OBIO advances this goal through collaborative partnerships with industry, the investment community, academia, patients and government.

Platform Life Sciences

www.goingpublic.de/lifesciences

The Life Sciences-Series - Launched in 2014 four issues of the Life Sciences-Series appear annually. Based on the three pillars – technology, financing, investment - the issues combine current topics of life sciences with knowledge and networking from corporate financing and capital market. The mission: Building a cross medial bridge between the life sciences and the financial industry by the help of the quarterly Life Sciences issues, the monthly digital newsletter Life-SciencesUpdate.

Swiss Biotech Association

www.swissbiotech.org

Swiss Biotech unites the four leading biotech regions of Switzerland (BioAlps, BaselArea, Biopolo Ticino and Greater Zurich Area). The regions have early on combined efforts with the SWX Swiss Exchange which holds a leading position in terms of life-science listings and services.

The National Industry Association named Swiss Biotech Association Represents more than 150 companies to date and acts as the operational arm for the marketing alliance. Swiss Biotech raises Switzerland’s profile as an economic center in Europe and profiles the biotech industry with its key research institutions and companies. Swiss Biotech’s mission is to spread the message of Switzerland as one of the top biotech locations in the world. This will be achieved by presenting a comprehensive picture of the drivers of biotechnology including research, education, economics, finance and industry. The bases for success in biotechnology are the critical mass of research institutes and accelerated technology transfer. The early integration of industry and well-trained workforce is another critical success factor for rapid economic growth. More than 40 technology parks throughout the country support the increasingly important and successful TechTransfer process.
Tiberend Strategic Advisors, Inc.

www.tiberendstrategicadvisors.com

Tiberend Strategic Advisors, Inc. is a corporate communications firm providing media strategy and execution for life science companies - biotech (therapeutics), medical devices and diagnostics. We work with both public and private emerging growth companies:

1. To enhance valuation
2. To build visibility for partnerships and strategic alliances
BACHEM AG [SWX: BANB]

COMPANY PROFILE

A listed technology-based company focused on peptide chemistry. The company provides a full range of services to the pharma and biotech industries. It specializes in the development of innovative, efficient manufacturing processes and the reliable production of peptide-based active pharmaceutical ingredients. A comprehensive catalog of biochemicals and exclusive custom syntheses for research labs complete the service portfolio. Headquartered in Switzerland with subsidiaries in Europe and the US, the group has a global reach with more experience and know-how than any other company in the industry. Towards its customers, Bachem shows total commitment to quality, innovation and partnership.
HOFFMANN & CO AG

COMPANY PROFILE

A leading independent professional services company based in Switzerland, offering a unique, integrated services model in the complex and specialist areas of valuations and mergers and acquisitions. We, the partners – Kaspar Kunz, Dr. Urs Breitenstein, Thomas Wenk, Marc Hoffmann und Patrick Schacher – attach great importance to deliver innovative solutions with true professionalism, commitment, transparency, integrity and personal customer care.
ITALIAN TRADE AGENCY (ITA)

COMPANY PROFILE

A governmental body promoting the connectivity between Italian tech-clusters and international partners. In the field of Health-Biotech, ITA promotes transnational cooperation in manufacturing and R&D. This is achieved by supporting match-making in Italy, and through ITA’s 80 worldwide offices also internationally. ITA serves as a one-stop window for international companies requiring support in doing business in Italy.
SYNCROSOME

COMPANY PROFILE

As more than 60% of new drugs fail in phase 2, we have chosen to focus our activities since 2000 on preclinical in Vivo Efficacy Studies to offer better predictability and anticipate clinical results.

Syncrosome offer relevant disease models, cutting-edge techniques, specific Biomarkers and a comprehensive background of physiopathology to assist drug discovery companies in selecting their compounds.

We have developed and validated so far more than 15 disease models, and our flexible and human-sized organization can design and operate tailored in vivo experimental protocols to give you appropriate answers.
SACHS ASSOCIATES

www.sachsforum.com

Sachs Associates is a long established international conference company with offices in Switzerland and the UK. It runs a limited number of high profile conferences in Europe and the USA which are focused on biopharma, medtech, and digital health. These conferences focus on licensing and investment opportunities and all provide presenting opportunities for companies and excellent meeting facilities for all delegates to network.

Sachs Associates is focused on the practical benefits accruing from conference participation, the exchange of ideas and information, and the facilitating of business transactions.

THE BENEFITS OF CONFERENCE PARTICIPATION WITH SACHS ASSOCIATES MAY BE SUMMARISED AS follows:

ONLINE ONE-2-ONE MEETING SYSTEM

In order to offer the best possible provision for networking opportunities and dealmaking Sachs Associates provides all delegates access to our online One-2-One meeting system, allowing you to set up, accept or decline private One-2-One meetings with other conference attendees. These meetings last for 20 minutes in duration. Individual passwords and logins are provided to allow immediate access and ensure full security.

CUTTING EDGE CONTENT WITH EMINENT SPEAKERS

Sachs Associates is committed to ensuring that its events continue to provide forums with the participation of the most eminent speakers from the public and private sectors. Through its reputation and its long-established local relationships, the company has attracted very senior scientific and business personalities as speakers at its events.

SPONSORSHIP AND MARKETING OPPORTUNITIES FOR FORTHCOMING EVENTS

Sachs Associates has developed an extensive knowledge of the key individuals operating within the global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at the forefront of the industry and provides a powerful tool by which to increase your company’s position in this market. Sponsorship of any of our events allows you to raise your company’s profile directly with your potential clients. All of our sponsorship packages are tailor-made for each client, allowing your organisation to gain the most out of attending our industry driven events.

THE FOLLOWING SPONSORSHIP AND MARKETING OPPORTUNITIES ARE AVAILABLE AT FUTURE CONFERENCES:

• Conference Sponsor – including workshops and social events
• Exhibition Stands
• Distribution of Promotional Material

If your company is interested in exhibiting or sponsorship opportunities, please call Silvia Kar on +44 203 463 4890 or email Silvia@sachsforum.com.